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ABSTRACT 
Amanda Anne Seyerle: Pharmacogenomics of Ventricular Conduction in Multi-Ethnic 
Populations 
(Under the direction of Christy L. Avery) 
 
 Adverse drug reactions (ADRs) pose a serious public health burden, yet the role of 
genetics in drug response remains incompletely characterized.  Thiazide diuretics, commonly 
used anti-hypertensives, may cause QT interval (QT) prolongation, a major drug 
development barrier that increases risk for highly fatal and difficult to predict ventricular 
arrhythmias.  We thus examined whether common SNPs modified the association between 
thiazide use (17% mean prevalence) and QT or its component parts (QRS interval, JT 
interval) by performing ancestry-specific, trans-ethnic, and cross-phenotype genome-wide 
analyses of European (66%), African American (15%), and Hispanic (19%) populations (N-
78,199).  Analyses leveraged longitudinal data, incorporated corrected standard errors to 
account for underestimation of interaction estimate variances, and evaluated evidence for 
pathway enrichment.  Although no loci achieved genome-side significance (P<5x10
-8
), we 
found suggestive evidence (P<5x10
-6
) for SNPs modifying the thiazide-QT association at 22 
loci, including biologically plausible ion transport loci (e.g. NELL1, KCNQ3).  
Given our highly plausible, but only suggestive findings and our observational cohort 
setting, we next examined the influence of prevalent user bias and exposure misclassification 
on pharmacogenomics studies conducted in observational settings.  Specifically, we 
simulated three study designs (longitudinal, cross-sectional, new user), two control groups 
 iv 
(whole cohort, active comparator), and two scenarios (extreme or modest drug effects) to 
enable comparison of 12 settings.  For each setting, we simulated N=120,000 participants, 
conducted 10,000 iterations, applied an alpha=5x10
-8
, and introduced varying degrees of 
prevalent user bias and drug exposure misclassification.  When large drug effects (>10 ms 
change in QT) or exposure misclassification were present, drug-SNP interaction estimates 
were biased (bias range: 0.02–3.4 ms) across settings.  Under no settings did power to detect 
the drug-SNP interaction estimate exceed 80% for effects less than 2 ms; detection of drug 
effects below 2 ms required a longitudinal design with at least 150,000 participants.  Results 
from this dissertation suggest that despite leveraging longitudinal data in 78,199 participants, 
our study was likely underpowered to detect modest or clinically significant 
pharmacogenomics effects on QT.  Future pharmacogenomics efforts will require even larger 
sample sizes and innovative methods to enable prevention of ADRs in the large and 
increasingly at-risk population exposed to medications.   
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CHAPTER 1: OVERVIEW 
Over the past decade, the use of prescription drugs has skyrocketed, with nearly half 
of all Americans taking at least one prescription drug.
1
  Despite the considerable increases in 
drug exposure, variability in drug response, a significant cause of morbidity and mortality 
accounting for approximately 100,000 deaths and 2.2 million serious health effects 
annually,
2-5
 remains poorly understood.
6
  One promising avenue to understanding variability 
in drug response is offered by pharmacogenomics,
7
 which as the potential to illuminate novel 
pathways with the goal of informing drug development and selection,
8-10
 modifying dosing 
regimens,
11-15
 and avoiding adverse drug reactions.
16-18
 
Pharmacoepidemiology is a branch of epidemiology that seeks to understand both the 
use of and the effects of drugs in populations.  Pharmacogenomics is an extension of 
pharmacoepidemiology and evaluates the role of genetics in drug response.  This work will 
perform a genome-wide association study (GWAS) that examines whether common genetic 
variants modify the association between thiazide diuretics and the QT interval (QT), a 
measure of ventricular depolarization and repolarization taken from the electrocardiogram 
(ECG).  QT is a promising candidate for pharmacogenomic study, as it is a risk factor for 
ventricular tachyarrhythmia,
19
 coronary heart disease,
20
 congestive heart failure,
21
 stroke,
22
  
cardiovascular mortality, and all-cause mortality.
23
  Furthermore, QT is highly heritable (35-
40%),
24-28
 with early family studies identifying rare and highly penetrant mutations 
associated with long- and short-QT syndrome
29
 and more recent GWAS identifying multiple 
 2 
common single nucleotide polymorphisms (SNPs) associated with modest increases in QT.
30-
35
  Thiazide diuretics, an increasingly common antihypertensive therapy used by over a 
quarter of the hypertensive population in the U.S.,
36, 37
 are one of many common 
pharmaceuticals that may cause QT prolongation.
38-40
  However, the mechanisms underlying 
thiazide-induced QT prolongation is not well understood.
41-43
  Given the rising prevalence of 
thiazide use, the established genetic basis of QT, the inter-individual variability in thiazide 
response, and the Food and Drug Administration’s standard for regulating QT-prolonging 
medications, which requires a change of just 5 ms, a change easily obtained  through both 
pharmaceutical and genetic exposures,
44
 it is critical that pharmacogenomic interactions be 
identified.  Pharmacogenomics remains one of the few areas where genetic research has been 
translated into actionable results and the pharmacogenomics of thiazides and QT 
prolongation is an excellent candidate for pharmacogenomics study. 
Pharmacogenomics studies like the one presented herein often leverage the extensive 
data available in large observational study settings, a setting in which 
pharmacoepidemiologic studies are known to be prone to multiple forms of bias (e.g. 
prevalent user bias, indication/contraindication, healthy-user effects, etc.).
45-51
  However, it is 
unclear if pharmacogenomic studies are subject to the same biases.  For example, previous 
work has indicated that pharmacogenomics studies may not be subjected to the same degree 
of bias by indication/contraindication as pharmacoepidemiologic studies.
47
  However, to 
date, no one has evaluated how additional threats to internal validity, such as prevalent user 
bias, impacts pharmacogenomics studies conducted in observational settings.  This 
dissertation will examine the effect of prevalent user bias on pharmacogenomics studies, 
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work which could inform the future design and interpretation of pharmacogenomics studies 
in large cohort studies. 
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CHAPTER 2: SPECIFIC AIMS 
This work will be conducted through a collaboration between the Women’s Health 
Initiative (WHI),
52
 the Hispanic Community Health Study/Study of Latinos (SOL),
53
 and the 
Cohort for Heart and Aging Research in Genomic Epidemiology (CHARGE)
54
 
pharmacogenomics working group (PWG) investigators, yielding a diverse population of 
participants of European (N=58,813), African (N=15,625), and Hispanic (N=16,657) descent.  
We therefore will: 
Specific Aim 1:  Identify genetic variants that modify the association between thiazide 
diuretics and QT and its component parts (QRS complex [QRS]; JT interval [JT]) in 
European descent, African descent, and Hispanic populations.  
a. Classify thiazide diuretic exposure among all cohorts using medication 
inventories, which have been validated in cohort studies against physiologic 
measurements,
55
 pharmacy databases,
56
 and serum measurements.
57
 
b. Conduct genome-wide, race-stratified analyses to identify significant interactions 
between genetic variants, thiazides, and QT and its component parts (QRS; JT), 
leveraging longitudinal data when possible.  Study and race/ethnic-stratified 
results will be combined across studies using fixed-effect, trans-ethnic, and cross-
phenotypic meta-analytic techniques (Ntotal=78,199).  
c. Characterize identified genetic variants using in silico functional characterization 
techniques including computer databases and pathway analysis. 
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Specific Aim 2:  Examine the influence of prevalent user bias and exposure misclassification 
caused by prevalent user bias on a pharmacogenomics study conducted in an observational 
setting. 
a. Using simulations, evaluate bias, power, and type I error in the drug-SNP 
interaction caused by prevalent user bias and exposure misclassification   
b. Compare the results of aim 2a under different study designs (e.g. whole cohort, 
active comparator, new-user).  
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CHAPTER 3: BACKGROUND AND SIGNIFICANCE 
Ventricular Conduction 
  The role of electrical impulses in cardiac conduction was first identified in the mid-
19
th
 century by Rudolf Kollicker and Johannes Mueller, who showed that the same electrical 
impulses which caused a frog’s legs to kick could also cause the heart to beat.58   During the 
next fifty years, researchers identified and characterized all of the primary structures 
involved in conducting electrical impulses throughout the heart (Table 1, Figure 1).
59
  These 
structures control the coordinated contraction and relaxation of the cardiac muscle cells, first 
with the rapid contraction of the atria and followed by the slower contraction of the 
ventricles, and together form the cardiac electrical conduction system. 
Table 1.  Discovery of the Structures of the Cardiac Conduction System 
Year Structure Scientist 
1845 Purkinje Fibers J.E. Purkinje 
1865/1893 Bundle of Kent G. Paladino and A.F.S. Kent 
1893 Bundle of His W. His, Jr. 
1906 AV Node L. Aschoff and S. Tawara 
1906/1907 Wenckebach Bundle K.F. Wenckebach 
1907 Sinus Node A.G. Keith and M.W. Flack 
1916 Bachmann Bundle J.G. Bachmann 
Adapted from Oto and Breithardt, 200159 
A. Electrical Conduction of the Heart 
 Electrical activity in the heart results from the rapid depolarization and subsequent 
repolarization of the cardiac cells, which creates an action potential.  There are two types of 
cardiac cells: pacemaker cells and non-pacemaker cells, hereafter referred to as myocytes.  
Pacemaker cells are capable of generating regular, spontaneous action potentials and are 
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primarily found in the sinoatrial (SA) node and the atrioventricular (AV) node.  These cells 
are responsible for generating the initial depolarizing current of the heartbeat.  Myocytes 
make up the majority of cardiac cells but cannot generate their own action potential.  
 Action potentials in the heart are primarily initiated in the SA node, which is the 
heart’s primary pacemaker site and provide an intrinsically automated rate of depolarizations 
that drives the overall electrical activity of the heart.
60
  From the SA node, the depolarization 
current spreads through the myocytes of the atria.  However, the AV valves, which separate 
the atria and the ventricles, are composed on non-conductive connective tissue which 
prevents the action potentials generated by the SA node from entering the ventricles 
directly.
58, 60
  Instead, the action potential enters through the AV node, a specialized region of 
pacemaker cells in the wall between the atria and ventricles.  The AV node conducts 
electrical impulses at 1/10
th
 the rate of the atrial cells and thus delays the conduction between 
the atria and ventricles, ensuring enough time for blood to exit the atria and fill the ventricles.  
However, once the action potential leaves the AV node, it spreads rapidly through the His-
Purkinje system (Figure 1) in a process known as rapid depolarization, ensuring the spread of 
Figure 1.  Electrical Conduction System of the Heart 
Adapted from http://en.wikipedia.org/wiki/Atrioventricular_node
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depolarization throughout the ventricles simultaneously.  From here, the action potential 
spreads to the remaining myocytes of the ventricles through cell-to-cell conduction, causing 
the ventricles to contract. 
Rapid ventricular depolarization (Phase 0) is followed by a much slower period of 
repolarization, which consists of four phases (Figure 2).  Phase 1 consists of a short, initial 
burst of repolarization which is then followed by a plateau phase (Phase 2), where there is 
minimal repolarization activity.  Finally, cells undergo rapid repolarization (Phase 3) and 
return to their resting state (Phase 4).  
 Progression through each of the five action potential phases is controlled by the 
movement of sodium, calcium, and potassium ions into and out of the cardiac cells.  Both 
pacemaker cells and non-pacemaker cells have multiple ion channels embedded in their 
membranes which control the movement of ions into and out of the cells.  In their resting 
Figure 2.  Action Potential of the Ventricular Cell 
and Associated Ion Conductances 
Adapted from Klabunde 2012
56 
Phase 0: Rapid depolarization; Phase 1: Initial 
repolarization; Phase 2: Plateau phase; Phase 3: 
Repolarization; Phase 4: Resting potential; gK
+
: 
Potassium conductance; gNa
+
: Sodium conductance; 
gCa
++
: Calcium conductance 
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state, cardiac cells have a negative electrical potential relative to the outside of the cell.
58, 60
  
The net negative electrical potential is produced through a combination of ion concentrations.  
K
+
 ions are present in higher concentrations inside the cell relative to outside while both Ca
++
 
and Na
+
 ions are present in higher concentrations outside the cell relative to inside.
60
  
Depolarization (Phase 0) occurs with the movement of Na
+
 into the cell.  Phase 1 of 
repolarization is caused by the movement of K
+
 ions out of the cell and is then slowed (Phase 
2) by the continued, slow movement of Ca
++
 into the cell.  Phase 3 is brought about by the 
end of inward Ca
++
 movement and the continued outward movement of K
+
.  Resting potential 
(Phase 4) is maintained through the movement of K
+
 ions back into the cell.  The ion 
gradients needed to control the electrical impulses of the heart are controlled by a series of 
ion channels. 
A.1. Sodium Channels 
Table 2.  Cardiac Ion Channels 
Channels Gating Characteristics 
Sodium 
     Fast Na
+
 Voltage Phase 0 of myocytes 
     Slow Na
+
 Voltage/Receptor Contributes to Phase 4 pacemaker current in SA and AV 
nodal cells 
Calcium 
     L-type Voltage Slow inward, long-lasting current; Phase 2 of myocytes 
and phases 4 and 0 of SA and AV nodal cells 
     T-type Voltage Transient current; contributes to Phase 4 pacemaker 
current in SA and AV nodal cells 
Potassium 
     Inward rectifier Voltage Maintains negative potential in Phase 4; Closes with 
Depolarization 
     Transient outward Voltage Contributes to Phase 1 in myocytes 
     Delayed rectifier Voltage Phase 3 repolarization 
     ATP-sensitive Receptor Inhibited by ATP; opens when ATP decreases during 
cellular hypoxia 
     Acetylcholine activated Receptor Activated by acetylcholine and adenosine; Gi-protein 
coupled; Slows SA nodal firing 
     Calcium activated Receptor Activated by high cytosolic calcium; Accelerates 
repolarization 
Adapted from Klabunde 2012
60 
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Sodium channels are the most common ion channels found in cardiac cells, with over 
100,000 sodium channels expressed in each cardiac cell and over 1 million expressed in cells 
of the Purkinje fibers.
61
  Two types of sodium channels are critical to regulating the electrical 
activity of the heart: fast acting and slow acting (Table 2).  Fast acting sodium channels are 
responsible for the rapid depolarization of the myocyte.  The activation gates are opened 
when the depolarization current spreads from cell to cell, which increases the conductance of 
Na
+
 across the cell membrane (Figure 2).  This allows Na
+
 to move into the cell but the 
channels close rapidly, limiting the length of time in which sodium can enter the cell.
60
  Slow 
acting sodium channels play a minor role in myocytes but are involved in the spontaneous 
depolarization of cardiac pacemaker cells where the slow inward movement of Na
+
 is partly 
responsible for the spontaneous depolarizing current, or pacemaker current, which 
differentiates pacemaker cells from myocytes.
60
 
 Sodium channels are expressed in virtually all eukaryotic organisms; Ren et al. 
identified a primitive counterpart to the eukaryotic sodium channel which is expressed in 
prokaryotes,
61, 62
 and the genes encoding sodium channel genes are highly conserved across 
organisms.
61
  The primary gene involved in the cardiac isoform of the sodium channels is 
SCN5A.
61, 63
  However, many additional genes are involved in the encoding of human sodium 
channels in the heart, including many from the sodium channel (SC) family of genes such as 
SCN10A, SCN4B, SCN1B, SCN2B, SCN3B, and SNC4B.
64-66
  Mutations in the genes 
encoding the primary cardiac isoforms have been implicated in rare familial cardiac 
conduction disorders (See Section QT Interval Genetics). 
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A.2. Calcium Channels 
Similarly to sodium channels, there are two types of calcium channels influencing 
cardiac conduction: L-type and T-type (Table 2).
60
  However, the average myocyte has 
approximately 1/5
th
  as many calcium channels as sodium channels.
61
  Despite the smaller 
number, calcium channels play a critical role in cardiac electrophysiology.  After 
depolarization, L-type calcium channels continue to allow Ca
++
 to flow into the myocyte.  
Unlike the fast acting sodium channels which cause depolarization, L-type calcium channels 
remain open for a longer period of time and are the primary cause of the plateau phase (Phase 
2 in Figure 2).
60
  T-type calcium channels are, similarly to slow acting sodium channels, 
primarily involved in the spontaneous depolarization of pacemaker cells and play little role in 
the action potential of general myocytes. 
Calcium channel genes are highly conserved across vertebrates.
64
  There are at least 
ten calcium channel genes in the human genome but only half are expressed in cardiac cells.  
Calcium channel genes belong to the CACN gene family and include CACNA1C, CACNA1D, 
CACNA1E, CACNA1G, and CACNA1H.
61
  The first three CACN genes encode isoforms of 
the L-type channel while the latter two encode isoforms of the T-type channel.  Of the three 
L-type calcium channel genes, CACNA1C produces the primary isoform found in cardiac 
cells.
61
     
A.3. Potassium Channels 
Unlike sodium and calcium channels which both have two main subtypes, potassium 
channels have six main subtypes (Table 2) and transient outward channels and delayed 
rectifier channels can be further broken down into subclasses based on their speed of action 
(Table 3).  Transient outward K
+
 channels are responsible for initial repolarization (Phase 1 
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in Figure 2) while delayed rectifier K
+
 channels are responsible for the increase in K
+
 
conductance that causes Phase 3 repolarization.
60
  Inward rectifiers are involved in the last 
phases of repolarization and in setting the resting potential (Phase 4).
61
 
Given the wide range of potassium channel subtypes, it is therefore unsurprising to find 
a wide variety of genes encode potassium channel subunits.  These genes are highly 
conserved across eukaryotes and comprise the KCN gene family.
66, 67
  The KCN gene family 
is composed of over 90 genes but only a subset are expressed in the heart.
65
  In addition to 
the genes which encode alpha subunits of the numerous cardiac potassium channels (Table 
3), multiple accessory subunits are also expressed in cardiac cells: KCNIP2, KCNAB1, 
KCNAB2, KCNE2, and KCNE1.
61
  Mutations in genes in the KCN family have been linked to 
inherited forms of Long QT Syndrome (LQTS), a Mendelian disorder with an increased 
duration of ventricular repolarization, and with the overall duration of ventricular 
repolarization (See Section QT Interval Genetics).  
Table 3.  Alpha Subunits of Cardiac Potassium Channels 
Current Description Gene(s) 
Action 
Potential 
Phase Activation Mechanism 
Ito,f Transient Outward Current 
(Fast) 
KCND2, KCND3 Phase 1 Voltage (depolarization) 
Ito,s Transient Outward Current 
(Slow) 
KCNA4, KCNA7, 
KCNC4 
Phase 1 Voltage (depolarization) 
IKur Ultra-Rapid Delayed Rectifier KCNA5, KCNC1 Phase 2 Voltage (depolarization) 
IKr Rapid Delayed Rectifier KCNH2 Phase 3 Voltage (depolarization) 
IKs Slow Delayed Rectifier KCNQ1 Phase 3 Voltage (depolarization) 
IK1 Inward Rectifier (Strong) KCNJ2, KCNJ12 Phase 3, 
Phase 4 
Voltage (depolarization) 
IKATP ADP Activated KCNJ11 Phase 1, 
Phase 2 
↑ADP/ATP Ratio (ATP 
depletion) 
IKACh M2 Receptor Gated K
+
 
Channel 
KCNJ3, KCNJ5 Phase 4 Acetylcholine 
IKp Background K
+
 Channels KCNK1/6, 
KCNK3, KCNK4 
All Phases Metabolic parameters, 
Membrane stretch 
Ih Pacemaker Channel
 
HCN2, HCN4 Phase 4 Voltage 
(hyperpolarization) 
Adapted from Zipes 2004
61 
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B. Ventricular Conduction on the Electrocardiogram 
In 1887,  a French scientist by the name of Gabriel Lippmann first demonstrated that 
the electrical impulses of the heart could be recorded from the body’s surface.59  Fifteen 
years later, Dutch physiologist Willem Einthoven published the first modern tracings from a 
surface electrocardiogram (ECG).
59
  He identified five distinct points on the ECG rhythm, 
which he labeled P, Q, R, S, and T, nomenclature which is still used over a century later to 
describe points on the ECG (Figure 3).    The P wave is produced as a depolarization wave is 
sent from the SA node and spreads through the atria.  The break between the P wave and the 
Q point corresponds to the slowing of the depolarization wave as it enters the AV node.  As 
depolarization is rapidly spread through the ventricles, the QRS complex (QRS) is produced 
(Figure 4).
68
  This is then followed by another break, which represents the plateau phase of 
repolarization.  The final wave on the ECG, the T wave, represents the rapid phase of 
repolarization (Figure 4).
58, 68
  Together, these points produce a number of commonly studied 
intervals (Figure 3).  The PR interval (PR) represents the period of atrial depolarization and 
AV nodal conduction, including the propagation of the impulse through the bundle of His, 
the bundle branches, and the Purkinje fibers.
69
  The QT interval (QT) is a measure of the 
ventricular action potential and can be broken down into the QRS complex (QRS, ventricular 
depolarization) and the JT interval (JT, ventricular repolarization).
60, 69
      
B.1. QT Interval 
The QT interval, the subject of this dissertation, is a measure of both ventricular 
depolarization and repolarization.  It is measured from the onset of the QRS complex to the 
end of the T wave. In a standard 12-lead ECG, with 3 standard limb leads, 3 augmented limb 
leads, and 6 precordial chest leads, QT can vary between leads, a phenomenon called QT 
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dispersion.  To standardize measurement, QT is measured from the lead that has the largest T 
wave with the most distinct termination.
69
  The latter feature is particularly important, as the 
T wave can sometimes be difficult to define and can be influenced with by the presence of a 
U wave.
68, 70
  The U wave is a small wave sometimes seen on the ECG following the T wave; 
its origins are unknown but it is believed to represent repolarization of the Purkinje fibers or 
the prolonged repolarization of cells in the mid-myocardium.
71
   
 Despite the potential introduction of measurement error through lead placement or 
external environmental factors, repeatability studies have found that QT measurements are 
reliable.
72-74
  Savelieva et al. found that, over the course of 10 consecutive ECGs, QT interval 
measurement demonstrated a modest 1-2% coefficient of variation, or the ratio of the 
standard deviation to the mean, among the general population, among a population of 
myocardial infarction (MI) patients, and among patients with hypertrophic cardiomyopathy.
73
  
Similarly, Vaidean et al. found that the interclass correlation coefficient (ICC), which is the 
Figure 3.  ECG Rhythm with Labeled Intervals 
Adapted from http://en.wikipedia.org/wiki/QT interval
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ratio of between-person variance to the total variance in the study, for QT was 0.86 (95% 
Confidence Interval [CI]: 0.81 – 0.92),74 suggesting low within-person variance in QT.  
Furthermore, Vaidean and colleagues demonstrated that, as the total sample size increases, 
the precision of the mean QT measurement for a group of study participants increases 
significantly, allowing studies with large sample sizes to reliably study QT and QT 
correlates.
74
 
Heart Rate Correction Formulas for QT Interval 
Table 4.  Heart Rate Correction Formulae for QT Interval 
Formula Mathematical Form 
Bazett
75
 𝑄𝑇𝑐 =
𝑄𝑇
√𝑅𝑅
 
Fridericia
76
 𝑄𝑇𝑐 =
𝑄𝑇
√𝑅𝑅
3  
Hodges
77
 𝑄𝑇𝑐 = 𝑄𝑇 + 1.75(𝐻𝑒𝑎𝑟𝑡 𝑅𝑎𝑡𝑒 − 60) 
Framingham
78
 𝑄𝑇𝑐 = 𝑄𝑇 + 0.154(1 − 𝑅𝑅) 
Normogram
79
 𝑄𝑇𝑐 = 𝑄𝑇 + 𝐶𝑜𝑟𝑟𝑒𝑐𝑡𝑖𝑜𝑛 𝐹𝑎𝑐𝑡𝑜𝑟 
Adapted from Aytemir 1999
80 
QT: Uncorrected QT interval; QTc: Corrected QT interval; RR: RR interval 
Normal QT intervals range from 200 to 400 ms.
60
  However, despite the overall 
reliability of QT measurements, inter-individual variation remains high, largely reflecting the 
Figure 4.  Action Potential of the Ventricle Cell and 
Corresponding Surface ECG Components 
Adapted from Bednar 200168 
Phase 0: Rapid depolarization; Phase 1: Initial repolarization; 
Phase 2: Plateau phase; Phase 3: Repolarization; Phase 4: 
Resting potential 
 16 
influence of heart rate.  QT is expected to be prolonged at slower heart rates and shortened at 
faster heart rates.
38, 75, 81, 82
  This range can be extreme.  Data from the Framingham Heart 
Study (FHS) have shown that in men, QT can range from 450 ms at 40 beats per minute 
(bpm) to 300 ms at 120 bpm, and in women, QT can range from 465 ms at 40 bpm to 310 ms 
at 120 bpm.
69, 78
  Because of the large influence of heart rate, studies of QT commonly 
account for heart rate in their analysis, either through simple adjustment or through the use of 
one of the numerous correction formulae available in the literature.  After adjustment, 
corrected QT (QTc) is expected to be no greater than 440 ms and QTc greater than 500 ms is 
considered critically prolonged.
38, 60
  One of the most commonly used correction formula is 
Bazett’s formula.38, 75  However, Bazett’s correction can be inaccurate at elevated heart 
rates.
38
 
Because of the potential for inaccuracy when using Bazett’s formula, numerous 
alternatives have been suggested.  Fridericia, a contemporary of Bazett’s, suggested using the 
cubed root of the RR interval (RR), an inverse measure of heart rate, rather than the squared 
root.
76
  In 1936, Shipley and Hallaran modified Bazett’s formula to 𝑄𝑇𝑐 = 𝑘√𝑅𝑅 where k is 
0.397 in men and 0.415 in women.
69, 83
  Despite these alternatives, many researchers have 
remained skeptical of the accuracy of the existing formulas and multiple additional formulas 
have been proposed (Table 4).
80
  In 1992, the FHS offered a new method to correct for heart 
rate based on a large population based cohort.
78
  The normogram formula attempted to 
develop a heart rate correction formula that had a correction factor that varied by heart rate, 
making it more accurate at the extreme heart rates and allowing it to vary by population.  
Rautaharju et al.  have also proposed the QT prolongation index (QTI), which is calculated 
as a proportion of the limiting value of QT when heart rate approaches zero (QTmax): 
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𝑄𝑇𝐼 =
𝑄𝑇 × (𝐻𝑒𝑎𝑟𝑡 𝑅𝑎𝑡𝑒 + 100)
𝑄𝑇𝑚𝑎𝑥
 
where QTmax = 656 ms; because this is a proportion, the mean value is 100 and the upper 2% 
of prolonged QT have a value greater than 110, making it difficult to compare to other 
studies which used one of the standard correction formulae.
84, 85
  However even with the 
wide variety of correction formulae available, there is still no consensus on the preferred 
approach, but the suggestion has been made that it is may be necessary for each individual 
study to investigate which correction model best fits their data.
80, 86, 87
 
B.2. QRS Complex 
The QRS complex, sometimes referred to the QRS interval, is a measure of 
ventricular depolarization (Figure 3, Figure 4).  It also measures an early component of 
ventricular repolarization (Phase 1).
88
  Its duration is controlled by the His-Purkinje system, 
composed of the His bundle, the left and right bundle branches, and the Purkinje fibers 
(Figure 1).  The His-Purkinje system ensures the spread of the depolarization impulse from 
the AV node through both ventricles simultaneously.  It is also during the QRS that atrial 
repolarization occurs but, due to its short duration and small amplitude, this process is 
masked by ventricular repolarization on the surface ECG.
60
  QRS is measured on the lead 
with the widest QRS complex with the sharpest onset and termination, usually one of the six 
precordial chest leads.
69
  Because QRS includes an early phase of repolarization, the 
transition from the QRS complex to the ST segment can be gradual making it hard to define 
the J point (Figure 4).  Further complicating the definition of the QRS complex is the Q 
wave, which is often absent on ECGs.
58
 
When the Q wave is present, its duration is used in the diagnosis of MI.  A widened Q 
wave on limb leads I, II, aVL, or aVF is indicative of an MI.  However, use of limb lead III or 
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aVR can lead to a false diagnosis, as the Q wave is typically wider on these leads.
69
  
Widening of the whole QRS complex can also be indicative of malfunctions of the cardiac 
conduction system, e.g. bundle branch blocks.  The QRS is typically wider in young 
populations,
89
 in males,
90, 91
 and in Whites.
92
  Widening of the interval is also seen in 
hyperkalemic populations,
93-95
 in obese populations,
96
 in populations using certain anti-
arrhythmic medications
93, 97, 98
 and in populations on hemodialysis.
99
  A normal QRS 
duration is between 60 and 100 ms, with about half of the general population falling near 80 
ms,
60, 69
 although a QRS duration of as high as 110 ms is not considered abnormal.
69
  
However, a QRS greater than 120 ms is a very specific marker of ventricular dysfunction.
100, 
101
  
B.3. JT Interval 
 The JT interval is a measure of ventricular repolarization and is composed of the ST 
segment and the T wave.  The ST segment represents the plateau phase of repolarization 
while the T wave represents phase 3 repolarization.
58
  JT is generally calculated as 𝐽𝑇 =
𝑄𝑇 − 𝑄𝑅𝑆 rather than measured directly from the surface ECG.  JT is highly correlated with 
QT but, unlike QT and QRS, JT has not been as commonly studied.
28
  However, it has been 
suggested that, JT is better than QT for monitoring increased risks due to prolongation of 
ventricular repolarization, as JT represents the repolarization phase of QT and it is this phase 
which is predicted to be most clinically relevant.
102
  Tsai et al. have demonstrated that JT is a 
better marker of changes in repolarization duration when monitoring patients on 
antiarrhythmic drug therapy, a common cause of prolonged QT (See Section Drug-Induced 
QT Prolongation).
103
  Additionally, JT is a better marker than QT when studying conditions 
with a wide QRS.
104
  For example, prolonged QT is considered a risk factor for coronary 
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heart disease (CHD) (See Section Coronary Heart Disease); however, Crow et al. found that 
JT was actually a better predictor of CHD mortality than QT in cases where a wide QRS was 
present.
105
  These findings indicate that studies of JT are informative in addition to studies of 
QT and QRS.     
QT Interval Prolongation 
 
QT ranges from 200-400 ms in the general population; after adjustment for heart rate, 
the distribution of QT shifts upward so that intervals up to 440 ms are considered normal.  
QT is normally distributed and is shifted upwards in females and in older populations (Figure 
5).
75, 106, 107
  However, malfunction of the ion channels associated with the cardiac conduction 
system and disruptions in the action potential of the heart, both achieved through multiple 
mechanisms, can lead to a shortening or lengthening of the QT interval beyond the normal 
range.  While short QT syndrome can be pathogenic, it is exceedingly rare and is primarily 
congenital.
108, 109
  QT prolongation, however, is more prevalent in the population and can be 
caused by many common innate and acquired risk factors.   
Adapted from Benoit 2005
106
 
Data from the Third National Health and Nutrition Evaluation Survey, 1988 – 1994 
QTc corrected for heart rate using the Fridericia formula  
 
B A 
Figure 5. QTc Distribution in the U.S. Population by Age and Sex 
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C. Risk Factors 
QT prolongation can occur through multiple mechanisms and numerous risk factors for 
prolonged QT have been identified.  Broadly, risk factors for prolonged QT can be classified 
into three categories: clinical conditions, congenital conditions, and electrolyte imbalances. 
C.1. Acquired Clinical Conditions 
Table 5.  Acquired Clinical Causes of QT Prolongation 
Myocardial Infarction 
Valvular Disease* 
Cardiomyopathy* 
Bradycardia 
Subclinical Cardiovascular Disease 
Liver Function Impairment 
Diabetes Mellitus 
Hypothyroidism 
Obesity 
Anorexia 
Use of QT-Prolonging Medications 
*Can be either acquired or congenital 
 Numerous clinical conditions have been identified as risk factors for QT 
prolongation (Table 5).  Multiple diseases of the heart can interfere with normal cardiac 
conduction, including myocardial infarction,
69, 110, 111
 structural heart disease (e.g. valvular 
disease, cardiomyopathy),
65, 108
 and bradycardia (slow heart rate),
112, 113
 all of which can lead 
to QT prolongation.  Furthermore, some research has suggested that QT prolongation could 
serve as a marker of subclinical CVD
114, 115
   
 
Non-cardiac diseases also confer a risk of QT prolongation.  QT prolongation is 
present in populations with cirrhosis of the liver,
116-118
 with diabetes,
119
 and with 
hypothyroidism.
120, 121
   Liver disease has been shown to confer a 3-4 fold increase in the risk 
of QT prolongation associated with liver disease.
122
  Based on NHANES data, diabetes 
confers a 1.6-fold increase in risk (95% CI: 1.1-2.3) of prolonged QT,
123
 and hypothyroidism 
could increase the risk of QT prolongation by over 2-fold.
106
  Additionally, studies have 
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found between 20-30% of obese individuals have a prolonged QT,
124-126
 which suggests that, 
given the high prevalence of obesity in the U.S. (~35% of adults), obesity may be one of the 
most common causes of prolonged QT.
69, 127
  On the opposite end of the weight spectrum, 
QT prolongation is also more common in cases of anorexia nervosa than in the general 
population.
128-130
  Finally, many prescription medications can cause QT prolongation (See 
Section Drug-Induced QT Prolongation).
39
    
C.2. Congenital Conditions 
Several congenital conditions have been associated with a prolonged QT, including 
the congenital versions of several structural heart diseases including valvular disease and 
cardiomyopathy, which manifest similarly to their acquired counterparts.
110, 111
  QT 
prolongation also has a strong genetic component.
24, 25, 33, 131
  Congenital LQTS was first 
described in 1957 by Anton Jervell and Fred Lange-Nielsen.
132
    There are two predominant 
forms, Jervell and Lang-Nielsen syndrome and Romano-Ward syndrome, named after the 
researchers who first described the two subtypes.
59
  These conditions are caused by mutations 
in the genes encoding the Na
+
, K
+
, and Ca
++
 ion channel expressed in the heart.
69
  For greater 
detail on the genetics of the QT interval, see Section QT Interval Genetics. 
C.3. Electrolyte Imbalances 
Electrolyte imbalances are a common cause of QT prolongation, second only to drug-
induced LQTS (diLQTS).
133
  In fact, it has been suggested that electrolyte imbalances may 
be responsible for the underlying mechanism of the associations seen with several clinical 
conditions discussed above, such as anorexia and diabetes.
134, 135
  The three most common 
electrolyte imbalances associated with QT prolongation are hypokalemia, hypocalcemia, and 
hypomagnesemia, three disorders which represent decreased levels of potassium, calcium, 
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and magnesium, respectively, in the blood.
111
  Linkages between electrolytes and QT were 
first documented in case reports in the late twentieth century.
136-138
  Subsequently, Zeltser 
and colleagues found that hypokalemia was present in 28% of a population of 249 patients 
who developed a highly fatal ventricular arrhythmia associated with prolonged QT, torsades 
de pointes (TdP).
139
  The prevalence of hypokalemia in Zeltser’s study was significantly 
higher than that seen in the general U.S. populations according to the NHANES study 
(3%).
140
  Larger, population-based studies have shown that the risk of developing prolonged 
QT increases between 2 and 4-fold in the presence of hypokalemia, although it is unclear if 
this association is the same in both men and women.
106, 122
  Additional evidence of the role of 
electrolyte imbalances in the role of QT prolongation was provided by Hoshino and 
colleagues, who showed that treatment with magnesium sulfate was successful in the 
treatment of TdP associated with prolonged QT in the presence of hypomagnesemia.
141
  A 
study by Benoit et al. in the NHANES III population with over 4,000 men and 4,000 women, 
suggested that hypocalcemia conferred an increased risk of QT prolongation (OR=6.12 [95% 
CI: 1.03-36.53]).
106
  However, given the imprecision of the results, further work is needed to 
confirm this association.  One possible avenue to investigate is the effect of electrolyte 
imbalances on mean QT, rather on QT prolongation.  However, few studies to date have 
examined the association any QT risk factors other than genetics with mean QT.  The role of 
electrolyte imbalances in QT prolongation is unsurprising; these electrolyte imbalances can 
impair the function of the ion channels which are responsible for the electrical conduction of 
the heart, especially the Ikr current, which plays a critical role in ventricular repolarization 
(Table 3).
134, 142
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D. Drug-Induced QT Prolongation 
The most common cause of acquired LQTS is the use of prescription drugs.
133
  In 
1964, Seizer and Wray first identified drug-induced Long QT Syndrome in patients using the 
antiarrhythmic quinidine.
143, 144
  Drug-induced QT prolongation was the most common cause 
for medications to withdrawn from the market after approval by the U.S. Food and Drug 
Administration (FDA) over the past decade.
39, 145
  FDA guidelines begin regulating 
medications after an increase in QT duration of just 5 ms, a modest change in the overall 
length of the QT interval relative to the mean.
44
  As the use of prescription drugs continues to 
rise
1
 and the number of QT prolonging medications identified continues to grow,
146, 147
 the 
importance of understanding the mechanisms of diLQTS will remain critical. 
D.1. QT-Prolonging Medications 
The University of Arizona’s Center for Education and Research on Therapeutics 
(UAZ-CERT) maintains a database of all medications reported to prolong the QT interval.
146
  
This database currently includes over 170 medications, most of which are still available in 
the U.S. market.  Of these 170 medications, 107 are known to prolong QT, 36 prolong QT 
under specific conditions, and a further 28 should be avoided by those with congenital 
LQTS.
146
  Of medications which prolong QT beyond FDA guidelines, there is a broad range 
of prolongation.  A recent study by Iribarren et al. found that aripirazole, an antipsychotic, 
prolonged QT by 7.6 ms while amiodarone, an antiarrhythmic , prolonged QT by 25.2 ms.
148
  
Cardiac Medications 
Numerous medications used to treat CVD can result in QT prolongation (Table 6).  
Unsurprisingly, many additional anti-arrhythmic medications have also been found to 
prolong QT, as these medications interfere directly with the ion channels of the heart.
69
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Table 6.  List of Cardiac Medications by Category That Prolong the QT Interval 
Anti-anginal Antiarrhythmic Antihypertensive Diuretics Vasodilators 
Bepridil Amiodarone Isradipine Furosemide Anagrelide 
Ivabradine Disopyramide Moexipril Hydrochlorothiazide Vardenafil 
Ranolazine Dofetilide Nicardipine Indapamide  
 Dronedarone    
 Flecainide    
 Ibutilide    
 Procainamide    
 Quinidine    
 Sotalol    
List obtained from UAZ-CERT crediblemeds.org on November 17, 2014
146 
 
 Class 1A antiarrhythmics (disopyramide, procainamide, quinidine) are also known to 
prolong the QRS interval and JT intervals when examined separately, while class III 
antiarrhythmics (amiodarone, dofetilide, ibutilide, sotalol) prolong only the JT interval of 
QT; conversely, class 1C antiarrhythmics (flecainide, trycyclic anti-depressants) are known 
to prolong QRS but not JT.
69
  In addition to antiarrhythmics, anti-anginals, antihypertensives, 
diuretics, and vasodilators are also known to prolong QT.  Of particular interest, 
hydrochlorothiazide is included in the UAZ-CERT database as a conditional QT prolonging 
agent but is still a commonly used anti-hypertensive.   
Additionally, Iribarren and colleagues found that indapamide, a thiazide-like diuretic, 
prolonged QT by an average of 9.4 ms and by more than 20 ms in 43% of participants.
148
 For 
greater detail on hydrochlorothiazide and other thiazide and thiazide-like diuretics, the 
subject of this proposal, see Section Thiazide Diuretics. 
Non-Cardiac Medications 
In addition to cardiac medications, there are many medications that are not designed 
for CVD treatment which also have a risk of QT prolongation.  In fact, more than 120 of the 
drugs listed on the UAZ-CERT QT prolonging drug list are not primarily designed to CVD 
(Table 7).
146
  These medications cover a broad range of therapeutic classes, including
  
2
5
 
Table 7.  List of Non-Cardiac Medications by Category That Prolong the QT Interval 
Antibiotic Anti-cancer Anticonvulsant Antidepressant Antifungal Antihistamine 
Azithromycin Tamoxifen Felbamate Trazodone Fluconazole Astemizole 
Ciprofloxacin Lapatinib Fosphenytoin Venlafaxine Itraconazole Terfenadine 
Clarithromycin Arsenic trioxide  Citalopram Ketoconazole Diphenhydra-mine 
Gatifloxacin Antimalarial Fluoxetine Posaconazole 
Grepafloxacin Nilotinib Dihydroartemisinin+ 
Piperaquine 
Paroxetine Voriconazole Anti-nausea 
Gemifloxacin Vorinostat Sertraline  Domperidone 
Grepafloxacin Dabrafenib Chloroquine Escitalopram Antipsychotic Dolasetron 
Levofloxacin Eribulin Halofantrine Amoxapine Pipamperone Granisetron 
Moxifloxacin Sunitinib Quinine sulfate Mirtazapine Mesoridazine  
Norfloxacin Vandetanib  Amitriptyline Thioridazine Anti-viral 
Ofloxacin  Kinase Inhibitor Clomipramine Haloperidol Amantadine 
Roxithromycin Muscle Relaxant Crizotinib Desipramine Pimozide Telaprevir 
Sparfloxacin Vemurafenib Doxepin Droperidol Atazanavir 
Telavancin Tolterodine Pazopanib Imipramine Promethazine Foscarnet 
Trimethoprim-
Sulfamethoxazole 
Tizanidine Sorafenib Nortriptyline Chlorpromazine Nelfinavir 
Solifenacin Bosutinib Protriptyline Sertindole Rilpivirine 
Erythromycin  Dasatinib Trimipramine Amisulpride Ritonavir 
Pentamidine Opiate   Aripiprazole Saquinavir 
Metronidazole Levomethadyl Miscellaneous Clozapine  
Bedaquiline Methadone Famotidine Sevoflurane Iloperidone Sedative 
  Tacrolimus Ondansetron Paliperidone Dexmedeto-mide 
  Cocaine Probucol Quetiapine 
  Tetrabenazine Lithium Risperidone Chloral hydrate 
  Oxytocin Mirabegron Sulpiride  
  Mifepristone Galantamine Ziprasidone  
  Bortezomib Apomorphine Olanzapine  
  Pantoprazole Toremifene   
  Pasireotide Cisapride   
  Fingolimod    
List obtained from UAZ-CERT crediblemeds.org on November 17, 2014
146 
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antibiotics and antivirals, cancer treatments, antidepressants and antipsychotics, sedatives, 
and pain medications, in addition to numerous others.  However, identifying non-cardiac 
medications is particularly difficult because the risk of QT prolongation is rarely identified in 
clinical trials but is rather identified after the medications have been approved, marketed to 
the public, and commonly used, sometimes after many years.
149
  For example, in a large, 
population based study based in the Netherlands, van Noord et al. studied antipsychotics and 
anti-depressants, two classes of medication which are commonly found to prolong QT.  In 
the study, the antipsychotic thioridazine was found to prolong QT 28.3 ms (95% C.I.: 5.9-
50.8) compared with nonusers.
150
  A further six medications which significantly prolonged 
QT were found to increase QT by more than the minimum FDA guidelines (5 ms): lithium 
(10.1 ms), olanzapine (22.9 ms), amitriptyline (5.1 ms), maprotiline (9.6 ms), imipralnine 
(12.8 ms), and nortriptyline (23.3 ms).
150
  Furthermore, when Iribarren et al. examined 90 
medications that had been reported to prolong QT in a population-based cohort (N=59,531), 
they found 78 (87%) significantly prolonged QT and of these 78 medications, 63 were non-
cardiac medications.
148
   
D.2.  Prevalence of QT-Prolonging Medication Use 
Despite the rising awareness in both clinical and research settings, the use of QT 
prolonging drugs continues to be a concern.  In a study of 2 million members of health 
maintenance organizations (HMOs) over a two and a half year period, over 180,000 members 
filled a prescription for a high-risk QT prolonging medication.
151
  Among patients who were 
admitted to a hospital in Switzerland over a 3 month period who had prolonged QT at 
admission, defined as QTc ≥ 450 ms in men and 460 ms in women, half were subsequently 
administered a known QT prolonging medication.
122
  Similarly, in a study of admissions to a 
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cardiac care unit, a third of patients who had prolonged QT at admission were later 
administered a QT prolonging medication and 42% of those who had a QTc ≥ 500 ms 
(extreme prolongation) were administered a QT prolonging agent.
152
  These findings indicate 
that diLQTS remains a prominent concern and more work is needed to prevent diLQTS, 
either through the development of new medications that do not prolong QT or through the 
identification of those most at risk for QT prolongation in order to better prescribe QT 
prolonging medications and avoid potential adverse reactions. 
D.3. Clinical Considerations 
 The continued use of QT prolonging medications despite the risk of severe negative 
outcomes has been widely acknowledged by the medical community.
151, 152
  Physicians must 
weigh the risks and benefits of the use of such medications.  In cases where effective 
alternative treatments are available, the risks of using a QT prolonging agent would outweigh 
the benefits.
39
  Also, in cases where multiple risk factors for prolonged QT are present, 
adding a QT prolonging medication presents particular concern.
38
  However, in cases where 
an effective alternative treatment is not available, such as with the use of arsenic trioxide to 
treat a relapse of promyelocytic leukemia, then these medications can and should be used.
39
  
But in these cases, it is critical to monitor patients.  While some clinicians do not consider 
regular ECGs, both before and after subscribing a QT prolonging agent, cost effective, as for 
many of these drugs, a thousand patients would need to be assessed to identify a single 
person at risk, experts in QT pharmacology recommend that patients be screened by ECG 
prior to administering a QT prolonging medication.
38
  Continued, long term monitoring is 
also important, as Zeltser et al. found that, among published cases of torsades de pointes 
(TdP), an arrhythmia which results diLQTS, only 18% of patients developed TdP within 72 
 28 
hours of the onset of drug therapy, while 42% developed TdP between 3 and 30 days after 
the onset of therapy and 40% developed TdP more than a month after the onset of therapy.
139
  
It is critical that both researchers and clinicians continue to work to identify those at risk of 
QT prolongation and the mechanisms of this risk to better prescribe, monitor, and prevent 
diLQTS. 
D.4. Mechanisms 
Drug-induced LQTS is caused when prescription medications interfere with the 
normal action of the ion channels of the cardiac conduction system.  The ion channel most 
commonly disrupted is the rapid delayed rectifier K
+
 channel, or the IKr.  This channel, 
encoded by the KCNH2 gene, also known as the human ether-a-go-go related gene (HERG).  
The HERG channel is composed of six transmembrane subunits and it is on the sixth subunit 
that the two most important drug binding sites are located: Tyr652 and Phe656 (Figure 6).
143
  
Adapted from Ponte 2010
144
 
The fourth membrane’s planning unit (S4) contains positively 
charged residues and functions as the voltage sensor. 
The residues between S5 and S6 form the ion selective pore. 
Tyr652 (Tyr) and Phe656 (Phe), marked in the diagram, are the 
two most important drug binding sites 
Figure 6.  Schematic Representation of the HERG (KCNH2) 
Channel 
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When drugs bind to the tyrosine located at the 652
nd
 amino acid or phenylalanine at the 656
th
 
amino acid, they can reorient these amino acids, subsequently trapping the drug in the central 
cavity of the channel and preventing the conduction of K
+
 ions.
143, 153
  The blockage of the IKr 
current primarily affects the Purkinje fibers and the mid-myocardium (M cells).
143
  The M 
cells are particularly responsive to drug exposure.
154
  In addition to blockage of the HERG 
channel, M cells can prolong QT through pharmacologic interference of the slow delayed 
rectifier potassium channel, the sodium channels, and the sodium-calcium exchangers, which 
while less common than the disruption of the IKr, make the M cells a primary source in 
prolongation of Phase 2 and 3 of the action potential of the heart.
154
 
E. Categorical Versus Continuous Measures of QT Prolongation 
QT prolongation does not have a single, standard threshold.  When evaluating QT 
prolongation suing a threshold, a common cut-point is 450 ms in men and 460 ms in 
women,
20, 155-158
 a threshold which, according to the NHANES population, only 2% of men 
and 3% of women exceed.
159
  In clinical settings, the risk of adverse outcomes is believed to 
increase substantially at 500 ms.
39, 111
  Despite these commonly-used cutpoints, there is no 
clear threshold at which risks due to QT prolongation increase, and many studies of QT use 
alternate cut-points or study QT as a continuous outcome.  Another alternative is to study QT 
as a continuous variable and report results for a standard deviation of the population 
distribution.
160, 161
  However, reporting results for a standard deviation prevents 
generalization across populations and cannot be used in meta-analysis efforts, such as large 
genetics consortia.  Furthermore, it is conceivable that risk factors for QT prolongation may 
prolong QT a small amount and it is only through a combination of risk factors that higher 
levels of prolongation are achieved.  This is particularly true of the genetic component of QT 
duration (See Section QT Interval Genetics).  Thus, we have chosen to evaluate QT as a 
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continuous outcome in order to identify risk factors which have smaller although still 
important effects on QT. 
F. Potential Clinical Outcomes of Prolonged QT 
QT prolongation has been extensively studied.  QT prolongation was first described 
in association with sudden death in 1957 by Anton Jervell and Fred Lange-Nielsen, for 
whom the subtype of familial long QT syndrome (LQTS) which they described is named.
132
  
Torsades de pointes (TdP), the ventricular tachyarrhythmia commonly associated with 
prolonged QT, was also first described in the mid-20
th
 century (1966) by the French scientist 
Dessertenne.
162, 163
  Since then, prolonged QT has been identified as a risk factor for not just 
TdP but also numerous other clinical conditions, including coronary heart disease (CHD),
20
 
congestive heart failure (CHF),
164
 stroke,
165
 and both cardiovascular and all-cause 
mortality.
23
    
F.1. Arrhythmias 
Cardiac arrhythmias, or abnormal heart rhythms, are the most common cause of 
sudden cardiac death (SCD), which is defined as unexpected death which occurs within one 
hour of the onset of symptoms if the death is witnessed or within 24 hours of last being seen 
alive if the death was unwitnessed.
166
  SCD accounts for between 200,000 and 400,000 
deaths annually in the U.S. and for more than 60% of all cardiovascular deaths, the leading 
cause of the death in the U.S.
166-168
  TdP is the distinctive ventricular tachycardia, a rapid 
heart rhythm, associated with both congenital and acquired LQTS.
68, 163, 169
  TdP is thusly 
named because it is characterized by a twisting of the QRS peaks through the axis of the 
ECG (Figure 7).  Intermittent TdP often results in syncope (loss of consciousness) before 
reverting back to a normal rhythm while sustained TdP often devolves into ventricular 
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fibrillation and cardiac arrest, often leading to SCD.
19, 163
  SCD peaks both in elderly age and 
in infancy, the latter peak associated with sudden infant death syndrome (SIDS).
166, 167
  
Very little is known about the underlying epidemiology of TdP.  Drug-induced TdP is 
the most closely monitored form of TdP and is reported as an adverse drug reaction (ADR) to 
the World Health Organization’s (WHO) Drug Monitoring Centre.  For drug-induced TdP, 
there were 750 total cases reported from 1990 to 1999,
149
 a number likely to be an extreme 
underrepresentation, given the high level of underreporting found for ADRs (as high as 
95%).
170
   Further complicating the measurement of TdP prevalence are cases of syncope and 
SCD.  In both cases, patients usually present without ECG, making it unclear if TdP was the 
underlying cause.
171
        
It is also worth noting that both a widened QRS and a severely prolonged QTc were 
independent predictors of another arrhythmia, atrial fibrillation.
172
  In a study of 42,751 
participants, 1,050 of whom developed atrial fibrillation during the study period, QRS > 
110ms was associated with a hazard ratio (HR) of 1.9 (95% CI: 1.7-2.2) and QTc > 450 ms 
was associated with HR = 1.7 (95% CI: 1.5-2.0) of developing atrial fibrillation.
172
  Atrial 
fibrillation is the most common arrhythmia in the U.S., affecting an estimated 2.2 million 
Adapted from Yap and Camm 2003153 
Figure 7.  ECG Rhythm Strip in a Patient with Torsades de Pointes 
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people.
173
  It is highly associated with both stroke and mortality, accounting for 
approximately 75,000 strokes per year
174
 and a nearly 2-fold increase in the risk of death.
175
  
The association between QT prolongation and both TdP and atrial fibrillation, one a highly 
fatal arrhythmia, the other a highly prevalent arrhythmia, underscores the importance of 
studying QT prolongation and its risk factors. 
F.2. Coronary Heart Disease 
Coronary heart disease (CHD) is the clinical manifestation of the blockage of the 
arteries supplying blood to the myocardium, most often through atherosclerosis of the 
coronary arteries.  As of 2010, CHD affected an estimated 15.4 million Americans over the 
age of 20 and makes up more than half of all CVD events in men and women under age 75.
36
  
QTc prolongation is an established risk factor for CHD and CHD mortality.
20, 158, 176-180
  
Multiple studies have found that QTc prolongation, corrected using Bazett’s formula, is 
associated with CHD in both black and white men and women (Table 8).  Broadly, a 
prolonged QT has been found to have between a 1.5 and a 2-fold increase in the risk of 
developing incident CHD or CHD mortality.  Using data from the Atherosclerosis Risk in 
Communities (ARIC) study, Dekker and colleagues found that prolonged QTc imparted a 
greater risk of CHD in blacks than in whites when comparing the top 10% of the QTc 
distribution to the rest of the population (HR = 2.07 [95% CI: 1.24-3.46] and 1.39 [95%CI: 
1.00-1.92], respectively).
20
  Maebuchi et al. also conducted a study of prolonged QT and 
CHD in Japanese adults and reported that prolonged QTc, corrected using Bazett’s formula, 
was associated with incident CHD in Japanese men but not in women (HR = 4.50 [95% CI: 
2.18-9.27] and 0.99 [95% CI: 0.37-2.65], respectively) when comparing prolonged QTc,  
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Table 8.  Review of Four Studies of QT Prolongation and CHD Risk in Black and White Men and Women 
Author Year Study N % Male % Black Outcome 
Prolonged  
QT (ms) 
Reference 
QT (ms) 
HR 
(95% CI) 
Dekker
176 
1994 Zutphen 851 100 0 
CHD 
Mortality 
>420 <385 
4.4 
(1.2-16.4) 
Dekker
27 
2004 ARIC 14,548 43.4 27.0 Incident CHD 
Male: >440 
Female: >454 
<403 
2.34* 
(1.72-3.19) 
1.55**  
(1.08-2.23) 
Male: >450 
Female: >465 
Male: ≤450 
Female: ≤465 
2.14 * 
(1.71-2.69) 
1.51** 
 (1.15-1.89) 
Robbins
113 
2003 CHS 4,988 40.1 14.7 
CHD 
Mortality 
>450 ≤410 
1.6† 
(1.0-2.5) 
2.0†† 
(1.1-3.7) 
Schillaci
179 
2006 PIUMA 2,110 55 0 Incident CHD 
Male: >440 
Female: >450 
Male: ≤440 
Female: ≤450 
1.95 
(1.12-3.42) 
*Adjusted for age, gender, and race 
**Adjusted for age, gender, race, and CVD risk factors (heart rate, hypertension, systolic blood pressure, ECG abnormalities, body mass index, waist-hip 
ratio, cigarette smoking status, cigarette years, total cholesterol, HDL cholesterol, triglycerides, cardiac medications, diabetes, intima-media thickness 
†Hazard ratio among participants without CHD at baseline 
††Hazard ratio among participants with CHD at baseline 
ARIC: Atherosclerosis Risk in Communities; CHD: Coronary heart disease; CHS: Cardiovascular Health Study; CI: Confidence Interval; HR: Hazard ratio; 
N: Number of study participants; PIUMA: Progetto Ipertensione Umbria Monitoraggio Ambulatoriale 
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defined as QTc ≥ 440 ms to the referent category of QTc < 400 ms, although results were 
imprecise.
178
  This association has also been generalized to populations with other CHD risk 
factors (type II diabetes mellitus, hypertension, and chronic kidney disease [CKD]).
177, 179, 180
  
It has been hypothesized that the underlying mechanisms of this association may be irregular 
regulation of cardiac ion channels, leading to cardiac instability, a mechanism also believed 
to be the cause of QT-related arrhythmias.
179
 
F.3.  Chronic Heart Failure 
Congestive heart failure (CHF) is characterized by the impaired pumping function of 
the left ventricle, which results in the heart’s inability to meet the body’s cardiometabolic 
demands.  CHF is estimated to affect more than 5 million Americans over the age of 20 and 
is expected to increase in prevalence by 25% between 2013 and 2030.
36, 181
  Both prolonged 
QT and QRS have been associated with CHF.
21, 164, 177, 182
  Dhingra et al. found that, in an 
elderly population of 1,759 white men and women, extreme values of QRS (QRS ≥ 120 ms) 
conferred a significant increase in heart failure risk over normal QRS (QRS < 100 ms), with 
a HR of 1.74 (95% CI: 1.28-2.35).  Furthermore, intermediate levels of QRS prolongation 
(QRS 100-119 ms) had a HR for risk of heart failure of 1.43 (95% CI: 1.05-1.96) when 
compared to normal QRS.
182
  Similarly, studies have found that prolonged QT confers 
approximately a 2-fold risk of incident CHF.  In a study of 32,283 multiethnic participants in 
the Women’s Health Initiative (WHI), prolonged QT (QTc ≥ 437 ms corrected using the 
linear-scale model) conferred an HR of 1.80 (95% CI: 1.40-2.31) of incident heart failure 
compared to the rest of the population; this represented an additional 26 cases of incident 
CHF for every 10,000 women attributable to prolonged QT.
21
  A study of 13,555 participants 
from the ARIC study (57% female, 26% black) found that prolonged QT (QTc > 436 ms in 
 35 
men and 442 ms in women, corrected using the linear-scale model) resulted in a HR of 1.99 
(95% CI: 1.53-2.58) in men.
164
  It has also been shown that the risk of CHF associated with 
prolonged QT is higher in populations with decreased kidney function compared to 
populations with normal kidney function (HR=4.95 [95% CI: 1.99-12.34], HR=1.66 [95% 
CI: 1.08-2.58], respectively).
177
  It is speculated that both QT and QRS are markers of other 
underlying causes of CHF, such as structural heart defects or electrolyte abnormalities, rather 
than direct causes of CHF.   
F.4. Stroke 
Strokes are a cardiovascular event caused by the acute interruption of blood flow to 
one or more sections of the brain; there are two main types of stroke: ischemic (most 
common form) caused by the formation of a blood clot, and hemorrhagic caused by the 
buildup of blood in the brain or skull.  An estimated 6.8 million Americans over age 20 have 
suffered at least one stroke, with nearly 800,000 new and recurrent strokes occurring 
annually and over 125,000 annual deaths due to stroke.
36
  Several studies have found 
prolonged QT to be a predictor of incident stroke (both ischemic and hemorrhagic).  Early 
work by Goldstein suggested an association between QT and stroke, finding that 45% of 
acute stroke patients had a prolonged QT compared with only 12% of the control group, 
although the direction of the association was not clear.
183
  Cardoso  and colleagues expanded 
this work and examined a population of 471 participants with type II diabetes mellitus and 
found prolonged QT (QTc  ≥ 470 ms, corrected using Bazett’s formula), increased the risk of 
incident stroke 2.78-fold (95% CI: 1.33-5.81) and increased the risk of incident or recurrent 
stroke 2.63-fold (95% CI: 1.21-5.28).
22
  Soliman and colleagues further expanded this, 
examining a population of 27,411 participants in the REasons for Geographic and Racial 
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Differences in Stroke (REGARDS) study.  They found a prolonged QT (QTc ≥ 460 ms in 
women and 450 ms in men, corrected using the Framingham formula) was associated with a 
smaller increase in the risk of incident stroke (HR = 1.12 [95% CI: 1.03-1.21]) and that using 
a continuous measure of QT also produced associations as good as using the cut-points, 
suggesting that the use of specific thresholds may mask some associations.
165
  Sensitivity 
analysis found the same association for ischemic stroke as for both stroke types combined.
165
  
Similarly to the association between CHF and QT, researchers hypothesize that QT is 
actually marking subclinical atherosclerosis, which is responsible for the association between 
QT and stroke. 
F.5. Mortality 
CVD is the number one cause of death worldwide.
181
  The relationship between ECG 
traits and mortality has been extensively studied and both QT and QRS prolongation have 
been associated with CVD and all-cause mortality (Table 9).  This relationship generally falls 
around a 1.5-3-fold increase in the risk of death with a prolonged QT or QRS interval, 
although modest variation by heart rate correction method has been observed.
184, 185
  It is also 
unclear if there is a difference in associated risk in men versus women.
184, 186
  However, the 
relationship between QT, QRS, and mortality has been broadly studied and, while most 
studies have been conducted in white populations, some work has been done in blacks,
20, 158, 
177, 185
 Hispanics,
185
 and American Indians,
157
 suggesting that the association generalizes 
across race/ethnicities.  Finally, a recent meta-analysis of the extensive literature on the 
association between QT and mortality and found that prolonged QT was associated with a 
1.35-fold increase in risk (95% CI: 1.24-1.46) of all-cause mortality and a 1.51-fold increase 
in risk (95% CI: 1.29-1.78) of CVD mortality.  However, it is worth noting that, as is 
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evidenced in Table 9, there is no single definition for prolonged QT or for the reference 
category used by these studies and, as mentioned above in regards to stroke, the relationship 
is likely more continuous than indicated with the use of thresholds. 
QT Interval Genetics 
As described above, many genes are involved in the electrical conduction system of the 
heart.  These include the many genes in the gene families encoding the multitude of different 
ion channels involved in cardiac conduction (SCN, CACN, and KCN gene families) as well 
as numerous other genes or gene regions (loci) which have been implicated in cardiac 
conduction.  In many cases, the genes in addition to ion channels have been associated with 
measures of cardiac conduction but their function remains unknown.   
A. Heritability 
 The QT interval is heavily influenced by an individual’s genetic code.  Broadly, a 
trait’s heritability takes into account both Mendelian inheritance patterns (i.e. dominant, 
recessive, etc.) and the more complex modes of inheritance, most commonly represented as 
additive effects.  While it is difficult to measure a broad sense of heritability, population-
specific heritability (h
2
), estimated using only genetic effects which are additive, can be 
measured, which is interpreted as the proportion of the inter-individual variability of a 
particular phenotype, or trait, which is determined by genetics.  For QT, estimates indicate 
that between a quarter and a half of the phenotypic variation is explained by genetics, which 
represents a moderately strong genetic influence.
24, 26, 28, 131, 187-190
  Given the known forms of 
congenital LQTS which are caused by dominant, loss-of-function mutations and are therefore 
not accounted for in the above h
2
 estimates, it can therefore be expected that the actual broad 
heritability of QT is larger than 25-50%.   
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Table 9.  Review of 11 Studies of QT Prolongation and All-Cause or CVD Mortality Risk 
Author Year N Race 
Prolonged 
(ms) 
Reference 
(ms) 
Outcome 
(Mortality) 
HR 
(95% CI) 
Algra
191
 1991 6,693 White ≥440 <440 All-Cause 2.1 
(1.4-3.1) 
de Bruyne
184
 1999 5,241 White >446
a 
>437
b 
<418
a
 
<406
b
 
All-Cause 1.8 
(1.3-2.4) 
      CVD 1.7 
(1.0-2.7) 
Dekker
27 
2004 14,548 
 
27% Black 
73% White 
>454
a
 
>440
b 
<417
a
 
<403
b
 
All-Cause 2.28 
(1.73-3.00) 
      CVD 3.91 
(2.40-6.37) 
Elming
192
 1998 3,455 White ≥440 310-380 All-Cause 1.89 
(1.04-3.37) 
      CVD 3.31 
(1.04-9.91) 
Hage
155 
2010 280 White ≥460a 
≥450b 
<460
a
 
<450
b
 
All-Cause 1.008 
(1.001-1.014) 
Nilsson
193
 2006 433 White ≥430 <430 All-Cause 2.4 
(1.5-3.7) 
Noseworthy
156
  2012 6,895 White >470
a
 
>450
b 
≤470a 
≤450b 
All-Cause 1.21 
(0.88-1.66) 
      CVD 1.78 
(0.90-3.50) 
Okin
157 
2000 1,839 American 
Indian 
>460 ≤460 All-Cause 2.6 
(1.8-3.7) 
      CVD 2.3 
(1.2-4.6) 
Schillaci
179
  2006 2,110 White ≥450a 
≥440b 
<450
a
 
<440
b 
CVD 2.05 
(1.03-4.37) 
Sohaib
161
 2008 3,596 White 1 SD (26 ms)
c
 All-Cause 1.13 
(1.05-1.22) 
      CVD 1.17 
(1.05-1.31) 
Zhang
185
 2011 7,828 9% Black 
4% Hispanic 
87% White 
≥439 401-421 All-Cause 2.03 
(1.46-2.81) 
     CVD 2.55 
(1.59-4.09) 
CI: Confidence interval; CVD: Cardiovascular disease; HR: Hazard ratio; ms: millisecond; N: Number of 
participants; QT: QT interval; SD: Standard deviation 
a. In female populations 
b. In male populations 
c. Linear regression used with ECG variable as continuous variable; HR reported for a unit increase 
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Several studies have attempted to better understand the heritability of QT.  
Dalageorgou et al., who found the heritability of QT to be upwards of 50%; 16% of the 
estimated heritability was explained by genetic factors unique to QT, while the remainder 
was explained by genetic factors which were also associated with resting heart rate, a 
relationship which was also mimicked in the environmental determinants of QT (Figure 8).
187
  
Yang et al. determined the amount of the variance which was explained by common single 
nucleotide polymorphisms (SNPs) and found a lower heritability estimate for QT (h
2
 = 21%) 
using only common variants.
189
  They also evaluated heritability by chromosomes and found 
that the heritability estimates for QT explained by each chromosome were proportional to 
both the length of the individual chromosome and the length of the genes on the 
chromosome.
189
  Furthermore, Yang and colleagues found that a substantial portion of the 
21% heritability they found was explained by intergenic variants (7.5%), with the remainder 
Adapted from Dalageorgou 2008
190
 
LogHR refers to the logarithmic transformation of resting heart rate 
Figure 8.  Sources of Variance in QT Interval 
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explained by genic variants (13.5%).
189
    Researchers have also sought to understand the 
heritability of not just QT but also its component parts.  Two studies of twins found 
heritability estimates between 40-50% for QRS.
26, 190
  A more recent study by Newton-Cheh 
et al. found the heritability of JT to be 25%.
28
  Combined, these findings suggest that QT and 
its component parts are strong candidates for genetic study and that researchers are likely to 
find genetic variants influencing QT in both the coding and noncoding regions of the human 
genome.  
B. Early Studies 
Early work in genetics focused on two research strategies.  Monogenic diseases, 
which often followed a Mendelian mode of inheritance (i.e. dominant, recessive), were 
studied using segregation and linkage analysis.
194
  In relation to QT, these included 
congenital long and short QT syndromes.  The second strategy used family and twin studies 
that were not ascertained for Mendelian diseases to identify genes associated with complex 
diseases and traits, again using segregation and linkage analysis methods.  These early 
studies were successful in identifying several highly associated regions but struggled to 
replicate findings across studies and failed to explain much of the heritability observed in the 
above studies. 
B.1. Congenital Long and Short QT Syndrome 
As stated above, congenital long QT syndrome was first described by Jervell and 
Lange-Nielsen in 1957.
132
  However, it wasn’t until 1999 that the first case of congenital 
short QT syndrome (SQTS) was described in humans.
195 
 With both LQTS and SQTS, 
researchers have since identified numerous genetic mutations believed to cause the two 
disorders, almost all in gene encoding cardiac ion channels (Table 10).  Overall, hundreds of 
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distinct rare mutations have been linked to congenital LQTS within the six ion channel genes 
associated with the disorder.
29
   
 In addition to rare mutations in ion channels, a single mutation in ANK2, which 
encodes ankyrin B, a scaffolding protein, has been linked to LQTS, highlighting the role of 
non-ion channel genes in QT duration.
196
  Ankyrin B influences the functional expression of 
both ion channels and transporter proteins.
29
   
Table 10.  Genes Associated With Congenital Forms of Long and Short QT Syndrome 
Disease Subtype Chromosome Gene Protein Protein Function 
Inheritance 
Pattern 
LQTS      
    LQT1 11p15 KCNQ1 KvLQT1 (IKs) IKs channel (α subunit) AD 
    LQT2 7q35 KCNH2 HERG (IKr) IKr channel (α subunit) AD 
    LQT3 3p21 SCN5A Na Channel INa channel AD 
    LQT4 4q25 ANK2 Ankyrin B Ankyrin AD 
    LQT5 21q22 KCNE1 MinK (IKs) IKs channel (β subunit) AD 
    LQT6 21q22 KCNE2 MiRP1 (IKr) IKr channel (β subunit) AD 
    LQT7 17 KCNJ2 IK1 IK1 channel (α subunit) AD 
    LQT-JLN1 11p15 KCNQ1 KvLQT1 (IKs) IKs channel (α subunit) AR 
    LQT-JLN2 21q22 KCNE1 MinK (IKs) IKs channel (β subunit) AR 
SQTS      
    SQTS 7 KCNH2 HERG (IKr) IKr channel (α subunit) AD 
    SQTS 11 KCNQ1 KvLQT1 (IKs) IKs channel (α subunit) AD 
Adapted from Shah 2005
36
 and Zipes 2004
61 
AD, Autosomal dominant; AR, Autosomal recessive 
 
 
 SQTS is similarly associated with numerous ion channel genes.  The first to be 
identified was KCNH2 (also known as HERG), where Brugada et al. identified two missense 
mutations, both of which change the 588
th
 amino acid in the HERG protein from an 
asparagine (neutrally charged) to a lysine (positively charged), causing a substantial increase 
in IKr.
197
  Additionally, five more genes have been associated with SQTS, beyond those 
described in Table 10, when patients with both SQTS and Brugada syndrome phenotypes are 
studied.
29
  Brugada syndrome is another disorder that is characterized by ECG abnormalities, 
in this case elevation of the ST segment.  The five genes include one potassium ion channel 
gene (KCNJ2) and three calcium channel genes (CACNA1C, CACNB2B, CACNA2D1).
29, 198-
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200
  In total, there have been ten genes associated with congenital forms of LQTS and SQTS 
and they further enhance the evidence for ion channels, particularly potassium channels, 
involvement in prolonging QT.  
B.2. Family/Twin Studies 
While research in families with LQTS or SQTS worked in identifying the genes 
associated with the rare congenital forms of the disorders, they did not establish if the same 
genes, or others, influenced QT variability on a population level.  To determine if the same 
genes were involved, early research on QT used linkage analysis in twin and family studies 
taken from populations without congenital LQTS.  These linkage studies often focused on 
regions of the genome harboring genes already associated with the congenital form of LQTS.  
One of the first studies to successfully link a LQTS gene to QT duration in a population not 
ascertained for LQTS or SQTS was conducted by Busjahn and colleagues in 1999.  Busjahn 
et al. examined 166 pairs of twins and found strong evidence for linkage between QT and the 
genetic regions containing KCNQ1 and ANK2.
190
  Newton-Cheh et al. expanded on this work 
in 2005, using FHS families to conduct a genome-wide linkage scan in 10 centimorgan (cM) 
intervals.  A cM measures a genetic distance in which 0.01 crossover events are expected to 
occur each generation.  This family-based linkage study was a precursor to the later genome 
wide association studies discussed in the next section and allowed Newton-Cheh and 
colleagues to identify linkages between QT and three genetic regions including the region 
surrounding SCN5A on chromosome 3, a region on chromosome 9 at 104 cM, and a region 
on chromosome 15 at 102 cM.
28
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B.3. Candidate Gene Studies 
While linkage analyses of QT were successful in identifying many of the same 
regions that harbored genes associated with congenital LQTS, they only identified large 
regions of the genome.  Candidate gene studies, on the other hand, relied on genotyped SNPs 
and could evaluate specific genetic variants.  However, candidate gene studies required a 
priori hypotheses and were thus limited to examining a handful of SNPs from a limited 
number of loci underlying previously identified linkage peaks or loci associated with 
Mendelian forms of LQTS/SQTS.
201
  For example, Pfeufer et al. examined 174 SNPs from 
four candidate genes (KCN Q1, KCNH2, KCNE1, and KCNE2) and were able to identify 
one SNP in KCNQ1 and KCNE1 and two independent loci in KCNH2.
202
  However, the 
identified SNPs explained only 1% of the variance in QT.  Because of this, candidate gene 
studies, like linkage analyses, have not been successful in expanding our knowledge of the 
genetic underpinnings of ventricular conduction.  Instead, the field has moved into a GWAS 
era. 
C. Genome-Wide Association Studies 
The completion of the Human Genome Project (HGP), which sought to catalog human 
genetic variation by identifying all human genes and sequencing the three billion bases in the 
human genome, allowed researchers to conduct large-scale human genome studies such as 
GWAS.
203, 204
  Specifically, GWAS enabled researchers to test associations between complex 
traits of interest and thousands-to-millions of SNPs throughout the human genome, greatly 
increasing the coverage from linkage analyses and candidate gene studies.
8
  One reason for 
the success of GWAS is that they leverage an important property of SNPs in the human 
genome: linkage disequilibrium (LD).  LD describes the degree to which one allele, or 
variant, of a SNP is correlated with another SNP on the same chromosome within a 
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population.
205
  Two SNPs in high LD with each other tend to be inherited together and when 
the allele of one SNP is known, it can be used to infer the allele of the second SNP.  Because 
of LD, researchers do not need to genotype every SNP in the human genome to make 
inferences about large segments of the genome.  Instead, GWAS rely on indirect associations 
(Figure 9).  Using indirect association, researchers expect that in most cases, the specific 
SNP identified in a GWAS is not actually the causal SNP but is rather a marker of the causal 
SNP, with which it is in high LD.  Because GWAS can be conducted in large, unrelated 
populations and do not require a candidate region to be identified a priori, they have been 
highly successful in unraveling the genomic etiology of many complex diseases and 
identifying thousands of novel associations. 
ECG traits have been a popular phenotype for GWAS inquiry.  To date, there have 
been eleven GWAS performed for QT, two of which also evaluated QRS separately from 
QT, and another three which evaluated QRS but not for QT (Table 11).  The earliest of these 
was conducted by Arking and colleagues on approximately 4,000 European descent 
individuals and identified three genetic loci (regions) which were associated with QT, 
including NOS1AP, which has since become the top finding in many subsequent GWAS 
(Table 11, Appendix 1).
30
    However, Arking studied only the extremes of the QT 
Adapted from Bush 2012
201
 
Figure 9.  Indirect Associations in GWAS Using Linkage 
Disequilibrium 
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distribution.  Later GWAS which evaluated the whole QT distribution had even greater 
success in identifying and replicating novel associations which are now considered valid QT 
loci (Table 11).  Most GWAS of QT and QRS have been conducted in European descent 
populations; however, there have been three GWAS in Asian/Pacific Islander populations
31, 
206, 207
 and one in African descent populations.
208
  The results of these GWAS have confirmed 
the role of ion channel genes in ventricular conduction across global populations, as well as 
identified numerous novel associations. 
C.1. Ion Channel Genes 
Seven different ion channel genes have been associated with QT or QRS in at least 
one GWAS (Table 11).  The majority of the ion channel genes associated with QT are 
potassium channel genes (KCNE1, KCNH2, KCNJ2, KCNQ1).  All four of the potassium 
channel genes identified through GWAS were previously associated with congenital LQTS 
and SQTS (Table 10), but the identified variants are more common in the population than the 
rare variants associated with LQTS and SQTS.  Each of these four genes was identified by at 
least two different studies with approximately 10,000 participants or more.  Within the four 
potassium channel genes, fifteen different SNPs have been associated with QT in the five 
largest studies with ~10,000 participants or more, making it unclear what the causal SNP or 
SNPs are  (Appendix 1).  In addition to the potassium channel genes, two sodium channel 
genes have also been identified, SCN5A and SCN10A, two genes which are next to each other 
on the chromosome three but are not in strong LD.  However, while SCN5A has been 
associated with both QT and QRS,
35, 209, 210
 SCN10A has only been associated with QRS,
210, 
211
 suggesting that it may not be critical to the repolarization process but may be involved in 
depolarization.  While both sodium and potassium channels have been heavily implicated in 
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the duration of ventricular conduction, the evidence for calcium channels is far weaker.  Only 
one calcium channel gene (CACNA1D) has been associated with QRS and none have been 
associated with QT in a GWAS.
210
  Furthermore, the single calcium channel gene identified 
is not the same as the calcium channel genes potentially associated with congenital LQTS.
198, 
210
 
C.2. Novel Associations 
In addition to the ion channel genes, GWAS have identified a multitude of novel 
associations with QT.  In the five largest studies alone, more than 70 SNPs have been 
associated at more than 30 loci across the genome (Appendix 1).  The most consistently 
associated locus in GWAS of QT is NOS1AP.  Within this locus, rs12143842 is the most 
commonly identified SNP.  Six of the eleven GWAS of QT have found an association 
between rs12143842 and QT, with effect sizes near 3 ms.
31, 33-35, 208, 209
  This association has 
also undergone functional characterization.  Kapoor et al. examined rs12143842 as well as 
all SNPs in high LD with it and found that rs7539120 is the most likely functional variant 
underlying this association, as the T allele of rs7539120 increases expression of NOS1AP and 
that increased NOS1AP expression does alter cardiac electrophysiology, potentially through 
the propagation of the electrical current rather than directly through the depolarization and 
repolarization currents.
214
 
In addition to NOS1AP, other notable loci associated with QT are listed in Table 11.  
Many of these loci have been associated not just with QT but with other measures of cardiac 
conduction.  For example, in addition to its association with QT and QRS, TBX5 has also 
been associated with the PR interval, as have CAV1, SLC8A1, SCN5A, and SCN10A.
214-217
  
Furthermore, PLN has also been associated with left ventricular structure and is known to   
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Table 11.  Summary Results of QT and QRS Genome-Wide Association Studies 
Author, Year 
ECG 
Trait(s) Race N Populations 
Notable Results 
Ion 
Channel 
Genes 
Novel 
Associations 
Arking, 2006
37 
QT EU 3,996 FHS, KORA  NOS1AP 
Newton-Cheh, 2007
212
 QT EU 1,345 FHS  NOS1AP 
Marroni, 2009
32
 QT EU 2,325 EUROSPAN  NOS1AP 
Newton-Cheh, 2009
33
 QT EU 13,685 CHS, FHS, RS KCNH2 
KCNQ1 
SCN5A 
LIG3 
LITAF 
NDRG4 
NOS1AP 
PLN 
Nolte, 2009
34
 QT EU 3,558 BRIGHT, DCCT/EDIC, 
TwinsUK 
 NOS1AP 
PLN 
Pfeufer, 2009
35
 QT EU 15,842 ARIC, KORA, 
SardiNIA, GenNOVA, 
HNR 
KCNH2 
KCNJ2 
KCNQ1 
SCN5A 
ATP1B1 
LITAF 
NDRG4 
NOS1AP 
PLN 
Smith, 2009
207
 QRS AS 1,604 Kosrae   
Chambers, 2010
31
 QT 
QRS 
AS 6,543 London Life Sciences 
on the Indian 
Subcontinent 
KCNH2 
KCNJ2 
SCN5A 
SCN10A 
ATP1B1 
LITAF 
NOS1AP 
PLN 
Holm, 2010
213
 QT 
QRS 
EU 9,860 Icelandic Cohort KCNE1 
KCNH2 
KCNQ1 
ATP1B1 
LITAF 
NDRG4 
TBX5 
Sotoodehnia, 2010
210
 QRS EU 40,407 CHARGE CACNA1
D 
SCN10A 
SCN5A  
PLN  
TBX5 
Kim, 2012
206
 QT AS 6,805 KARE KCNH2 
KCNQ1 
SCN5A 
NDRG4 
NOS1AP 
PLN 
SLC8A1 
Smith, 2012
208
 QT AA 12,097 COGENT, CARe, WHI  ATP1B1 
NOS1AP 
SLC8A1 
Ritchie, 2013
211
 QRS EU 5,272 eMERGE SCN5A 
SCN10A 
 
Arking, 2014
209
 QT EU 76,061 QT-IGC KCNE1 
KCNH2 
KCNJ2 
KCNQ1 
SCN5A 
ATP1B1 
CAV1  
LIG3  
LITAF 
NDRG4 
NOS1AP 
PLN  
SLC8A1 
AA, African descent population; ARIC, Atherosclerosis Risk in Communities; AS, Asian descent 
population; BRIGHT, British Genetics of Hypertension; CARe, Candidate-gene Association Resource; 
CHARGE, Cohorts for Heart and Aging Research in Genetic Epidemiology; CHS, Cardiovascular Health 
Study; COGENT, Continental Origins and Genetic Epidemiology Network; DCCT/EDIC, Diabetes Control 
and Complications Trial/Epidemiology of Diabetes Interventions and Complications; eMERGE, Electronic 
Medical Records and Genomics; EU, European descent population; EUROSPAN, European Special 
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Population Research Network; FHS, Framingham Heart Study; GenNOVA, EURAC-Institute for Genetic 
Medicine; HNR, Heinz Nixdorf Recall Study; KARE, Korea Association Resource; KORA,  Cooperative 
Health Research in the Region of Agusburg; N, Number of study participants; QT-IGC, QT Interval-
International GWAS Consortium; RS, Rotterdam Study; SardiNIA, Progenia for the Sardinian public; 
TwinsUK, Twin Registry of the United Kingdom; WHI, Women’s Health Initiative 
affect rates of cardiac contraction in mice.
34, 218
  Together, these results suggest that 
ventricular conduction is influenced not just by the ion channels directly involved in 
ventricular depolarization and repolarization, but also by many other factors broadly involved 
in overall cardiac electrophysiology.  This emphasizes the potential for GWAS to identify 
novel biology underlying complex traits. 
C.3. Replication in Multi-Ethnic Populations 
As previously mentioned, most GWAS to date have been conducted in population of 
European descent.  However, there has been some effort to generalize the results from 
European descent populations (EU) to multi-ethnic populations.  In particular, results from 
the NOS1AP locus have been generalized to African descent (AA), Asian descent (AS), 
American Indian, and Hispanic/Latino populations (HL).
219-221
  Furthermore, SNPs from 
NDRG4, KCNE1, SCN5A, SCN10A, and KCNH2 have been generalized to AA populations 
for QT and QRS.
220, 222
  Additionally, the following loci have been generalized to American 
Indian populations: ATP1B1, SCN5A, PLN, KCNH2, KCNQ1, LITAF, and NDRG4.
220
  Only 
four additional loci have been generalized to HLs: ATP1B1, KCNH2, LITAF, and NDRG4.
220
  
However, global genetic architecture varies by race/ethnic group, with EU populations 
having the largest regions of LD and AA populations having the smallest regions of LD.
223
  
Given the underlying differences in LD patterns between different ancestral populations, it is 
not surprising that in many cases, the index, or most highly associated, SNP in EU 
populations is not associated with QT in multi-ethnic populations or there is a better marker 
of the signal in these populations.
224
  For example, a fine mapping study of QT found that of 
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the six loci which generalized to the AA, four had different index signals in the AA 
populations than the one which had been previously identified in EU populations and for two 
of these four, the index signal identified in EU populations was not significantly associated 
with QT.
225
  Furthermore, the SLC8A1 locus was not identified in EU populations but has 
been identified and replicated in AS populations for not only QT but also other ECG 
metrics.
206, 215, 226
  This illustrates why it is imperative to expand genetic studies beyond EU 
populations and include a diverse range of populations. 
D. Gene-Environment Studies 
Several lines of evidence suggest that environmental influences, including potassium 
levels, moderate the genetic associations with QT.  Two family studies of congenital LQTS 
identified two different mutations in the KCNQ1 gene, which is mutated in LQT1 patients, 
both of which are only identified in patients presenting with hypokalemia at the time of their 
ECG.
227, 228
  Furthermore, a recent study in AAs identified a mutation in SCN5A for which 
hypokalemia can moderate its association.
229
  Further evidence for the potential role of gene-
environment (GxE) interactions in QT is provided by the concept of “missing heritability.”  
While GWAS have identified a multitude of genetic variants associated with QT, they only 
explain 10% of the variance in QT.
209
  One common hypothesis for this “missing 
heritability” is GxE interactions.230  However, GxE studies require a much greater sample 
size to achieve sufficient power to detect associations and for this reason, there have been 
few well-powered GxE studies of QT.  To successfully identify GxE interactions, studies 
must often combine into large consortia, as is proposed in this work, to achieve the sample 
sizes required to detect GxE associations.  Such further work in GxE studies could help 
illuminate the underlying biology of the missing heritability of QT. 
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Thiazide Diuretics 
Thiazide diuretics are a promising candidate for GxE inquiry in QT, as this class of 
medications has been associated with QT prolongation (Section Thiazide-Induced QT 
Prolongation).  Briefly, thiazide and thiazide-like diuretics are members of a class of 
pharmaceuticals which increase renal excretion of sodium and water.  Thiazides were first 
released in 1957 as an antihypertensive and have since become a critical drug in hypertension 
treatment.
40, 231
  Thiazide and thiazide-like diuretics are distinguished by their molecular 
structure (Figure 10).  Thiazides are derived from the bezothiadiazine core while thiazide-
like diuretics are derived from sulfonamide.
40
  Thiazides and thiazide-like medications are 
commonly considered together, as they have a similar mechanism of action.  They will be 
referred to jointly as thiazides for the remainder of this proposal.  Below, I will examine the 
Adapted from Tamargo 2014
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Panel A: Thiazide diuretics with the characteristic 1,2,4-benzothiadiazine-1,1-dioxide   
Panel B: Thiazide-like diuretics with the sulfonamide group but not the benzothiadiazide group 
Figure 10.  Molecular Structure of Thiazide and Thiazide-Like Diuretics 
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pharmacology of thiazides and the association between thiazides and QT. 
A. Pharmacologic Characteristics 
Thiazide diuretics increase the excretion of sodium by inhibiting the reabsorption of 
Na
+
 in the kidneys.  Thiazides are actively excreted from the proximal tubule of the renal 
nephron from which they then move to block the electroneutral Na
+
-Cl
-
 cotransporter (NCC) 
on the apical membrane of the distal convoluted tubule (DCT) of the renal nephron (Figure 
11).
40
  The NCC is encoded by SLC12A3 from the SLC family of genes.
40, 66
  At the NCC, 
Na
+
 moves down its concentration gradient using energy produced by the Na
+
/K
+
-ATPase on 
the basolateral membrane of the DCT.  When Na
+
 absorption is inhibited, resulting in an 
increased delivery of Na
+
 to the DCT, K
+
 excretion is also increased, which can lead to 
hypokalemia.  An increase in Mg
++
 excretion, which can result in hypomagnesemia, is also 
seen with thiazide use but the mechanism underlying this phenomenon is not well understood 
but may result from a downregulation of the transient receptor potential cation channels on 
the apical membrane of the DCT, encoded by TRPM6.
40
  Conversely, thiazide use increases 
Adapted from Tamargo 2014
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Figure 11.  Transport Mechanisms of the Distal 
Convoluted Tubule 
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Ca
++
 reabsorption, thereby reducing calcium excretion.  When water and sodium excretion is 
increased with thiazide use, the contraction of the extracellular fluid volume triggers an 
increase in sodium reabsorption in the proximal tubules, which also causes passive Ca
++
 
transport.  Thiazides also stimulate Ca
++
 reabsorption in the DCT through the basolateral 
Na
+
/Ca
++
 exchanger (NCX1) and the Ca
++
-ATPase channel (PMCA1b).
40
   
B. Indications of Use 
Thiazides are most commonly used to treat hypertension and are effective in lowering 
blood pressure (BP) in hypertensive individuals without lowering BP in normotensive 
individuals.
40
  The “Seventh Report of the Joint National Committee on Prevention, 
Detection, Evaluation, and Treatment of High Blood Pressure” (JNC 7) recommend thiazide 
diuretics as the first choice medication, either as monotherapy or as part of a combination 
therapy, in the treatment of hypertension.
232
  Thiazides are also used to treat edema, or the 
accumulation of fluid in the body cavities, in patients with heart failure, although usually 
only in combination with a loop diuretic.
233
  Similarly, thiazides are used to treat edema 
associated with liver cirrhosis and renal therapy.
234
  Thiazides have also been found effective 
in treating osteoporosis, likely due to its effects on calcium reasbsorption.
235, 236
  The same 
mechanism leads to the usage of thiazides to treat calcium-based kidney stones.
237
 
B.1.  Contraindications 
Thiazides are contraindicated in patients with anuria, renal failure, an allergy to 
thiazides or other sulfonamide drugs, or hepatic coma.
234
  Thiazides are also contraindicated 
if BP control worsens in patients with chronic kidney disease that progresses to stage 4 or 5.  
Pregnant women should also avoid thiazides.  Furthermore, patients with impaired liver 
function, hypokalemia, hyponatremia, hyperuricemia, hypercalcemia, glucose intolerance, or 
diabetes should be closely monitored while using thiazides to prevent adverse outcomes.
40
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C.  Prevalence 
 Thiazide diuretics are an increasingly common antihypertensive therapy.  Over a 
quarter of the hypertensive population in the U.S. (1 in 3 U.S. adults) uses a thiazide diuretic, 
amounting to 13% of the total U.S. EU population, 10% of the HL population, and 23% of 
the AA population.
36, 37, 238
  The use of thiazides increased from 2001 to 2010, with 22% of 
hypertensive individuals using a thiazide in 2001 to almost 28% of hypertensives using a 
thiazide in 2010 (Table 12).
37
  The majority of those using a thiazide (>90%) were using it in 
conjunction with other drugs in polytherapy.
37
  Thiazide use is more common in females than 
males (32% and 23%, respectively).  These medications are also more commonly used by 
Blacks (34%) and least commonly by Hispanic populations (22%).  Of the different types of 
thiazide and thiazide-like diuretics, hydrochlorothiazide is the most commonly used (11% of 
the U.S. adult hypertensive population).
37, 40, 239
  However, despite the high prevalence of 
thiazide diuretic use, it is worth noting that adherence to thiazides is particularly low, with 
some of the lowest adherence rates among antihypertensive medications, with only 51% 
mean adherence, compared to 65% adherence to angiotensin receptor blockers, the drug class 
with the highest levels of adherence.
240, 241
  However, Smith et al. found that 
hydrochlorothiazide, the most commonly used thiazide, had good agreement between 
reported thiazide use and serum measurements of thiazides (kappa [degree of agreement 
beyond chance] = 0.62, 95% C.I.: 0.53-0.91).
57
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Table 12.  Prevalence of Thiazide Diuretic Use Among Hypertensive Adults Over Time in the United 
States 
Population 
2001-2002 
% (SE) 
2003-2004 
% (SE) 
2005-2006 
% (SE) 
2007-2008 
% (SE) 
2009-2010 
% (SE) 
P 
trend 
Overall 22.4 (2.1) 24.2 (1.4) 26.3 (1.9) 26.7 (1.8) 27.6 (1.3) 0.02 
Monotherapy NA 1.6 (0.4) 4.1 (0.6) 2.1 (0.5) 2.5 (0.4) 0.09 
Polytherapy 20.8 (1.9) 22.5 (1.4) 22.2 (1.7) 24.5 (1.6) 25.1 (1.3) 0.04 
       
Male 16.4 (2.1) 21.2 (2.0) 20.9 (2.4) 21.0 (1.9) 23.3 (1.4) 0.04 
Female 27.2 (2.1) 26.8 (1.7) 31.3 (2.1) 31.8 (2.0) 31.6 (2.1) 0.04 
       
Non-Hispanic White 23.3 (2.4) 23.8 (1.4) 26.6 (2.6) 27.4 (2.1) 27.4 (1.6) 0.07 
Non-Hispanic Black 26.0 (2.7) 29.0 (2.9) 32.0 (2.3) 30.7 (1.8) 34.2 (2.2) 0.02 
Mexican American 13.4 (3.2) 19.2 (2.8) 10.4 (2.8) 18.4 (2.0) 22.2 (2.4) 0.06 
Adapted from Gu 201244 
 
D.  Thiazide-Induced QT Prolongation 
Thiazide diuretic use has been linked to the development of QT prolongation and drug-
induced torsades de pointes, although the underlying mechanism of this association is not as 
well understood as that of many of the other QT prolonging drugs, making it an excellent 
candidate for pharmacogenomics inquiry.
38-40
  Both indapamide and hydrochlorothiazide are 
considered to have conditional risk of QT prolongation and TdP by the UAZ-CERT database 
but it is not well-established what the risk is conditional on.  Pharmacogenomics work can 
help elucidate what potential mechanisms are underlying the risk of QT prolongation and 
thiazide use, aiding in identification of those at highest risk of QT prolongation and TdP due 
to thiazide use. 
D.1. Pharmacoepidemiology 
Associations between thiazide diuretics, ECG abnormalities, and arrhythmogenic 
death was first reported in the 1980s,
242-245
 when Hollifield and Slaton found that patients 
taking hydrochlorothiazide were more likely to suffer SCD than patients not on a thiazide 
diuretic.
242
  The relationship between SCD and diuretic use was also reported by Hoes et al. 
and Cooper et al. in the 1990s.  While not restricted to thiazides, both studies found that the 
use of non-potassium sparing diuretics increased the risk of SCD: Cooper et al. found that 
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diuretics increased the risk of SCD 1.33-fold (95% CI: 1.05-1.69); Hoes et al. found an OR 
of 2.2 (95% CI: 1.1-4.6) if the diuretic was not taken with a beta blocker.
246, 247
  It was 
estimated that, in 1994, thiazide use was responsible for more than 10% of all SCD in the 
Netherlands, totaling 120 deaths.
248
  Furthermore, Siscovick and colleagues found that the 
relationship between cardiac arrest and thiazides was dose dependent.  A high dose (100 mg) 
was found to increase the risk of cardiac arrest compared to a low dose (25 mg) with an OR = 
3.6 (95% CI: 1.2-10.8).
249
  Together, these results suggested a link between thiazide use and 
SCD, a correlate of QT prolongation.   
 In addition to the link between thiazides and SCD, a link has also been found 
between thiazides and ECG abnormalities.  Hollifield and Slaton found that thiazide use was 
associated with an increased prevalence of premature ventricular contractions (PVCs) in the 
presence of exercise, which have been shown to precede TdP in cases of LQTS.
242, 250
  
Additionally, the Multiple Risk Factor Intervention Trial (MRFIT) identified an unexpected 
excess of CVD mortality, primarily sudden death, among hypertensive men with ECG 
abnormalities who received high-dose diuretic treatment (hydrochlorothiazide or 
chlorthalidone).
243
  Porthan et al. also found that hydrochlorothiazide use increased the 
length of the T wave component of the QT interval, which suggests an increase in the 
repolarization heterogeneity.
251
  Repolarization heterogeneity has been suggested as a marker 
of TdP development in the case of prolonged QT, indicating thiazide use may predispose 
individuals for fatal outcomes of QT prolongation.
251
   
The link between thiazides and prolonged QT has been specifically tested in several 
studies.  This was first shown by Struthers et al. who found that pretreatment with 
benzofluamethiazide was associated with prolongation of the QT interval in the presence of 
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adrenaline.
245
  However, it was not clear if prolonged QT was the result of the thiazide usage 
or adrenaline.  The Prevention of Atherosclerotic Complications with Ketanserin (PACK) 
trial was able to better separate the effects of the thiazide from that of ketanserin, the 
serotonin antagonist which was being tested in the trial, to get a clearer result.  The PACK 
trial found that, at randomization and prior to the introduction of ketanserin, patients who 
were taking a diuretic had a longer QT than those not on a diuretic by an average of 7 ms; 
when ketanserin was added, participants on a diuretic had a QT interval that was an average 
of 12 ms longer than those who were not taking a diuretic and just taking ketanserin alone.
244
  
Finally, Rautaharju et al. examined the association between thiazide usage and QT 
prolongation in a population of more than 4,000 men and women in the Cardiovascular 
Health Study (CHS).  They found that, after adjusting for the use of other QT prolonging 
agents, serum potassium levels, sex, gender, and other potential confounders, thiazide 
diuretic usage was associated with a significantly increased likelihood of QT-prolongation 
(OR = 1.73, 95% C.I.: 1.43-2.11).
252
 
Despite the above studies, there are still several areas of research that are lacking.  
For example, no studies to date have examined the relationship between thiazide use and QT 
prolongation in a large, population-based cohort.  Iribarren and colleagues did examine a 
single thiazide-like diuretic, indapamide, in a large cohort of almost 60,000 individuals and 
found indapamide increased QT by an average of 9.4 ms (95% C.I.: 4.9-14.0).
148
  However, 
no larger studies of additional thiazide class medications has been conducted for QT 
prolongation.  Furthermore, while both the study by Struthers and the PACK trial found that 
diuretic use was associated with an increased QT in the presence of other medications, few 
additional studies to date have specifically examined potential modifications of the thiazide-
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QT relationship.  Given the conditional nature of the thiazide-QT relationship, it is 
imperative to understand the conditions by which thiazides prolong QT, which calls for 
additional studies of potential modifiers, including genetics, which is the subject of this 
proposal. 
D.2. Proposed Mechanisms 
While thiazide diuretics interfere with cellular ion channels, the ion channels affected 
by thiazides have not yet been identified in cardiac conduction.  Therefore, it has been 
suggested the thiazide-induced QT prolongation is the result of the electrolyte imbalances 
induced by thiazide usage, primarily hypokalemia.  Potassium depletion is a well-known side 
effect of thiazides,
253-256
 and is also an established risk factor for QT prolongation and TdP, 
suggesting that QT prolongation may be caused by the thiazide-induced hypokalemia.
111
   
Further evidence supporting a potassium-mediated cause for QT prolongation in 
thiazide users comes from patients who suffer from Gitelman syndrome (GS).  GS is a 
familial hypokalemia-hypomagnesemia disorder affecting approximately 1 in 40,000 
individuals.
42
  Most cases of GS are caused by mutations in the SLC12A3 gene, which 
encodes the thiazide-sensitive NCC (Figure 11).
42
  Studies of patients with GS have found 
that QT is significantly prolonged in these patients and they are at higher risk for cardiac 
arrhythmias.
41, 257
 
However, there has been some evidence that thiazide diuretics interfere directly with 
cardiac conduction and that the mechanism of QT prolongation may not be solely through 
electrolyte levels.  For example, Lu et al. found that the thiazide-like diuretic agent 
indapamide inhibited the sodium currents in the heart, as well as two of the potassium 
currents directly involved in ventricular repolarization: the Ito (transient outward current), 
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involved in phase 1 of repolarization and the IKs (slow delayed rectifying current), involved 
in phase 3.
43
  Additionally, Fiset et al. demonstrated that the addition of indapamide to class 
III antiarrhythmic drugs, known QT prolonging medications, exacerbates the block of the IKs 
and can lead to excessive QT prolongation.
258
  While thiazides do not have as clear or strong 
direct effects on cardiac ion channels, these effects may still be significant enough to prolong 
ventricular conduction, especially when taken in combination with other QT prolonging 
agents. 
Pharmacogenomics 
Drug efficacy and safety are highly variable between individuals and this variability in 
drug response poses a significant problem in the effective treatment of disease.
2-4
  For 
example, as discussed above, many drug classes including thiazides can lead to QT 
prolongation but this potentially dangerous side effect does not occur in all individuals.  
However, it is often unclear what the underlying causes of this variability are.  Genetics are 
believed to play a major role in determining drug response.  Genetic variants are known to 
interfere in pharmacokinetic, or the relationship between drug dose and concentration, 
processes, which include absorption, distribution, metabolism, and excretion, as well as in 
pharmacodynamic, or the manifestation of drug action, processes, such as the interaction 
between the drug and drug targets.
61
  This has led to the field of pharmacogenomics, which 
studies gene-environment interactions relating to pharmaceuticals.   
 The most well-known example of applied pharmacogenomics is warfarin (a 
commonly used anticoagulant) dosing.
259
  Genetic variants identified in the CYP2C9 and 
VKORC1 explain up to 50% of the variability in dose response to warfarin.
259
  These two 
genes are responsible for metabolizing the pharmacologically active S-warfarin isomer and 
variants in these genes confer increased sensitivity to warfarin, resulting in a smaller 
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effective dose in patients with these variants.
7
  However, there have also been numerous 
other successful applications of pharmacogenomics research.  The FDA recommends genetic 
testing for AS populations before prescribing carbamazepine, an anticonvulsant, after a 
prospective trial found that variants in the HLA-B gene found on the Asian haplotype 
modified the risk of fatal toxic side effects.
7, 260
  The FDA also recommends screening for 
variants in the HLA-B gene before prescribing abacavir, an antiretroviral, after a randomized 
clinical trial showed that genetic screening significantly reduced cases of hypersensitivity.
259, 
261
  These examples illustrate the potential clinical significance of pharmacogenomics 
research. 
A. Pharmacogenomics of QT-Prolonging Drugs 
As drug-induced QT prolongation is a leading cause of withdrawal or restricted 
marketing of drugs, identifying the genetic component of diLQTS is a critical question for 
pharmacogenomics researchers.  There already exists a substantial body of research on this 
subject, although most studies have evaluated QT prolonging medications in aggregate rather 
than examining specific drug classes.  In other words, these studies evaluate populations 
taking any drug or combination of drugs that have been implicated in QT prolongation.  
Unsurprisingly, many of the genes involved in congenital LQTS have also been implicated in 
diLQTS.  In particular, KCNH2, KCNE1, KCNE2, KCNQ1, and SCN5A have been associated 
with diLQTS in multiple studies.
262-267
  A subset of the genetic variants associated with 
diLQTS within these five genes and their locations within the product protein can be seen in 
Figure 12.  The majority of variants identified are rare mutations (present in less than 1% of 
the population).
266, 268
  However, Kaab et al. identified a common polymorphism in KCNE1 
(rs1805128) which was associated with a high risk of diLQTS (OR=9.0, 95% CI: 3.5-
22.9).
264
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In addition to the genes involved in congenital LQTS, several other genes have been 
implicated in diLQTS.  Jamshidi and colleagues identified a common variant in NOS1AP 
(rs10800397), the top gene associated with QT in GWAS, which confers a three-fold 
increase in risk of diLQTS (OR=3.3, 95% CI: 1.0-10.8).
269
  A candidate gene analysis of 
antipsychotics and QT also identified NOS1AP as a modifier of diLQTS.
270
  In addition, two 
genes encoding cytochrome P450 enzymes, CYP2D6 and CYP3A4, enzymes involved in 
drug metabolism, have been associated with diLQTS.
263, 271
  Mutations in these cytochrome 
P450 enzymes can reduce the efficiency of drug metabolism, thus increasing the 
concentration of QT-prolonging medications in the heart and thus induce QT prolongation.
263
  
Additionally, two GWAS of the antipsychotic-QT association identified multiple genes in the 
SLC family of genes, including SLC22A23 and SLCO3A1.  While these findings support the 
Adapted from Aerssens 2004
263 
Mutations and Polymorphisms that have been associated with drug-induced LQTS are marked with blue 
dots and labeled 
 
Figure 12.  Structure of Ion Channel Proteins Involved in Drug-Induced Long QT Syndrome 
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role of genetics in determining those at risk of drug-induced QT prolongation, few loci have 
been replicated and studies have been underpowered.  Furthermore, the reported results are 
often imprecise and the field likely suffers from publication bias.  To confirm and expand on 
the above findings, larger GWAS of diLQTS are needed. 
B. Pharmacogenomics of Thiazide Diuretics 
Multiple genetic loci have been implicated and replicated in the antihypertensive 
response and risk of side effects of thiazide diuretics.  Unlike other genetic studies, 
pharmacogenomics work on antihypertensive response has been conducted in multiple racial 
groups, including EU, AA, and AS descent populations, and has been replicated across 
populations.  For example, genes involved in the renin-angiotensin-aldosterone system, 
including  have been implicated in all three populations, including ACE and CYP11B2, in 
which genetic variants can lead to a reduced blood pressure response in those take a 
thiazide.
272-274
  Additionally, multiple ligases and kinases involved in ion channels and ion 
handling have been identified in EU and AA populations, such as NEDD4L, PRKCA, WNK1, 
and WNK4.
274-276
  Finally, YEATS4, a gene believed to be involved in RNA transcription, has 
been associated with blood pressure response among thiazide users in two separate studies of 
both EU and AA populations.
277, 278
 
In addition to antihypertensive response, genetics has been implicated in the potential 
adverse drug reactions of thiazide diuretics.  In a study of 425 EU and 342 AA participants, 
Del-Aguila et al. identified two SNPs in AAs (rs12279250 and rs4319515) in the NELL1 
gene which were associated with fasting plasma triglyceride levels among thiazide users, for 
which hypertriglyceridemia is a known potential side effect.
279
  However, these results did 
not replicate in the EU cohort.  Additionally, hypokalemia, another side effect of thiazide 
use, has been shown to be modified by genes in the HEME pathway.
280
  Another study by 
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Vandell and colleagues identified a collection of genetic variants across five genetic loci 
which explained 11% of the variability in uric acid levels among AA thiazide users; a sixth 
region was associated with uric acid levels among an EU population of thiazide users which 
was not associated in AA populations.
281
  In each of these cases, the identified genetic loci 
have brought forth potentially new pathways involved in thiazide drug reactions but have 
rarely been replicated.  Additionally, many of these studies, as well as the studies of diLQTS 
in general, have often used a candidate gene approach to account for the fact that 
pharmacogenomic studies are often underpowered; however, as was previously discussed, 
candidate gene studies have not been successful in explaining the heritability of complex 
traits.  While the findings in the above pharmacogenomic studies demonstrate the need for 
further pharmacogenomic studies of thiazides and the variability in drug response, future 
work will need to be well-powered and consider genome-wide analyses.  
B.1. Thiazide Diuretics and QT Prolongation 
To date, one study of the pharmacogenomics of thiazides and QT in EU populations 
has been conducted.
282
  In this study, no SNPs reached the genome-wide significance 
threshold.  However, the study had several notable limitations.  The study was conducted 
with only cross-sectional data using many of the same study populations to be used in this 
proposal, despite the repeated ECG and medication measures available in many of the 
studies.  Additionally, the study only evaluated EU populations.  Furthermore, the analysis 
was significantly underpowered to detect drug-gene interaction effect sizes consistent with 
those observed in QT main effect GWAS studies.  However, the authors noted that by 
including the repeat measures, such as is suggested in this proposal, the power to detect even 
small interaction effects would be greater than 80%.  This suggests that the study proposed 
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here, which will incorporate both the repeated measures as well as additional populations and 
race/ethnic groups, has the potential to identify genetic variants which modify the potential of 
thiazides to prolong QT.  Additionally, this work failed to consider the effects of prevalent 
user bias, a form of selection bias known to impact pharmacoepidemiologic studies, on study 
results.  The work proposed here will consider the effects of this bias and interpret results 
accordingly.  
Bias in Pharmacoepidemiologic and Pharmacogenomic Studies 
It is well known that pharmacoepidemiologic studies, which seek to understand both 
the use of the effects of drugs in populations, are subject to a multitude of biases.
283
  
However, it is unclear if pharmacogenomic studies are similarly susceptible.  In an era where 
prescription drug use continues to rise and variability in drug response posing a growing 
public health burden, pharmacoepidemiologic and pharmacogenomic studies continue to be 
important for understanding the effects of these massive population exposures.  However, it 
is critical to consider the potential effects of bias on these studies.   
Randomized controlled trials (RCTs) are considered the gold standard of 
pharmacoepidemiologic research although an increasing number of studies are conducted in 
observational settings.
45, 48, 284
  Observational settings often provide larger sample sizes, 
greater statistical power, and better generalization to a broader population than RCTs.
284
  
Unfortunately, observational studies also are subject to many biases, such as selection bias.
284
  
Particularly concerning for pharmacoepidemiology studies is a form of selection bias 
sometimes called prevalent user bias, reflecting the potential enrichment for prevalent, long-
term drug users who are less likely to have experienced an ADR when compared to prior 
users.  Furthermore, prevalent user bias results from depletion of susceptibles and differential 
loss of follow-up, as participants at highest risk for an ADR are not observed at the measured 
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time points as they have died or dropped out.
284, 285
  Additionally, exposure misclassification, 
in which short-term users have a lower chance of being seen while on therapy is another 
concern leading to the enrichment of prevalent users; in cases of ADRs, participants may be 
taken off the medication soon after therapy initiation and thus the outcome of interest is not 
seen in the study and the participants are classified as non-users.  These issues result in the 
potential for bias in observational studies of pharmaceutical usage.   
Pharmacogenomic studies are similarly conducted in observational settings but GxE 
studies which, unlike pharmacoepidemiologic studies, incorporate a third parameter, the 
SNP.  Pharmacogenomic studies are different than studies of main effects or of non-genetic 
modifiers, as the modifying variable, the SNP, is assigned at conception and therefore is not 
affected by subsequent exposures, a difference which is paramount in determining the effects 
of bias, and in particular, selection bias, in pharmacogenomics studies.  Supporting this 
assertion is prior research that has shown that interaction effects in genetic studies do not 
suffer from selection biases when the genotype does not influence selection other than 
through an association with the disease or the second exposure.
286-288
  In other words, there is 
no bias in cases where the selection proportions are the same between populations with the 
same genotypes even if they differ between categories of disease or environmental exposure 
status, in this case, pharmaceutical use.   
Another scenario distinguishing pharmacoepidemiologic studies from 
pharmacogenomic studies is presented by a previous study that evaluated the influence of 
confounding by contraindication.
47
  Confounding by contraindication is a form of bias 
present when an outside factor is associated with an avoidance of treatment and with the 
outcome of interest and is a common threat to internal validity in pharmacoepidemiology.
47, 
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48
  However, a pharmacogenomic simulation study found that, while there may be modest 
bias present in the interaction term when very large SNP main effects were simulated, the 
amount of bias varies by study design and the magnitude of the bias may be negligible given 
the size of effects observed in published QT GWAS.
47
  This suggests that when conducting 
pharmacogenomic studies, researchers must consider the potential effects of bias under 
different scenarios and then, if this bias is not negligible, interpret results accordingly. 
Multi-Ethnic Populations 
Minority populations are historically underrepresented in clinical and health 
research.
289-291
  Because of the lack of research in multi-ethnic populations, many health 
policies and recommendations which were developed in EU populations do not account for 
differences in disease burden and etiology found in multi-ethnic populations.
292
  Minority 
populations hold a disproportionate burden of negative health outcomes compared to the EU 
populations which represent the majority of healthcare research to date.
293, 294
  In particular, 
AAs have a higher risk of diLQTS,
295
 a higher risk of mortality due to QT prolongation,
296
 
and a higher prevalence of thiazide use compared to other race/ethnic groups.
37
   
As has been previously stated, underrepresentation of minority groups is particularly 
prominent in genomics research, where the majority of participants included in genetic 
studies to date are of EU descent.
297
  This poses multiple problems, which have been briefly 
described in the previous sections.  First among these is the limited relevance of current 
research to medical genomics and pharmacogenomics in populations of non-EU descent.
298
  
As of 2014, there are over 130 pharmaceuticals with FDA-approved genetic information on 
their labels.
299
  However, the research behind the genetic information included on these 
labels has been predominantly conducted in EU populations.  The lack of representation of 
multi-ethnic populations is particularly concerning in pharmacogenomics, as Ramos and 
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colleagues have demonstrated that the underlying genetic architecture of multi-ethnic 
populations, including genetic variants associated with drug absorption, distribution, 
metabolism, and excretion, varies widely, indicating that it is inadequate to extrapolate 
genetic findings from EU populations to diverse ancestral populations.
300
  Furthermore, in the 
pharmacogenomics of warfarin dosing, Perera et al. found a genetic variant, rs12777823, in 
the CYP2C18 gene which is associated with warfarin dosing and is population-specific, in 
this case to AA populations.
15
  According to this study, failing to account for this SNP 
accounts for 21% of the dose variability explained by the current warfarin dosing formula 
and results in higher doses than needed in AA populations with an A allele at rs12777823.
15
  
These findings emphasize the need to include minority populations in future 
pharmacogenomics research.  The work proposed herein will make use of large AA and HL 
populations in addition to the EU populations in the participating cohorts, thus enabling this 
research to incorporate multi-ethnic populations from the onset.  
Public Health Significance 
Variable drug response poses a significant problem in the effective treatment of 
disease.
2-4
  Dose response and overall therapeutic response can vary between individuals and 
is influenced by a variety of factors, such as age, diet, smoking status, temporal trends, 
chemical exposures, drug-drug interactions, genetic variants, and drug-gene interactions.
2-4, 
301-313
  As of 2002, the FDA’s Adverse Event Reporting System, begun in 1969, had recorded 
2.3 million cases of adverse events.
314
  However, this number is likely low given the 
widespread under-reporting of ADRs.
170
  Efforts to correct for this under-reporting estimate 
that ADRs cause 2.2 million serious health events, 106,000 deaths, and account for 6-7% of 
all hospital admissions annually.
5, 315
  Pharmacogenomics research represents a promising 
step forward in both the progression of genetic knowledge from academic research to applied 
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public health and medical science and the potential to better understand the mechanisms of 
and reduce the burden of variable drug response.   
The potential public health and clinical applications of this pharmacogenomics work 
are numerous.  Thiazides are commonly used pharmaceuticals, used by almost a fifth of the 
U.S. population, providing a broad potential for impact of any findings from this study.
37
  
Furthermore, genetic information has the potential to be incorporated into drug selection and 
dosing in a clinical setting, as has been done with warfarin dosing
316
 or clopidogrel 
prescribing.
317
  Furthermore, pharmacogenomics findings can be used to alter medication 
labels, or, in extreme cases, remove drugs from the market.
318, 319
  Understanding the 
pharmacogenomics of drug response can also provide insight into the mechanism of drug 
response, and consequently, ADRs, which can then be used to better understand the etiology 
of the disease or even to develop better, more effective medications.
17, 18
  As we come to 
understand more about the genetic underpinnings of human health, the possibility for 
personalized, genomic medicine moves ever closer and pharmacogenomics is on the leading 
edge of this potential. 
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CHAPTER 4: RESEARCH PLAN 
Overview 
This work will be conducted in two parts.  Specific Aim 1 will be a 
pharmacogenomics study of the thiazide-QT relationship.  Specific aim 1 will be conducted 
using extant cohort data from a collaboration between the Women’s Health Initiative (WHI), 
the Hispanic Community Health Study/Study of Latinos (SOL), and the Cohorts for Heart 
and Aging Research in Genetic Epidemiology (CHARGE) consortium’s pharmacogenomics 
working group (PWG).  All participating studies have extensive genotyping data and have 
detailed and, in many cases, repeated measurements across multiple time points on 
electrocardiograms (ECGs) and medication use.  In specific aim 2, a simulation study will be 
conducted to determine the effects of prevalent user bias on pharmacogenomics studies.  This 
simulation study will be conducted using published clinical and genome-wide association 
studies (GWAS) to inform specification of the relationship between the QT interval (QT), 
QT-prolonging medication use, and genotypes.   
Specific Aim 1 
Identify genetic variants that modify the association between thiazide diuretics and 
QT and its component parts (QRS complex [QRS]; JT interval [JT]) in European descent, 
African descent, and Hispanic populations.  
1. Classify thiazide diuretic exposure among all cohorts using medication 
inventories, which have been validated in cohort studies against physiologic 
measurements,
55
 pharmacy databases,
56
 and serum measurements.
57
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2. Conduct genome-wide, race-stratified analyses to identify significant interactions 
between genetic variants, thiazides, and QT and its component parts (QRS; JT), 
leveraging longitudinal data when possible.  Study and race/ethnic-stratified 
results will be combined across studies using fixed-effect, trans-ethnic, and cross-
phenotypic meta-analytic techniques (Ntotal=78,199).  
3. Characterize identified genetic variants using in silico functional characterization 
techniques including computer databases and pathway analysis. 
A. Study Populations 
This study will make use of fifteen separate population-based cohort studies (Table 
13).  All study participants from each participating study who have genotype data as well as 
ECG measurements and medication data will be eligible for inclusion in this study.  
Furthermore, all time points at which both ECG and medication data were measured will be 
eligible for inclusion in the analysis.  For distributions of pertinent population characteristics 
across all fifteen cohorts, see Table 13.   
A.1. Women’s Health Initiative 
The WHI is a population-based study consisted of two arms.
52
  A total of 161,808 
participants from 40 study centers were enrolled, 62,132 into the clinical trial arm and 93,676 
into the observational study.  All participants were female between the ages of 50 and 79 
years at enrollment, were postmenopausal, and did not suffer from alcoholism, drug 
dependency, mental illness, or dementia.  Participants were subsequently brought back for 
four additional visits at which ECGs and medication were measured. 
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Table 13.  Study Population Characteristics 
Characteristic WHI SOL 
 CHARGE 
AGES ARIC CHS FHS RS ERF 
Health 
2000 
Health 
ABC MESA PROSPER NEO JHS 
N, Total 161,808 16,479 5,764 15,792 5,888 14,518 14,926
 
1,503 8,028 3,075 8,313 5,804 6,673 5,301 
N, 
Genotyped+ECG 
20,395 12,456 2,587 11,132 3,856 3,168 7,196 1,503 2,124 2,802 8,313 4,556 
6,673 
1,962
1 
Baseline Visit 
93-98 09-11 02-06 87-89 
89-
90
2 
48-
53
3,4 
90-
93
5,6 02-05 00-01 97-98 00-02 97-99 
08-
12 
00-04 
Length of 
Follow-up (yrs) 
9 0
 
5 24 11
2 
60
3,4 
20
5,6 
0 0 10 10 0 0 9 
Mean Age (yrs) 64 46 77 54 72 55 65 48 50 74 62 75 56 55 
% Female 100 46 58 55 61 53 58 59 52 52 54 54 57 55 
Mean QT 401 415 406 398 414 414 399 398 389 413 412 414 NA 413 
% Thiazides 18 NA 24 12 21 3 3 2 7 11 13 26 NA 25 
% Race/Eth                
European Am 65 0 100 77 85 100 94 100 100 60 32 100 100 0 
African Am 24 0 0 23 15 0 0 0 0 40 33 0 0 100 
Hispanic 10 100 0 0 0 0 0 0 0 0 26 0 0 0 
Other 1 0 0 0 0 0 6 0 0 0 9 0 0 0 
AGES, Age, Gene/Environment Susceptibility – Reykjavik Study; ARIC, Atherosclerosis Risk in Communities; CHARGE, Cohorts for Heart and 
Aging Research in Genetic Epidemiology; CHS, Cardiovascular Health Study; ERF, Erasmus Rucphen Family Study; FHS, Framingham Heart Study; 
Health ABC, Health, Aging, Body, and Composition; JHS, Jackson Heart Study; MESA, Multi-Ethnic Study of Atherosclerosis; NEO, the Netherlands 
Epidemiology of Obesity; PROSPER, Prospective Study of Pravastatin in the Elderly at Risk; RS, Rotterdam Study; SOL, Hispanic Community 
Health Study/Study of Latinos; WHI, Women’s Health Initiative    
NA indicates that this data was available as of this proposal.  The final dissertation project will have these numbers available. 
1
Excludes overlap of participates who are also included in the ARIC cohort 
2
The CHS African American cohort (N=687) was recruited in 1992-93 and has a length of follow-up of 7 years (4 visits) 
3
The FHS Offspring cohort (N=5,124) was recruited in 1971-75 and has a length of follow-up of 34 years (8 visits) 
4
The FHS 3
rd
 Generation cohort (N=4,095) was recruited in 2002-05 and has a length of follow-up of 6 years (2 visits) 
5
The RS-II cohort (N=3,011) was recruited in 2000-01 and has a length of follow-up of 11 years (3 visits) 
6
The RS-III cohort (N=3,932) was recruited in 2006-08 and has a length of follow-up of 6 years (2 visits) 
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A.2. Hispanic Community Health Study/Study of Latinos 
The SOL study collected data on approximately 16,000 Hispanic individuals from 
four communities: Miami, Florida; the Bronx, New York; Chicago, Illinois; and San Diego, 
California.
53
  Participants were aged 18-74 years at baseline and were sampled from 
communities with large HL populations, targeting the following subgroups: Mexicans, 
Cubans, Puerto Ricans, Dominicans, Central Americans, and South Americans.  Active duty 
military personnel and those physically unable to attend clinic visits were deemed ineligible.  
To avoid a language barrier, exams were conducted in both English and Spanish. 
A.3. Cohorts for Heart and Aging Research in Genetic Epidemiology 
The CHARGE consortium was formed to facilitate genome-wide association studies, 
meta-analyses, and replication opportunities among large, well-phenotyped longitudinal 
cohort studies with genetic data.
54
  CHARGE has five founding cohorts but has since grown 
to include more than ten large cohort studies.  Analyses are conducted through working 
groups.  This project will fall under the auspices of the pharmacogenomics working group 
(PWG).  
Age, Gene/Environment Susceptibility – Reykjavik Study 
The Age, Gene/Environment Susceptibility – Reykjavík Study (AGES) is the follow-
up study to the Reykjavik study in Iceland.  The Reykjavik study was a longitudinal study 
conducted from 1967-94 of 30,795 participants born between 1907 and 1935.
320
  Participants 
were selected from a random sample of the Reykjavik population.  Between 2002-06, the 
AGES study recruited 5,764 participants from the surviving 11,549 members of the 
Reykjavik Study. 
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Atherosclerosis Risk in Communities Study 
The Atherosclerosis Risk in Communities Study (ARIC) is a population-based cohort 
study of 15,792 individuals from four communities: Forsyth County, North Carolina; 
Jackson, Mississippi; Minneapolis, Minnesota; and Washington County, Maryland.
321
  
Participants ranged in age from 45 to 64 years at baseline.  Recruitment was concentrated on 
EU and AA populations.  All individuals in the targeted age range residing in households 
identified through area sampling were considered eligible for study participation. 
Cardiovascular Health Study 
The Cardiovascular Health Study (CHS) collected data on 5,201 individuals sampled 
from Medicare eligibility lists from four communities: Forsyth County, North Carolina; 
Sacramento County, California; Washington County, Maryland; and Pittsburgh, 
Pennsylvania.
322
  Participants were 65 years or older at study entry.  In 1992-93, an 
additional 687 AA individuals were recruited.  Participants who were home-bound, receiving 
hospice care, or receiving radiation or chemotherapy treatment were excluded. 
Erasmus Rucphen Family Study 
The Erasmus Rucphen Family study (ERF) is part of the Genetic Research in Isolated 
Populations (GRIP) program in the southwest Netherlands.
323, 324
  The ERF identified twenty-
two families with a minimum of six children baptized in the community church between 
1850 and 1900 through detailed genealogical records.  All living descendants of these 
couples and their spouses were invited to take part in this study, for which 3,200 individuals 
participated between 2002 and 2005. 
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Framingham Heart Study 
The Framingham Heart Study (FHS) collected data on 5,209 participants aged 28 – 
62 from residents of Framingham, Massachusetts.
325-327
  In 1971, 5,214 additional 
participants were enrolled in the FHS Offspring Study, recruiting from children and spouses 
of children of the original cohort.  In 2002, 4,095 additional participants were recruited from 
the population of children from the offspring cohort and enrolled into the 3
rd
 Generation 
cohort. 
Health, Aging, Body and Composition 
The Health, Aging, Body and Composition (Health ABC) study is a prospective 
cohort study that recruited individuals aged 70 – 79 from Medicare enrollees in Pittsburgh, 
Pennsylvania and Memphis, Tennessee.
328
  Participants were excluded if they had difficulty 
performing basic daily activities, difficulty walking a quarter mile or climbing steps, or had a 
life-threatening illness. 
Health 2000 
The Health 2000 study is a population-based health examination survey carried out in 
Finland from 2000 to 2001.
329, 330
  The survey was conducted with a two-stage stratified 
cluster sample representative of the Finnish adult population 30 years of age or older.  The 
Health 2000 performed a comprehensive health examination including questionnaires, 
clinical measurements, and physical examinations on 8,028 individuals. 
Jackson Heart Study 
The Jackson Heart Study (JHS) collected data on 5,301 non-institutionalized AA 
individuals from Jackson, Mississippi, aged 35 – 84 years.331  Participants who were 
physically or mentally incompetent were excluded. 
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Multi-Ethnic Study of Atherosclerosis 
The Multi-Ethnic Study of Atherosclerosis (MESA) study collected data on 6,814 
participants aged 45 – 84 and free of clinical cardiovascular disease from six communities: 
Forsyth County, North Carolina; Northern Manhattan and the Bronx, New York; Baltimore 
County, Maryland; St. Paul, Minnesota; Chicago, Illinois; and Los Angeles County, 
California.
332
  Participants were recruited from a diverse range of ethnic backgrounds.  
Exams were conducted in English, Spanish, Cantonese, and Mandarin.  Individuals 
undergoing active cancer treatment, who were pregnant, weighted more than 300 pounds, or 
were in a nursing home were excluded. 
The Netherlands Epidemiology of Obesity Study 
The Netherlands Epidemiology of Obesity (NEO) study is a population-based, 
prospective cohort of 6,673 individuals from the greater Leiden area of the Netherlands.
333
  
Between 2008 and 2012, all individuals aged 45-65 from Leiderdorp, a municipality of 
Leiden, and individuals with a reported body mass index greater than 27 kg/m
2
 from the 
greater Leiden area were recruited, resulting in an oversampling of overweight (43%) and 
obese (45%) individuals.  Participants answered questionnaires and were administered 
physical and medical examinations at baseline examinations, including medical histories, 
medication inventories, blood sampling, and resting ECGs. 
Prospective Study of Pravastatin in the Elderly at Risk 
The Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) study was a 
prospective, multicenter, randomized, placebo-controlled trial to assess whether treatment 
with pravastatin diminishes the risk of major vascular events in the elderly.
334, 335
  Between 
1997 and 1999, participants aged 70-82 years were screened and enrolled from Glasgow, 
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Scotland, Cork, Ireland, and Leiden, the Netherlands, resulting in a total cohort of 5, 804 
individuals. 
Rotterdam Study 
The Rotterdam Study (RS) recruited 7,893 subjects over the age of 55 from the 
Ommoord suburb of Rotterdam in the Netherlands for baseline examination.
336, 337
  In 2002, 
the RS-II recruited an additional 3,011 participants who were not eligible for the first round 
of the RS but had since turned 55 years of age or who had moved into the region since the 
start of the RS-I.  In 2006, an additional 3,932 participants were recruited into the RS-III.  
The RS-III recruited participants aged 45-54 years from the same base population as the 
previous RS recruitments.  
A.4. Exclusion Criteria 
Table 14.  Visit-Specific Exclusion Criteria 
Poor ECG Quality 
Atrial Fibrillation indicated on ECG 
Pacemaker Implantation 
2
nd
/3
rd
 Degree Atrioventricular Heart Block 
QRS > 120 ms 
Prevalent Heart Failure 
Pregnant 
Only study visits which measured both medication and ECGs will be considered for 
this analysis.  Individuals from the above studies will be excluded from this analysis based on 
the criteria listed in Table 14, which for studies with longitudinal data are visit-specific.  
Furthermore, individuals who did not consent to genetic analysis or who are not of EU, AA, 
or HL descent based on self-report or assessment of ancestry through principal component 
analysis will be excluded. 
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B. Outcome Assessment 
QT is measured, in milliseconds, using a standard 12-lead electrocardiogram (ECG).  
The 12-lead ECG involves the placement of electrodes on both arms, the left leg, and across 
the chest.  In each participating study, technicians recorded resting, supine or semi-
recumbent, standard 12-lead ECGs.  Studies used Marquette MAC 5000, MAC 12, or MAC 
PC (GE Healthcare, Milwaukee, Wisconsin, USA), or ACTA (EASOTE, Florence, Italy) 
machines.  Comparable procedures were used for preparing participants, placing electrodes, 
recording, transmitting, processing, and controlling quality of ECGs.  QT was measured 
electronically using one of the following programs: Marquette 12SL, MEANS, Burdick 
Eclips 850i, Digital calipers, or Health 2000 custom-made software.   
C. Exposure Assessment 
C.1. Medication Assessment 
Medication inventories were collected at examinations by each participating study 
except the RS on the same day as ECGs.  The RS assessment medication using pharmacy 
databases, recording all prescriptions filled less than or equal to 30 days before examination 
visits.  All other medication data was collected through a drug inventory.  The RS has 
validated this method of medication data collection against pharmacy databases, showing a 
94% concordance rate with pharmacy records.
56
  The CHS has also validated medication 
inventories against physiologic measurements
55
 and serum measurements.
57
  Medication 
inventories were either conducted during clinic visits or home interviews, varying by study.  
In both settings, medication data was recorded directly from medication containers, rather 
than through participant recall.  Recorded data included drug name, strength, and in some 
cases, dosing instructions.  Using recorded data and ingredient lists provided by drug 
companies, all participants will be classified as thiazide users or nonusers at each study visit.  
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Table 13 shows the prevalence of individuals taking a thiazide diuretic at a minimum of one 
study visit.  
C.2. Genotyping 
Each study conducted genome-wide genotyping independently prior to this study.  
WHI participants were genotyped through four sub-studies: GWAS of Treatment Response 
in Randomized Clinical Trials (GARNET); Modification of Particulate Matter-Mediated 
Arrhythmogenesis in Populations (MOPMAP); the SNP Health Association Resource 
(SHARe); and the WHI Memory Study (WHIMS).  The SOL study conducted genotyping 
using a custom array which included 109,571 ancestry informative markers.  See Table 15 
for a complete list of genotyping platforms using across all fourteen participating studies.  
All studies excluded SNPs which failed to meet Hardy-Weinberg equilibrium, had a MAF of 
less than 1%, or had a low call rate (<90-97%, varied by study).  To maximize genome 
coverage and comparisons across genotyping platforms, typed genotypes were used in each 
study to impute genotypes using HapMap2
338-341
 or 1000 Genomes
342, 343
 data. 
D. Data Analysis 
D.1. Genome-Wide Analysis 
Pharmacogenomic analyses will be conducted using a genome-wide analysis.  Each 
study will conduct race-stratified analyses with EU, AA, and HL populations for QT.  
Longitudinal data will be used whenever available and analyses will be conducted using a 
combination of linear regression, mixed effects models (MEM) and generalized estimating 
equations (GEE) depending on their study design and the availability of longitudinal data.  
All analyses will be adjusted for age (measured in years), sex, visit-specific RR  interval, 
visit specific QT altering medications defined using UAZ drug list (Table 6, Table 7), and  
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Table 15.  Genotyping Platforms 
Study Genotyping Array # of SNPs 
WHI   
GARNET Illumina HumanOmni1 Quad 1,051,295 
MOPMAP 
Affymetrix Genome-wide Human 
SNP Array 6.0 
934,940 
SHARe 
Affymetrix Genome-wide Human 
SNP Array 6.0 
934,940 
WHIMS Illumina HumanOmni Express 733,202 
SOL Illumina custom array 2,536,661 
CHARGE   
AGES Illumina 370 CNV 370,404 
ARIC 
Affymetrix Genome-wide Human 
SNP Array 6.0 
934,940 
CHS Illumina HumanOmni1 Quad 1,051,295 
FHS 
Multiple Affymetrix Mapping 
Arrays 
>262,264 
RS 
Illumina Infinium II HumanHap 
550 
555,352 
ERF Illumina 6K/318K/370K 374,496 
Health 2000 
Illumina Human610-Quad 
BeadChip 
601,273 
Health ABC Illumina 1M  1,049,348 
MESA 
Affymetrix Genome-wide Human 
SNP Array 6.0 
934,940 
PROSPER Illumina 660K 557,192 
NEO 
Illumina HumanCoreExome-
24v1_A Beadchip 
361,046 
JHS 
Affymetrix Genome-wide Human 
SNP Array 6.0 
934,940 
 
study specific measures of principal components of genetic ancestry,study site or region, and 
relatedness when appropriate. 
Cross-Sectional Studies 
Studies for which only one ECG/drug measure per participant is available will 
conduct linear regression using robust estimates of standard errors if using populations of 
unrelated individuals or MEM if using populations of related individuals.  Using the 
following model: 
𝐸[𝑌𝑖] =  𝛽0 + 𝛽𝐸𝐼𝑖 + 𝛽𝐺𝑆𝑁𝑃𝑖 + 𝛽𝐺:𝐸𝐼𝑖𝑆𝑁𝑃𝑖 + 𝛽4𝐶𝑖 
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where Yi is our outcome of interest (QT, QRS, or JT in ms) for the i
th
 participant, β0 is the 
intercept, Ii is an indicator for thiazide use, SNPi is the (dosage of the) genetic variant, and Ci 
is the vector of covariates.  The primary parameter of interest is βG:E, the multiplicative 
interaction term between genotype and thiazide use. 
Longitudinal Studies 
Studies for which there are two or more study visits measuring both ECG and 
medication use will use GEE models with independence working correlation if using 
populations of unrelated individuals or MEM if using populations of related individuals, in 
both cases using robust estimates of standard errors.  All data from as many visits as possible 
with be used within each study.  Using the following model: 
𝐸[𝑌𝑖𝑗] =  𝛽0 + 𝛽𝐸𝐼𝑖𝑗 + 𝛽𝐺𝑆𝑁𝑃𝑖 + 𝛽𝐺:𝐸𝐼𝑖𝑗𝑆𝑁𝑃𝑖 + 𝛽4𝐶𝑖𝑗 
where Yij is our outcome of interest (QT, QRS, or JT in ms) for the i
th
 participant at the j
th
 
timepoint, β0 is the intercept, Iij is an indicator for thiazide use, SNPi is the (dosage of the) 
genetic variant, and Cij is the vector of covariates.  The primary parameter of interest is βG:E, 
the multiplicative interaction term between genotype and thiazide use. 
D.2. Meta-Analytic Techniques 
Two separate meta-analytic techniques will be used to combine data across studies.  
First will be a race-stratified, fixed-effect, inverse variance weighted meta-analysis 
conducted using the METAL program.
344
  However, the assumption that each contributing 
population will have the same underlying effect does not always hold across multiple 
race/ethnicities because of differences in patterns of LD across ancestral populations, 
potential allelic heterogeneity, differences in gene-environment interactions, differences in 
gene-gene interactions, and differences in environmental and lifestyle factors between 
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different race/ethnic groups.  Thus, to allow for underlying differences between race/ethnic 
groups, we will also conduct trans-ethnic meta-analysis using a Bayesian approach developed 
by Morris using the MANTRA program.
345
 
Fixed Effects Inverse Variance Weighted Meta-Analysis 
Fixed effects meta-analysis will be conducted, stratified by race, using METAL, 
using a genome-wide significance level of P < 5x10
-8
.
344
  However, in previous 
pharmacogenomics work conducted by the PWG has indicated that there is a possibility for 
early departure of the test statistic from the null distribution.  In such scenarios, a t-
distribution approach will be used.
346
  P-values will be recalculated by applying a t reference 
distribution to the drug-SNP interaction estimates of β (standard error [SE]), and then meta-
analyzed using a weighted Z-statistic, with weights based on the SNP imputation quality 
multiplied by the estimated number of independent observations exposed to thiazides 
(Nexposed).  Nexposed will be estimated as follows: 
1. In cross-sectional studies, Nexposed equals the number of participants classified as 
thiazide users. 
2. In longitudinal studies, Nexposed will be calculated as follows: 
𝑁𝑒𝑥𝑝𝑜𝑠𝑒𝑑 =∑
𝑛𝑖
1 + (𝑛𝑖 − 1)?̂?
#{𝐸𝑖𝑡 = 1}
𝑛𝑖
𝑖
 
where ni is the number of observations for participant i, ?̂? is an estimate of the 
pairwise visit-to-visit correlation within participants from a GEE-exchangeable 
model that does not contain genetic data, and #{𝐸𝑖𝑡 = 1} is the number of 
observations in which participant i is exposed. 
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Ideally, the cohort- and SNP-specific degrees of freedom (df) for the t reference distribution 
will be estimated using Satterthwaite’s method,347 both for cross-sectional and for 
longitudinal analyses: 
1. For cross-sectional studies, df will be calculated as follows: 
𝑑𝑓 = 2
𝐸[𝑉𝑎𝑟(?̂?)]
2
𝑉𝑎𝑟[𝑉𝑎𝑟(?̂?)]
 
Estimates of 𝐸[𝑉𝑎𝑟(?̂?)]
2
and 𝑉𝑎𝑟[𝑉𝑎𝑟(?̂?)] are calculated using an R code 
developed by Ken Rice, Thomas Lumley, et al. that is available on the CHARGE 
PWG wiki page: http://depts.washington.edu/chargeco/wiki/Pharmacogenetics. 
2. For longitudinal studies, df will be calculated as follows:  
𝑑𝑓 = 2
𝐸[𝑉𝑎𝑟(?̂?)]
2
𝑉𝑎𝑟[𝑉𝑎𝑟(?̂?)]
 
where 𝐸[𝑉𝑎𝑟(?̂?)]
2
 is assumed to equal 𝑉𝑎𝑟(?̂?) and the formula for estimating 
𝑉𝑎𝑟[𝑉𝑎𝑟(?̂?)] is based on the method presented by Pan and Wall.348  Longitudinal 
df estimates are calculated using the R bossWithdf package, available on the 
CHARGE PWG wiki page:  
http://depts.washington.edu/chargeco/wiki/Pharmacogenetics. 
If Satterthwaite’s method cannot be implemented in a particular cohort, then an approximate 
df will be calculated as the cohort- and SNP-specific product of the SNP imputation quality 
(range: 0,1), the MAF (range: 0, 0.50), and Nexposed. 
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Trans-Ethnic Meta-Analysis 
To allow for underlying differences between race/ethnic groups while also enabling 
us to take full advantage of the large sample size found across all three included race/ethnic 
groups, we will conduct a trans-ethnic meta-analysis using alternative methods.  The trans-
ethnic meta-analysis will use a Bayesian approach developed by Morris and implemented in 
MANTRA.
345
  MANTRA utilizes allele frequencies in each population to cluster studies 
according to genetic-relatedness and then generates a Bayes factor for each SNP.  Morris has 
determined that a significance level of 10
5
 is approximately equivalent to a genome-wide 
significant level of 5x10
-8
 and will be used as our significance level in these Bayesian 
analyses.
345
  However, this method does not provide an over-all effect estimate and so can be 
used to identify significant SNPs but cannot be used to estimate an effect size across 
race/ethnicities.  
Cross-Phenotype Meta-Analysis 
Previous studies have demonstrated the potential to increase power and detect 
evidence of pleiotropy by conducting multi-trait analysis across correlated traits.
349, 350
  To 
examine potential pleiotropy across ventricular depolarization and repolarization, we 
conducted cross-phenotype meta-analysis combining t-statistics across QRS and JT using an 
adaptive sum of powered score (aSPU) test, which tests for both concordant and discordant 
associations across some or all of the included traits.
351
  The reference distribution for the 
aSPU test was calculated using 10
8
 simulations. 
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D.3. Sensitivity Analyses 
It is important to remember that QT is a measure of both ventricular depolarization 
and repolarization, two processes that, although related, are opposites and can thus, under 
certain conditions, be oppositely affected.
60
  In the case identified by Akylbekova et al., the 
genetic effects underlying the QT interval work in opposite directions on QRS and JT and the 
associations with all intervals studied were substantially enhanced in patients with 
hypokalemia.  For example, before accounting for hypokalemia, the coded allele increased 
QTc by only 3.3 ms; however, when the interaction with hypokalemia was added, the coded 
allele increased QTc by 20.2 ms.
229
  This makes it imperative that we consider not just QT 
but also QRS and JT separately in order to fully capture the effects underlying QT 
prolongation, particularly when studying diuretics, which are known to alter potassium 
levels. 
To account for this, this work will conduct sensitivity analyses, examining both QRS 
and JT duration as outcomes.  QRS, like QT, was measured in ms using a standard 12-lead 
ECG.  For more detail, see Section Outcome Assessment.  JT will be calculated from QT and 
QRS as follows: 𝐽𝑇 = 𝑄𝑇 − 𝑄𝑅𝑆.  All analyses will be conducted using the same analysis 
plan that is used for QT, including exclusions, covariates, statistical analyses, and meta-
analysis.   
D.4. In-Silico Functional Characterization 
For all SNPs identified in the above analyses as genome-wide significant, including 
the sensitivity analyses, I will conduct in-silico functional characterization.  The in-silico 
characterization will be carried out in four stages (Figure 13).  First, I will use race-specific 
LD patterns to identify SNPs that are in high HD (r
2 
> 0.5) with the index SNPs identified in 
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the above analyses.  LD patterns will be based off the most recent release of the 1000 
Genomes
342, 343
 data and linked SNPs will be determined using two online databases: 
SNAP
352
 and HaploReg.
353
  The two databases complement each other, as the SNAP 
database examines a larger list of SNPs but HaploReg provides a greater degree of 
information, including structural details on nine cell types, conservation across different 
mammal species, and mutation type (i.e. nonsense, missense, silent, etc.).  In the second stage 
of characterization, I will examine the index SNPs, as well as all SNPs in high LD as 
determined by the first stage, in the dbSNP database
354
 and the UCSC GenomeBrowser,
355
 
which makes use of previous functional characterization, as well as the recent ENCODE 
project,
356
 which sought to characterize the non-coding regions of the genome.  I expect most 
findings will occur in the non-coding regions, such as promoter regions, and thus will impact 
expression levels rather than protein structure and function.  However, I do expect to find a 
subset of missense and nonsense mutations within the coding region of the genome, 
particularly among population-specific variants.  For this subset of SNPs, I will move onto 
the third stage of characterization, which will utilize SIFT
357-359
 and PolyPhen 2
360
 to predict 
the functional effects of the amino acid substitutions or premature terminations.  Finally, the 
fourth phase of characterization will examine each of the genetic loci identified in a pathway 
analysis using Ingenuity Pathway Analysis (IPA)
361
 to identify potential linkages within the 
genome between the genetic loci associated with drug response.  
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Figure 13.  Flowchart of In-Silico Functional 
Characterization 
Figure 14.  Statistical Power Curves, Presented for K=1, 3, and 5 Variants and a Range of 
Minor Allele Frequencies 
K represents the number of independent SNPs modifying the thiazide-QT association.  Curves 
represent the power to detect at least one SNP assuming K SNPs modify the association. 
Minor Allele Frequencies: 5% (Purple), 10% (Blue), 25% (Green), and 45% (Red) 
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E. Sample Size and Statistical Power 
Power was calculated using Quanto
362
 with a two-sided α = 5x10-8 and conservatively 
assuming a cross-sectional study design.  It is worth noting that 69% of the total population 
has multiple measures of medications and QT, indicating that our actual power will be higher 
than that estimated here.  Power estimates were calculated across a range of MAF (5-45%), 
an estimated 14% prevalence of thiazide use (based on Table 13), an expected main effect for 
both the SNP and thiazide of 2 ms, and a sample size of 94,479.  The power is low at low 
MAFs (interaction effects of >4 ms needed to achieve 80% power at MAF = 10%).  
However, at more common MAFs, this study is better powered.  At 25% MAF, there is 80% 
power to detect interaction effects of 2.8 ms and at 45% MAF, there is 80% power to detect 
interaction effects of 2.4 ms.  However, we expect multiple independent SNPs to be 
modifying the thiazide-QT association.  Therefore, assuming no between population variance 
in the interaction, I calculated the power to detect at least one association assuming that K 
independent SNPs modify the association between thiazides and QT (Figure 14).  At powers 
P0, P1…PN, the probability of detecting at least one variant of the K independent variants is 
1-(1-P0)(1-P1)…(1-PN).   Assuming only 3 independent SNPs modifying the thiazide-QT 
association, the threshold for 80% power decreases to 3.37 ms, 2.33 ms, and 2.03 ms for 
MAFs of 10%, 25%, and 45%, respectively.  At K=5, the threshold for 80% further decreases 
to 3.12 ms, 2.16 ms, and 1.88 ms for MAFs of 10%, 25%, and 45%, respectively.  As has 
been pointed out, these thresholds are expected to be lower given the inclusion of 
longitudinal data.  
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Specific Aim 2 
Examine the influence of prevalent user bias and exposure misclassification caused 
by prevalent user bias on a pharmacogenomics study conducted in an observational setting. 
a. Using simulations, evaluate bias, power, and type I error in the drug-SNP 
interaction caused by prevalent user bias and exposure misclassification.   
b. Compare the results of aim 2a under different study designs (e.g. whole cohort, 
active comparator, new-user). 
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A. Simulation Overview 
The simulation will begin with a literature review to design the relationships between 
QT, QT-prolonging medication use, and the genetic modification (Figure 15).  Using the 
results of this literature review, I will determine plausible effect sizes for thiazide, SNP, and 
drug-SNP effects on QT and determine important risk factors for QT prolongation.  The 
conceptual model includes seven covariates besides the SNP: age, sex, U, which represents 
unknown/unmeasured confounders of the drug-QT relationship, hypertension (HTN), 
Figure 15.  Conceptual Model of Relationship Between Study Variables 
→ Indicates a directed relationship between two variables 
┬ Indicates effect measure modification by one variable on the relationship between two other variables 
i indicates visit 1-4, ADR indicates the occurrence of an adverse drug reaction, U represents 
unknown/unmeasured correlation between QT between visits, Comparator represents an active 
comparator drug class, Drug represents the drug of interest, in this scenario modeled after a thiazide 
diuretic, SNP represents the genetic variant of interest that modifies the drug-QT relationship, and QT 
represents the QT interval 
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treatment of hypertension, diabetes, adverse drug reaction (ADR), and loss to follow-up.  
Furthermore, an active comparator is included in the model.  For our simulation analysis, we 
will simulate four visits.  The correlation between variables at Visit i and Visit i-1 will 
calculated based on correlation between visits 1 and 2 in the Atherosclerosis Risk in 
Communities (ARIC) study.  Furthermore, we will compare results across three study 
designs: whole cohort (WC), active comparator (AC), and new-user (NU). 
B. Simulation Parameters and Values 
For a summary of all variables to be simulated in this analysis, see Table 16.   
B.1. Covariates 
Age for each observation will be simulated using a normal distribution with a mean 
value determined using the ARIC baseline visit.  Sex will be simulated as a uniform random 
variable with a defined probability of being male.  Unknown/Unmeasured confounders (U) 
will be simulated using a normal distribution with a set mean and SD determined by the 
correlation seen between QT in visit 1 and visit 2 of the ARIC study.  Diabetes, hypertension, 
adverse events, and loss to follow-up will be simulated using binomial distributions as 
defined in Table 16. 
B.2. Genotype 
The genotype of the SNP will be simulated with a uniform distribution using a 
specified minor allele frequency (MAF), which will be varied across simulation runs and 
range between 5% and 45%.  The probability of an observation being heterozygous or 
homozygous for the major or minor allele will be calculated under the assumption of Hardy-
Weinberg equilibrium.  
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B.3. Drug Use 
QT-prolonging drug use at visit i will be predicted conditional on age and sex using a 
logit function:  
𝑖𝑓 {
𝑇𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡𝑖 = 0 𝑡ℎ𝑒𝑛 𝑝𝑟(𝐷𝑟𝑢𝑔𝑖) = 0 
𝑇𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡𝑖 = 1 𝑡ℎ𝑒𝑛 𝐿𝑜𝑔𝑖𝑡(𝑝𝑟(𝐷𝑟𝑢𝑔𝑖 = 1)) = 𝛼0 + 𝛼1𝐷𝑖𝑎𝑏𝑒𝑡𝑒𝑠𝑖
+𝛼2𝐷𝑟𝑢𝑔𝑖−1|𝑖>1 + 𝛼3𝐴𝐷𝑅𝑖 + 𝜀
} 
where 𝛼0 will correspond to a preset prevalence of QT-prolonging drug use, which will then 
be assigned using a binomial distribution and this calculated probability.  An active 
comparator drug will be simulated as: 
𝑖𝑓 {
𝑇𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡𝑖 = 0 𝑡ℎ𝑒𝑛 𝑝𝑟(𝐶𝑜𝑚𝑝𝑎𝑟𝑎𝑡𝑜𝑟𝑖) = 0
𝑇𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡𝑖 = 1 𝑡ℎ𝑒𝑛 𝐿𝑜𝑔𝑖𝑡(𝑝𝑟((𝐶𝑜𝑚𝑝𝑎𝑟𝑎𝑡𝑜𝑟𝑖)) = 1 − 𝑝𝑟(𝐷𝑟𝑢𝑔𝑖) + 𝜀
} 
B.4. QT Interval 
QT at the ith visit will be calculated using a linear model:  
𝑄𝑇𝑖 = 𝛽0 + 𝛽1𝐷𝑟𝑢𝑔𝑖 + 𝛽2𝑆𝑁𝑃 + 𝛽3𝐷𝑟𝑢𝑔𝑖 × 𝑆𝑁𝑃 + 𝛽4𝐴𝑔𝑒𝑖 + 𝛽5𝑆𝑒𝑥 + 𝛽6𝐷𝑖𝑎𝑏𝑒𝑡𝑒𝑠 
+𝛽7𝐻𝑇𝑁 + 𝛽8𝑈 + 𝜀 
where the mean and SD of QT will be set based on ARIC’s baseline visit.   
C. Simulation Models and Analyses 
Multiple simulation models will be run to compare different conditions.  The effect of 
age, sex, heart rate, HTN, diabetes, and U will not vary across models.  The SNP main effect, 
drug-SNP interaction, and the MAF will be varied across models.  Furthermore, to test the 
effect of prevalent user bias on the interaction effect, different levels of informative 
missingness (through adverse events and loss to follow-up) will be tested.  Figure 17 presents 
different scenarios which could lead to prevalent user bias in a longitudinal study with two 
visits, spaced two years apart.  Scenario 1 represents a prevalent user.  Scenario 2 represents 
an incident user.  Scenarios 3-6 represent possible scenarios which could lead to prevalent 
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Table 16.  Simulation Parameters and Scenarios  
Parameter Simulation Scenario 
Age Normal distribution, mean determined using ARIC data 
Sex Uniform random variable with defined probability of being male 
Unmeasured/Unknown 
Confounders (U) 
Normal distribution, mean determined by the correlation between QT in visits 1 
and 2 in ARIC study 
SNP Uniform distribution with defined minor allele frequency, which will vary 
across models, and with probability of being heterozygous/homozygous 
calculated under Hardy-Weinberg equilibrium 
Diabetes (Diabetes) 
 
Binomial distribution with probability of Diabetes=1 defined as follows: 
𝐿𝑜𝑔𝑖𝑡(𝑝𝑟(𝐷𝑖𝑎𝑏𝑒𝑡𝑒𝑠 = 1)) = 𝛼0 + 𝛼1𝐴𝑔𝑒 + 𝜀 
Hypertension at visit i 
(HTNi) 
 
Binomial distribution with probability of HTN=1 defined as follows:  
𝐿𝑜𝑔𝑖𝑡(𝑝𝑟(𝐻𝑇𝑁𝑖 = 1)) = 𝛼0 + 𝛼1𝐴𝑔𝑒 + 𝛼2𝑆𝑒𝑥 + 𝛼3𝐻𝑇𝑁𝑖−1|𝑖>1 + 𝜀 
Treated HTN at visit i 
(Treatmenti) 
Binomial distribution with probability of Treatment=1 defined as follows: 
𝑖𝑓 {
𝐻𝑇𝑁𝑖 = 0 𝑡ℎ𝑒𝑛 𝑝𝑟(𝑇𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡𝑖) = 0
𝐻𝑇𝑁𝑖 = 1 𝑡ℎ𝑒𝑛 𝐿𝑜𝑔𝑖𝑡(𝑝𝑟(𝑇𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡𝑖 = 1)) = 𝛼1𝑅 + 𝜀
𝑤ℎ𝑒𝑟𝑒 𝑅 𝑟𝑒𝑝𝑟𝑒𝑠𝑒𝑛𝑡𝑠 𝑎 𝑟𝑎𝑛𝑑𝑜𝑚 𝑛𝑢𝑚𝑏𝑒𝑟
 
QT Prolonging Drug Use 
at Visit i  (Drugi) 
or Alternative Drug at 
Visit i (Comparatori) 
 
 
 
Binomial distribution with probability of Comparator=1 defined as follows: 
𝑖𝑓
{
 
 
 
 
𝑇𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡𝑖 = 0 𝑡ℎ𝑒𝑛 𝑝𝑟(𝐷𝑟𝑢𝑔𝑖) = 0 𝑎𝑛𝑑 𝑝𝑟(𝐶𝑜𝑚𝑝𝑎𝑟𝑎𝑡𝑜𝑟𝑖) = 0
𝑇𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡𝑖 = 1 𝑡ℎ𝑒𝑛 𝐿𝑜𝑔𝑖𝑡(𝑝𝑟(𝐷𝑟𝑢𝑔𝑖 = 1)) = 𝛼0 + 𝛼1𝐷𝑖𝑎𝑏𝑒𝑡𝑒𝑠𝑖
+𝛼2𝐷𝑟𝑢𝑔𝑖−1|𝑖>1 + 𝛼3𝐴𝐷𝑅𝑖 + 𝜀
𝑎𝑛𝑑 𝐿𝑜𝑔𝑖𝑡(𝑝𝑟((𝐶𝑜𝑚𝑝𝑎𝑟𝑎𝑡𝑜𝑟𝑖)) = 1 − 𝑝𝑟(𝐷𝑟𝑢𝑔𝑖) + 𝜀
 
QT at Visit i (QTi) 
 
 
𝑄𝑇𝑖 = 𝛽0 + 𝛽1𝐷𝑟𝑢𝑔𝑖 + 𝛽2𝑆𝑁𝑃 + 𝛽3𝐷𝑟𝑢𝑔𝑖 × 𝑆𝑁𝑃 + 𝛽4𝐴𝑔𝑒𝑖 + 𝛽5𝑆𝑒𝑥 + 𝛽6𝑈
+ 𝛽7𝐷𝑖𝑎𝑏𝑒𝑡𝑒𝑠𝑖 + 𝛽8𝐻𝑇𝑁𝑖 + 𝜀 
Adverse Event (ADR) Binomial distribution with probability of ADR defined as follows: 
𝑖𝑓 {
𝐷𝑟𝑢𝑔𝑖−1 = 0 𝑡ℎ𝑒𝑛 𝑝𝑟(𝐴𝐷𝑅) = 0
𝐷𝑟𝑢𝑔𝑖−1 = 1 𝑡ℎ𝑒𝑛 𝐿𝑜𝑔𝑖𝑡(𝑝𝑟(𝐴𝐷𝑅𝑖 = 1)) = 𝛼0 + 𝛼1𝑄𝑇𝐿𝑜𝑛𝑔
𝑤ℎ𝑒𝑟𝑒 𝑄𝑇𝐿𝑜𝑛𝑔  𝑖𝑠 𝑑𝑒𝑓𝑖𝑛𝑒𝑑 𝑢𝑠𝑖𝑛𝑔 𝑄𝑇𝑖−1 + 𝜀
 
 
Loss to Follow-up at Visit 
i (Lossi) 
Binomial distribution with probability of Loss=1 defined as follows: 
𝑖𝑓 {
𝐿𝑜𝑠𝑠𝑖−1|𝑖>1 = 1 𝑡ℎ𝑒𝑛 𝑝𝑟(𝐿𝑜𝑠𝑠𝑖) = 1
𝐿𝑜𝑠𝑠𝑖−1|𝑖>1 = 0 𝑡ℎ𝑒𝑛 𝐿𝑜𝑔𝑖𝑡(𝑝𝑟(𝐿𝑜𝑠𝑠𝑖 = 1)) = 𝛼0 +
+𝛼2𝐴𝐷𝑅 + 𝜀
𝛼1𝐴𝑔𝑒 
   
   
user bias through differential misclassification (scenarios 3-4) or depletion of susceptibles 
(scenarios 5-6).  The simulation of Drugi accounts for scenario 3 by accounting for the 
probability that an ADR occurred.  Scenarios 4-6 will be accounted for by allowing ADRs 
and loss to follow-up between visits 1 and 4.   
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Figure 16.  Flowchart of Simulation Analysis 
Process 
Figure 17.  Scenarios Leading to Prevalent User Bias in Pharmacoepidemiology Studies 
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The following parameters will be varied across models: MAF, probability of an 
ADR/loss to follow-up, SNP main effect, and SNP-drug interaction effect.  Variable MAF 
will cause the SNP parameter to vary across models.  The variable ADR will cause the Drugi 
parameter to vary across models.  Variation in the SNP and Drugi parameters will 
subsequently cause the QTi parameter to vary across models. 
I will then use the simulations to contrast three different study designs: whole cohort 
(WC), active comparator (AC), and new-user (NU).  For WC simulations, no cohort 
observations will be excluded.  For AC simulations, analyses will be restricted to those on a 
QT-prolonging drug or those on the simulated alternative drug.  Finally, for NU simulations, 
prevalent QT-prolonging drug users at visit 1 will be excluded from analyses.  For each study 
design, I will evaluate all model conditions as discussed above.  For a breakdown of the 
simulation process, see Figure 16.  All models will estimate the QT-prolonging drug-SNP 
interaction using generalized estimating equations with an independence working correlation 
matrix and be run for both longitudinal data (visits 1-4) and a stacked cross-sectional 
approach (visit 1 and 4 only). 
Integration of Specific Aims 1 and 2 
I will use the results of Specific Aim 2 to inform the interpretation of results from 
Specific Aim 1.  In an ideal scenario, the simulation study from the first aim will indicate that 
the potential impacts of prevalent user bias on a pharmacogenomics study are negligible 
under the given parameters.  However, in the event that Aim 2 indicates that prevalent user 
bias is a cause for concern, there are several potential steps which can be taken, depending on 
the level of concern.  For example, if the potential bias is only of concern in SNPs with small 
MAF, these SNPs can be excluded from the analysis on a study-by-study basis.  Furthermore, 
we can filter on effect size for bias associated with effect size.  If there is a greater potential 
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for prevalent user bias to affect the results of the pharmacogenomics study, results will be 
interpreted conditional on the level of concern indicated.  While I appreciate that 
probabilistic sensitivity analysis or inverse-probability-of-treatment-weighting are potential 
steps for handling bias in single-exposure studies, both the scale and the scope (i.e. 2.5 
million SNPs examined in fifteen studies) of this interaction study make the potential burden 
of these methods unreasonable.  Therefore, I will instead consider the results of Specific Aim 
1 conditional on the results of Specific Aim 2. 
Strengths and Limitations 
This study represents the first large, multi-ethnic pharmacogenomics study of thiazide 
diuretics, a commonly used antihypertensive medication, and QT, the prolongation of which 
is a leading cause of the withdrawal or restricted marketing of pharmaceuticals.  This work 
will also make use of the deep phenotyping and genotyping available in the participating 
cohorts (the Women’s Health Initiative [WHI], the Hispanic Community Health Study/Study 
of Latinos [SOL], and the Cohorts for Heart and Aging Research in Genetic Epidemiology 
[CHARGE] consortium).  By bringing together these fourteen study populations (WHI, SOL, 
and twelve member studies in the CHARGE consortium), many of which have longitudinal 
measures of thiazide use and QT, this study will have a significantly larger population than 
previous pharmacogenomics studies, substantially increasing the power to detect a much 
greater range of interaction effects than was possible in previous studies.  Furthermore, I will 
take advantage of the large AA and HL populations available in the participating cohorts, 
broadening generalizability and allowing me to leverage the unique genetic architecture that 
characterizes AA and HL populations.  Finally, I will incorporate recently developed 
techniques for including functional annotations in genetic analyses, which will allow this 
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work to prioritize findings based on the probability of causality, something which much of 
the early genetics and pharmacogenomics work has failed to accomplish. 
However, there are several limitations to this work.  First, I am relying on 
observational cohort studies, which are known to be potentially biased in 
pharmacoepidemiologic studies.  Of particular concern is the chance of medication 
inventories to miss cases of short term medication use and acute ADRs.  To avoid this, 
pharmacy-linked databases with more complete medication-use data are preferable.  
Unfortunately, at this stage, these databases have no mechanism for linking genetic data or 
deep phenotyping data to individual records, making large, population based cohorts the best 
alternative.  Furthermore, it is unclear if these potential biases are a concern in 
pharmacogenomic studies, which study the drug-gene interaction.  This work will also run 
simulations to determine the potential issues with selection bias on pharmacogenomics work 
and the best study designs for handling this data, which can then be used to inform the 
subsequent work. 
Additionally, results of the trans-ethnic meta-analysis will be driven by the 
contributing EU population, which is more than 3.5 times larger than the next largest 
race/ethnic group (HL).  Furthermore, the power of this study is a concern, given that this is 
both a GxE interaction study and a genome-wide study, both of which negatively impact 
power.  However, this is the largest pharmacogenomics work on QT to date and has the 
largest populations of non-EU participants.  There have been extensive efforts to identify and 
include any studies with ECG, medication, and genotype data, with an emphasis on 
identifying cohorts with multi-ethnic populations.  In addition, this work leverages the 
longitudinal data available in many of the participating cohorts, further increasing our power 
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to detect interaction associations.  Finally, given the extensive efforts to identify and include 
all available studies with the needed data, there is no replication sample for this work.  
However, given the size of the populations (78,199), results are more robust to the potential 
of winner’s curse, a form of bias that results in the over-estimation of effect sizes and 
consequently results in false positives.  While most GWAS use replication samples to protect 
against winner’s curse, the large sample size in this work will aid in protecting this analysis 
from the selection that results in winner’s curse.        
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CHAPTER 5: RESEARCH PAPER 1-PHARMACOGENOMICS STUDY OF 
THIAZIDE DIURETICS AND QT INTERVAL IN MULTI-ETHNIC 
POPULATIONS: THE COHORTS FOR HEART AND AGING RESEARCH IN 
GENOMIC EPIDEMIOLOGY (CHARGE)
1
 
Introduction 
 Over the past decade, the use of prescription drugs has skyrocketed, with nearly half 
of all Americans now taking at least one prescription drug.
1
  Accompanying the increased 
prevalence of drug use is a high burden of adverse drug reactions (ADRs), which account for 
approximately 100,000 deaths and 2.2 million serious health effects annually.
2-4
  QT interval 
(QT) prolongation, which can trigger fatal ventricular arrhythmias, is a long-recognized 
adverse effect
185
 of numerous common medications such as antipsychotics, antibiotics, 
antiarrhythmics, and antihypertensives.
146
  Within the past ten years, QT prolongation has 
represented the most common cause for withdrawal of a drug from the market (or relabeling) 
after approval by the U.S. Food and Drug Administration (FDA).
39, 145
  However, drug-
induced QT prolongation remains difficult to predict.
38
    
 Genetic variants are known to mediate both pharmacokinetic and pharmacodynamic 
processes, thereby playing a major role in drug response. 
61
  Pharmacogenomics, which 
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evaluates the role of genetics in drug response, offers a promising avenue for understanding 
variation in drug response,
7
 illuminating novel pathways, informing drug development and 
selection,
8-10
 optimizing dosing regimens,
11-15
 and avoiding ADRs.
16-18
  QT is highly 
heritable (35-40%).
24-27, 363
 Previous pharmacogenomics studies of drugs associated with QT 
prolongation, including thiazide diuretics, a common antihypertensive therapy used by over a 
quarter of the U.S. hypertensive population,
37
 identified multiple loci associated with anti-
hypertensive response and ADRs.
272, 273, 275-278
  Therefore, the pharmacogenomics of thiazide-
induced QT prolongation represents an excellent but understudied candidate for 
pharmacogenomic inquiry. 
 We previously examined evidence for common single nucleotide polymorphisms 
(SNPs) that modified the association between thiazide use and QT and failed to identify any 
genome-wide significant (P<5x10
-8
) loci.
282
  However, our previous study was limited to 
European descent populations and cross-sectional analyses, despite many of the contributing 
studies having longitudinal drug and electrocardiographic data.
282
  Here, we expand upon that 
work, applying recent statistical innovations to leverage longitudinal data and including an 
additional 44,418 participants of European, African American, and Hispanic/Latino descent 
to perform the first trans-ethnic genome-wide association study (GWAS) to examine genetic 
associations that modify the association between thiazides and QT, as well as the component 
parts of QT (JT interval [JT], QRS interval [QRS]). 
Materials and Methods 
A. Study Populations 
 Fourteen cohorts participated in this analysis from in the Cohorts for Heart and Aging 
Research in Genomic Epidemiology (CHARGE)
54
 Pharmacogenomics Working Group 
(PWG), contributing 78,199 participants: European descent (51,601), African American 
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(11,482), and Hispanic/Latino (15,116) participants (Table 19, Supplementary Text).   
Among the fourteen cohorts, six (55% of the total population) had repeated measurements of 
medication use and electrocardiogram (ECG) assessments and contributed longitudinal data 
to the analysis: Age, Gene/Environment Susceptibility – Reykjavik Study (AGES), 
Atherosclerosis Risk in Communities (ARIC) Study, Cardiovascular Health Study (CHS), 
Rotterdam Study (RS), Multi-Ethnic Study of Atherosclerosis (MESA), and Women’s Health 
Initiative (WHI).  The remaining eight cohorts contributed cross-sectional data to the 
analysis: Framingham Heart Study (FHS), Erasmus Rucphen Family (ERF) Study, Health 
2000, Health, Aging, and Body Composition (Health ABC), Prospective Study of Pravastatin 
in the Elderly at Risk (PROSPER), Jackson Heart Study (JHS), Netherlands Epidemiology of 
Obesity (NEO) Study, and Hispanic Community Health Study/Study of Latinos 
(HCHS/SOL). 
B. Study Design 
Participants with electrocardiogram (ECG) measurements, medication assessment, 
and genome-wide genotype data were eligible for inclusion.  The following exclusion criteria 
were applied: poor ECG quality, atrial fibrillation detected by ECG, pacemaker implantation, 
second or third degree atrioventricular heart block, QRS greater than 120 milliseconds (ms), 
prevalent heart failure, pregnancy, missing ECG, missing medication assessment, missing 
genotype information, or race/ethnicity other than European descent, African American, or 
Hispanic/Latino.  For studies with longitudinal data, exclusion criteria were applied on a 
visit-specific basis.  
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C. Medication Assessment 
 Medication use was assessed through medication inventories conducted during clinic 
visits or home interviews or through pharmacy databases (Table 20).  Six studies captured 
medication used on the day of the study visit.  A further six of the 14 participating cohorts 
captured medications used one to two weeks preceding ECG assessment.  HCHS/SOL 
ascertained medications used within four weeks preceding ECG measurement and the RS 
captured medication used within 30 days preceding ECG assessment.  Participants were 
classified as thiazide diuretic users if they took a thiazide or thiazide-like diuretic in a single 
or combination preparation, with or without potassium (K)-sparing agents, and with or 
without K-supplements. 
For cross-sectional studies, the number of exposed participants (Nexposed) was defined 
as the number of participants classified as thiazide users.  For studies with longitudinal data, 
Nexposed was calculated as follows: 
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where ni is the number of observations for participant i, ˆ  is an estimate of the pairwise 
visit-to-visit correlation within participants from a Generalized Estimating Equation (GEE)-
exchangeable model that does not contain genetic data, and  1# itE  is the number of 
observations for which participant i was exposed.
346
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D. ECG Interval Measurement 
 QT and QRS were digitally recorded by each participating study using resting, supine 
or semi-recumbent, standard 12-lead ECGs (Table 21).  Comparable procedures were used 
for preparing participants, placing electrodes, recording, transmitting, processing, and 
controlling quality of ECGs.  Studies used Marquette MAC 5000, MAC 12, MAC 1200, or 
MAC PC (GE Healthcare, Milwaukee, Wisconsin, USA), University of Glasgow (Cardiac 
Science, Manchester, UK), or ACTA (EASOTE, Florence, Italy) machines.  Recordings were 
processed using one of the following programs (Marquette 12SL, MEANS, University of 
Glasgow, digital calipers, or Health 2000 custom-made software.  JT was calculated by the 
formula: JT=QT–QRS. 
E. Genotyping and Imputation 
 Each study conducted genome-wide genotyping independently using either 
Affymetrix (Santa Clara, CA, USA) or Illumina (San Diego, CA, USA) arrays (Table 22).  
Sex mismatches, duplicate samples, and first-degree relatives (except in ERF, FHS, 
HCHS/SOL, and JHS) were excluded.  DNA samples with call rates less than 95-98% were 
excluded as were SNPs with SNP call rates less than 90-98%, minor allele frequencies 
(MAF) less than 1%, or that failed Hardy-Weinberg equilibrium.  To maximize genome 
coverage and comparisons across genotyping platforms, genotypes were imputed using 
HapMap2,
338-340
 1000 Genomes Phase 1, or 1000 Genomes Phase 3 reference panels.
342, 343
  
Genotypes imputed using build 37 were lifted over to build 36
364, 365
 to enable comparisons 
between imputation platforms and results were restricted to SNPs present in HapMap2.  
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F. Statistical Analyses 
 Genome-wide pharmacogenomic analyses were performed by each cohort 
independently across approximately 2.5 million SNPs for QT, QRS, and JT separately.  
Drug-SNP interactions were estimated assuming an additive genetic model, using mixed 
effect models, GEE, or linear regression with robust standard errors.  The analytic model 
varied based on study design and the availability of longitudinal data (Table 23).  All 
analyses were adjusted for age (years), sex when applicable, study site or region, principal 
components of genetic ancestry, visit-specific RR interval (ms), and visit-specific QT 
altering medications defined using the University of Arizona Center for Education and 
Research on Therapeutics (UAZ CERT) QT-prolonging drug classification.
146
  Furthermore, 
ERF, FHS, and HCHS/SOL incorporated estimates of relatedness into all analyses.  Study-
specific results were corrected for genomic inflation (λ). 
 Previous simulations demonstrated that models using robust standard errors 
underestimate the variance of coefficient estimates for SNPs with low MAFs.
346
  To account 
for this underestimation, corrected standard errors were calculated using a (Student’s) t-
reference distribution.
346
  The degrees of freedom (df) for the t-reference distribution were 
estimated using Satterthwaite’s method.347  When cohorts were unable to implement 
Satterthwaite’s method, an approximate df was calculated as twice the cohort- and SNP-
specific product of the SNP imputation quality (range: 0,1), the MAF (range: 0.0,0.50), and 
Nexposed.  Standard errors were then “corrected” by assuming a normal reference distribution 
that yielded the t-distribution based P-values from the beta estimates.
346
  Furthermore, 
because simulations demonstrated that corrected standard errors were unstable when minor 
allele counts among the exposed were low, a cohort-specific df filter of 15 was applied across 
all SNPs.
346
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 For each trait, race-stratified and trans-ethnic betas and corrected standard errors were 
combined with inverse-variance weighted meta-analysis conducted in METAL.
344
  We used a 
genome-wide significance threshold of P<5x10
-8
 and a suggestive threshold of P<5x10
-6
.  
However, the assumptions of a fixed-effects meta-analysis do not always hold between 
race/ethnicities due to differences in patterns of linkage disequilibrium (LD) across ancestral 
populations, potential allelic heterogeneity, differences in gene-environment and gene-gene 
interactions, and differences in environmental and lifestyle factors.
300, 366
  Therefore, trans-
ethnic meta-analysis was also conducted using the Bayesian MANTRA approach and a 
genome-wide threshold of log10(Bayes Factor [BF])>6 and a suggestive threshold of 
log10(BF)>5.
345
  Additionally, previous studies have demonstrated the potential to increase 
power and detect evidence of pleiotropy by conducting multi-trait analysis across correlated 
traits.
349, 350
  To examine potential pleiotropy across ventricular depolarization and 
repolarization, we conducted cross-phenotype meta-analysis combining t-statistics across 
QRS and JT using an adaptive sum of powered score (aSPU) test, which tests for both 
concordant and discordant associations across some or all of the included traits.
351
  The 
reference distribution for the aSPU test was calculated using 10
8
 simulations. 
  Genome-wide significant and suggestive meta-analysis results were examined for 
gene or pathway enrichment.  Previous work has shown that it is beneficial to apply multiple 
methods of gene-set analysis (GSA) when the underlying etiology of the genetic mechanism 
is unclear.
367-369
   We therefore used two methods of GSA.  We performed a multiple 
regression gene analysis approach followed by a self-contained GSA using gene-level 
regression as implemented in MAGMA.
370
  Post-meta-analysis P-values were used as input 
in the analysis and gene-sets were collected from Ingenuity,
371
 Panter,
372
 KEGG,
373
 and 
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ConsensusPathDB
374, 375
 and restricted to biologically motivated pathways involved in the 
following: ion transport and homeostasis, transcription and translation, renal and cardiac 
development and function, and pharmacokinetic/dynamic pathways.  Additionally, we 
selected all SNPs with P<1x10
-5
 for analysis with DEPICT, which searches for gene, gene-
set, and tissue enrichment among 14,461 reconstituted gene-sets, eliminating the need to 
select candidate gene-sets.
376
  To account for multiple testing, we applied a false discovery 
rate (FDR) threshold of 5% for both GSA approaches.  
G. Statistical Power Simulations 
 Power to detect drug-SNP interactions using cross-sectional and longitudinal 
modeling approaches was estimated via simulation studies.  Assumptions, which were 
informed by European ancestry populations, included: (1) 50,000 participants; (2) a two-
sided, per-SNP α=5x10-8; (3) a mean heart rate-corrected QT (standard deviation)=400 (30) 
ms; (4) Nexposed=8,100; (5) a mean drug effect for those with zero copies of the minor allele=5 
ms; (6) a mean SNP effect for those not exposed to drug=0 ms; (7) a MAF=0.05 or 0.25; (8) 
an additive model of inheritance; (9) two study visits for longitudinal simulations; (10) 
within-person QT correlation=0.80; (11) an attrition rate between visits for longitudinal 
simulations=0.13; (12) random missingness rate across study visits=0.09; and (13) an 
independent GEE correlation structure for longitudinal simulations.  For longitudinal 
simulations, drug use was either temporally constant or variable.  When variable, drug 
exposure was assumed to be completely random at both visits.   
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Results 
A. Study Characteristics 
 A total of 78,199 participants were included in the analysis, of which 13,730 (18%) 
were exposed to thiazides (Table 19).  Thiazide use was most common among African 
Americans (36%), compared with 16% and 9% among European descent and 
Hispanic/Latino populations, respectively.  Mean age ranged from 40 (FHS) to 75 years 
(PROSPER) and the percentage of females ranged from 47% (NEO, PROSPER) to 100% 
(WHI).  Average QT was between 389 ms (H2000) and 416 ms (HCHS/SOL). 
B. Genome-Wide Analysis of Interaction Between Thiazides and QT Interval 
  Q-Q plots for individual study results, as well as for meta-analyzed results, 
demonstrated adequate calibration of study specific test statistics (Figure 18, Appendix 2).  
However, the family-based studies (ERF, FHS, HCHS/SOL) showed modest evidence of 
over-dispersion (λ=1.07 – 1.16). 
No genome-wide significant thiazide-SNP interaction effects were detected in any 
race/ethnic group (Figure 19).  However, suggestive interaction effects (P<5x10
-6
) were 
found for 22 loci in at least one race/ethnic group: European descent (seven loci), African 
American (six loci), Hispanic/Latino (six loci), or trans-ethnic (nine loci) (Figure 19, Table 
24).  Only the DNAH8/BTBD9 locus was suggestively significant in more than one 
race/ethnic group (rs862433 in African Americans, rs1950398 in Hispanic/Latinos).  Only 
two of the suggestive SNPs were heterogeneous across populations with Phet<0.05 
(rs4890550 and rs13223427). 
Additionally, examination of 35 loci previously associated with QT in a published 
main effects GWAS
209
 found no significant associations in European descent populations 
using a Bonferroni corrected threshold of P<0.001 (0.001=0.05/35; Table 25).  The 
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magnitude of the interaction effect was close to zero for all but six of the 35 SNP, which had 
interaction effects greater than 0.50 ms. 
Similarly, while no locus showed genome-wide significance in our trans-ethnic 
MANTRA analysis (Figure 20), one SNP (rs2765279) were above the suggestive threshold, 
with a log10(BF) of 5.2.  Rs2765279, located in RGSL1, a gene involved in G-protein 
signaling regulation, was also the most significant SNP in the fixed-effects trans-ethnic 
analysis (P=3x10
-7
). 
C. Genome-Wide Analysis of Interaction Between Thiazides and QRS Interval or JT 
Interval 
 Results for QRS showed a similar pattern to those for QT (Figure 21, Table 26).  
Whereas no results achieved genome-wide significance, 28 loci showed suggestive evidence 
of modifying the thiazide-QRS association (four loci in European descent populations, 11 in 
African Americans, eight in Hispanic/Latinos, and seven in trans-ethnic populations) and 
only one SNP had a Phet<0.05 (rs11591185).  The most significant SNP, rs7638855 (P=2x10
-
7
), located upstream from GAP43, was also suggestively significant after trans-ethnic 
analysis in MANTRA (log10(BF)=5.4; Figure 20).   
 Similarly, no SNPs showed genome-wide significant interaction for JT, although 19 
loci were suggestively associated (five loci in European descent populations, four in African 
Americans, five in Hispanic/Latino, and seven in trans-ethnic populations; Figure 21, Table 
27).  No SNPs showed significant heterogeneity between populations.  Moreover, MANTRA 
analysis identified two SNPs that achieved suggestive significance (Figure 20).  The 
rs1264878 variant near KCNIP4, a voltage-gated potassium channel interacting protein was 
the most significant SNP in our fixed-effects meta-analyses (P=3x10
-7
) and had a 
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log10(BF)=5.1.  However, most significant SNP in MANTRA meta-analyses was rs9303589, 
in CA10, with a log10(BF)=5.1. 
D. Cross-Phenotype Meta-Analysis 
 Cross-phenotype meta-analysis found no genome-wide significant evidence of 
pleiotropy across QRS and JT (Figure 22, Figure 23).  However, eight loci had a suggestive 
evidence of thiazide-SNP interaction after meta-analyzing QRS and JT results (Table 28).  
These included three loci that were nominally associated with QRS and JT (P<0.05), but 
whose effects did not reach the suggestive association threshold in either univariate analysis 
(rs1295230 [PIK3R6], rs6931354 [ADGRB3], and rs8119517 [PREX1]). 
E. Gene and Pathway Enrichment Analysis 
Although analysis with DEPICT found no gene or tissue enrichment, gene-set 
enrichment analysis in European descent populations found enrichment in the ATXN3 
subnetwork for the interactive effect of genotype and thiazide use on QT (P=1x10
-6
).  There 
was no enrichment found in QRS or JT analyses.  MAGMA analyses found significant 
enrichment in six genes among African Americans in the interactive effect of genotype and 
thiazide use on QRS: CNTRL, CPN1, FAM65B, RAB14, ISY1, NELL1 (Table 29).  No other 
analyses found gene enrichment.  MAGMA GSA for QT and JT analyses found significant 
enrichment for transcription and translational pathways, although no gene-set enrichment 
was found in QRS analyses (Table 30). 
F. Statistical Power 
Given the biologic plausibility of the suggestive results for all three traits, we 
examined statistical power for our analysis to assess our ability to detect interaction effects.  
Simulations demonstrated that all analyses were underpowered to detect thiazide-SNP 
interaction effects less than 3 ms (e.g. 15% power to detect an interactive effect of 2 ms; 
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Figure 24).  However, even with time-varying drug exposure (i.e. observed QT measurement 
on and off drug within an individual), which demonstrated the greatest power, analyses for 
SNPs with MAF=5% did not achieve 80% power until the thiazide-SNP interaction effect 
reached 6 ms. 
Discussion 
 In this study, we examined 78,199 participants of European, African American, or 
Hispanic/Latino descent for evidence of thiazide-SNP interactions influencing QT.  Although 
we used a comprehensive approach that considered multi-ethnic populations, leveraged 
pleiotropy, accommodated population heterogeneity, and examined QT as well as its 
component parts (QRS, JT), we did not identify any genome-wide significant SNPs 
modifying the association between thiazides and these ECG intervals.  However, we 
identified 74 loci with suggestive evidence of association through both univariate and cross-
phenotype analyses as well as evidence of enrichment in pathways involved in transcription 
and translation.   
Interestingly, our suggestive results included multiple loci involved in ion transport 
and handling, the disruption of which is believed to be an underlying mechanism in drug-
induced QT prolongation,
111
 supporting the hypothesis that common SNPs modify the 
thiazide-QT relationship.  For example, the NELL1 locus was previously associated with 
changes in fasting plasma triglyceride levels in response to hydrochlorothiazide use.
279
  Other 
interesting suggestive results include the PITX2 and RYR3 QRS loci identified in 
Hispanic/Latinos, which may directly regulate ion channel genes and genes involved in 
calcium handling.
377
  Moreover, we found suggestive evidence of thiazide-SNP interactions 
on QT, QRS, or JT in other genes involved in ion transport and handling, including STC2,
378
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EDN1,
379
 TRPC7,
380
 PKP2,
381
 and DISC1,
382
 as well as a voltage-gated potassium channel 
gene (KCNQ3). 
 Despite these intriguing results, our power simulations suggested there was limited 
power to detect interaction effects of 2 ms, sizes consistent with QT main effects analyses.
209
 
The low power suggests that larger sample sizes and/or innovative statistical methods may be 
required to study gene-environment interactions given the stringent genome-wide 
significance threshold.
383-385
  Furthermore, our power simulations demonstrated insufficient 
power to detect interaction effects of 5 ms or less for less common SNPs (MAF=5%).  
Therefore, future work should utilize larger sample sizes, particularly studies with 
longitudinal data, if available. 
 Another limitation of our work was that medication use data were collected 
infrequently, e.g. years apart.  Particularly, medication assessments covered only one to two 
weeks of medication use in most participating cohorts and variables such as medication 
dosage and duration of use were not available universally across studies.  Previous work has 
demonstrated a dose-dependent relationship between thiazide use and cardiac arrest, a 
potential outcome of QT prolongation.
249
  However, we were unable to identify participants 
using high dose thiazides because medication dosage data was unavailable in all cohorts.  
Furthermore, K
+
 measurements and information on K
+
 supplements was not obtained across 
all cohorts so we were unable to adjust for K
+
 levels in our analyses, despite the known role 
of thiazide diuretics in inducing hypokalemia and the role of hypokalemia in causing QT 
prolongation.
40, 252
 
Additionally, observational cohort studies are known to be susceptible to selection 
biases, such as prevalent user bias, whereby long-term medication users are least likely to 
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suffer from ADRs and users with ADRs often stop therapy and therefore have a lower chance 
of being seen while on therapy.
284, 285
  Unfortunately, without duration of use metrics, it 
remains difficult to assess the effects of prevalent user bias on study results.  Indeed, it is 
unclear if these biases are of concern in pharmacogenomic studies.
286, 287
  Additional work is 
needed to assess whether selection bias requires more consideration in pharmacogenomic 
research and to assess possible advantages of alternative designs, such as active comparator 
designs (whereby the control group contains participants using a different class of 
medications with similar indications to the medication of interest) or new user designs 
(whereby prevalent users are excluded).   Moreover, medication inventories may be 
associated with non-negligible measurement error.  For example, while Smith et al. reported 
good agreement between thiazide use measured using medication inventories and serum 
thiazide measurements, specificity remained moderate. 
57
  
 Given the challenges associated with assembling an adequately powered 
pharmacogenomics study, electronic medical records (EMRs) represent a potential untapped 
resource that may merit evaluation.  Strengths of EMRs include the potential to provide a 
more complete medication history, which could enable sensitivity analyses examining 
variables such as medication dose and duration of use.  Furthermore, consortia such as 
eMERGE have demonstrated the feasibility of linking EMRs to genetic data for use in 
genetic research,
386
 and have successfully identified genetic variants modifying drug 
response.
387
  However, EMRs have limitations.  Investigators using EMR data cannot control 
participant recruitment, timing and accuracy of data collection, or population 
representativeness.
388
  Considering ECG research specifically, cohort studies administer 
ECGs to all participants at study visits, whereas EMRs may capture ECGs for patients with 
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medical indications, providing an inherently different population.  EMRs therefore have the 
potential to greatly advance pharmacogenomic research but warrant further evaluation. 
In conclusion, our findings suggest that additional work is needed to fully elucidate 
potential pharmacogenomic effects influencing the thiazide-QT relationship.  Our suggestive 
results support a possible role of genetics in modifying the association between thiazides and 
QT.  However, these findings can inform the biology of thiazide-induced QT-prolongation 
and do not preclude the possibility of common variants with small effects or rare variants 
with larger effects.  Future work that leverages larger sample sizes, such as those available in 
EMRs, and innovative statistical methods to validate these suggestive findings is needed.  
The FDA considers further regulation of drugs that prolong QT by as little as 5 ms, a small 
increment easily achieved by the combination of genetic and pharmaceutical effects,
148, 282
 
making it critical that we unravel the complex etiology of drug-induced QT prolongation.
44
  
Pharmacogenomics remain a promising avenue for understanding variability in drug response 
and for utilizing genetics to improve public health but innovative solutions are needed to 
overcome inherent challenges. 
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Tables and Figures 
Table 17. Study Population Characteristics of 25 Contributing Study Populations 
Population Nexposed Ntotal 
QT in 
ms, 
mean 
(SD) 
QRS in 
ms, 
mean 
(SD) 
JT in 
ms, 
mean 
(SD) 
Age in 
years, 
mean (SD) 
Female, 
% 
European 
Descent 
       
AGES 435 2,256 405 (34) 90 (10) 316 (33) 75 (5) 64.2 
ARIC 1,449 8,567 399 (29) 91 (10) 308 (29) 54 (6) 52.6 
CHS 1,003 3,004 414 (32) 88 (10) 322 (30) 72 (5) 62.5 
ERF 29 1,792 398 (28) NA NA 48 (14) 59.0 
FHS 83 3,168 415 (30) 88 (10) 328 (30) 40 (9) 52.5 
H2000 104 1,973 389 (30) NA NA 50 (11) 52.0 
Health ABC 217 1,560 414 (32) 90 (11) 324 (32) 74 (3) 49.4 
MESA 453 2,216 412 (29) 93 (9) 320 (29) 62 (10) 52.1 
NEO 609 5,366 406 (29) 93 (10) 313 (29) 56 (6) 47.0 
PROSPER 1,175 4,556 414 (36) 94 (11) 320 (35) 75 (3) 47.0 
RS I 523 4,805 397 (29) 97 (11) 300 (28) 69 (9) 60.2 
RS II 161 1,889 403 (28) 98 (11) 305 (28) 65 (8) 56.6 
RS III 93 1,950 401 (26) 98 (11) 304 (26) 56 (6) 54.1 
WHI GARNET 431 1,981 401 (29) 86 (9) 315 (29) 66 (7) 100 
WHI MOPMAP 268 1,383 402 (30) 86 (8) 316 (30) 63 (7) 100 
WHI WHIMS 1,106 5,135 401 (30) 86 (9) 315 (29) 68 (6) 100 
Summary 8,139 51,601      
African American        
ARIC 916 2,169 400 (33) 90 (10) 310 (32) 53 (6) 62.3 
CHS 351 666 409 (35) 88 (11) 317 (36) 73 (6) 64.4 
Health ABC 268 1,151 411 (35) 88 (11) 322 (34) 73 (3) 57.6 
JHS 463 1,862 410 (32) 92 (10) 319 (30) 50 (12) 60.9 
MESA 467 1,464 410 (32) 91 (10) 319 (31) 62 (10) 54.4 
WHI SHARe 1,661 4,170 401 (34) 85 (9) 316 (33) 61 (7) 100 
Summary 4,215 11,482      
Hispanic/Latino        
HCHS/SOL 941 12,024 416 (28) 91 (10) 325 (29) 46 (14) 59.5 
MESA 211 1,316 409 (30) 91 (10) 318 (30) 61 (10) 51.8 
WHI SHARe 224 1,776 401 (30) 86 (9) 316 (30) 60 (6) 100 
Summary 1,376 15,116      
AGES, Age, Gene/Environment Susceptibility – Reykjavik Study; ARIC, Atherosclerosis Risk in 
Communities; CHS, Cardiovascular Health Study; ERF, Erasmus Rucphen Family Study; FHS, 
Framingham Heart Study; GARNET, Genome-wide Association Research Network into Effects of 
Treatment; HCHS/SOL, Hispanic Community Health Study/Study of Latinos; Health ABC, Health, Aging, 
and Body Composition Study; JHS, Jackson Heart Study; JT, JT interval; MESA, Multi-Ethnic Study of 
Atherosclerosis; MOPMAP, Modification of Particulate Matter-Mediated Arrhythmogenesis in 
Populations; NEO, the Netherlands Epidemiology of Obesity; Nexposed, Number of participants exposed to 
thiazides; Ntotal, Total number of participants in study population after exclusions; PROSPER, Prospective 
Study of Pravastatin in the Elderly at Risk; QRS, QRS interval; QT, QT interval; RS, Rotterdam Study; SD, 
Standard deviation; SHARe, The SNP Health Association Resource; WHI, Women’s Health Initiative; 
WHIMS, the WHI Memory Study 
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Table 18.  Description of Medication Assessment Methods for 14 Participating Studies 
Included in the Pharmacogenomic Analysis of QT, QRS, and JT in N=78,199 Participants 
Study 
Method of Medication 
Assessment* Time Period 
Number of Visits 
Included in 
Analysis 
AGES Medication Inventory At time of visit 2 
ARIC Medication Inventory 2 weeks before visit ≤4 
CHS Medication Inventory 2 weeks before visit up to 10 
ERF Medication Inventory At time of visit 1 
FHS Medication Inventory At time of visit 1 
Health ABC Medication Inventory 2 weeks before visit 1 
Health 2000 Medication Inventory 1 week before visit 1 
HCHS/SOL Medication Inventory 4 weeks before visit 1 
JHS Medication Inventory At time of visit 1 
MESA Medication Inventory 2 weeks before visit 2 
NEO Medication Inventory At time of visit 1 
PROSPER Medication Inventory At time of visit 1 
RS1 Pharmacy database Prescriptions filled ≤ 30 
days before visit 
5 
RS2 Pharmacy database Prescriptions filled ≤ 30 
days before visit 
3 
RS3 Pharmacy database Prescriptions filled ≤ 30 
days before visit 
1 
WHI GARNET Medication Inventory 2 weeks before visit ≤4 
WHI MOPMAP Medication Inventory 2 weeks before visit ≤4 
WHI WHIMS Medication Inventory 2 weeks before visit ≤4 
WHI CT SHARe Medication Inventory 2 weeks before visit ≤4 
*Medication inventory defined as a structured interview where trained staff member reviewed 
and recorded all medications with participant.   
AGES, Age, Gene/Environment Susceptibility – Reykjavik Study; ARIC, Atherosclerosis Risk 
in Communities; CHS, Cardiovascular Health Study; ERF, Erasmus Rucphen Family Study; 
FHS, Framingham Heart Study; GARNET, Genome-wide Association Research Network into 
Effects of Treatment; Health ABC, Health, Aging, and Body Composition Study;  HCHS/SOL, 
Hispanic Community Health Study/Study of Latinos; JHS, Jackson Heart Study; MESA, Multi-
Ethnic Study of Atherosclerosis; MOPMAP, Modification of Particulate Matter-Mediated 
Arrhythmogenesis in Populations; NEO, the Netherlands Epidemiology of Obesity; PROSPER, 
Prospective Study of Pravastatin in the Elderly at Risk; RS, Rotterdam Study; SHARe, The SNP 
Health Association Resource; WHI CT, Women’s Health Initiative Clinical Trial; WHIMS, the 
WHI Memory Study 
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Table 19.  ECG Measurement Methods for 14 Participating Studies Included in the 
Pharmacogenomic Analysis of QT, QRS, and JT in N=78,199 Participants 
Study ECG Machine Measurement System  
AGES Marquette / MAC 5000 Resting ECG  Marquette 12SL 
ARIC Marquette MAC PC Marquette 12SL 
CHS Marquette MAC PC Marquette 12SL 
ERF ACTA electrocardiographs (EASOTE, 
Florence, Italy) 
MEANS
389, 390
 
FHS GE MAC 5000 Digital calipers 
Health ABC Marquette MAC PC Marquette 12SL 
Health 2000 Marquette MAC 5000 Custom-made software 
HCHS/SOL GE MAC 1200 Marquette 12SL 
JHS Marquette MAC PC MEANS
389, 390
 
MESA Marquette MAC 1200 Marquette 12SL 
NEO University of Glasgow University of Glasgow 
PROSPER University of Glasgow University of Glasgow 
RS1 ACTA electrocardiographs (EASOTE, 
Florence, Italy) 
MEANS
389, 390
 
RS2 ACTA electrocardiographs (EASOTE, 
Florence, Italy) 
MEANS
389, 390
 
RS3 ACTA electrocardiographs (EASOTE, 
Florence, Italy) 
MEANS
389, 390
 
WHI GARNET Marquette MAC PC Marquette 12SL 
WHI MOPMAP Marquette MAC PC Marquette 12SL 
WHI WHIMS Marquette MAC PC Marquette 12SL 
WHI CT Share Marquette MAC PC Marquette 12SL 
AGES, Age, Gene/Environment Susceptibility – Reykjavik Study; ARIC, Atherosclerosis Risk in 
Communities; CHS, Cardiovascular Health Study; ERF, Erasmus Rucphen Family Study; FHS, 
Framingham Heart Study; GARNET, Genome-wide Association Research Network into Effects 
of Treatment; Health ABC, Health, Aging, and Body Composition Study;  HCHS/SOL, Hispanic 
Community Health Study/Study of Latinos; JHS, Jackson Heart Study; MESA, Multi-Ethnic 
Study of Atherosclerosis; MOPMAP, Modification of Particulate Matter-Mediated 
Arrhythmogenesis in Populations; NEO, the Netherlands Epidemiology of Obesity; PROSPER, 
Prospective Study of Pravastatin in the Elderly at Risk; RS, Rotterdam Study; SHARe, The SNP 
Health Association Resource; WHI CT, Women’s Health Initiative Clinical Trial; WHIMS, the 
WHI Memory Study 
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Table 20.  Genotyping Characteristics for the 14 Studies Included in the Pharmacogenomic Analysis of QT, QRS, and JT in N=78,199 
Participants 
Study Genotyping array 
Genotype 
calling 
algorithm 
Sample 
call 
rate 
filter 
SNP 
call 
rate 
filter 
SNP 
MAF 
filter 
HWE 
p-
value 
filter 
Imputation 
software 
Imputation 
Platform 
N. 
autoso
mal 
SNPs 
passing 
QC 
AGES Ilumina Hu370CNV BeadStudio >95% >97% <1% 10
-6
 MACHv.1.16 HapMap2 308,340 
ARIC 
Affymetrix 6.0 Birdseed <95% <90% <1% <10
-5
 MACH v1.16 
HapMap2 Build 
36 
669,450 
CHS Illumina 370CNV GenomeStudio <95% <97% NA <10
-5
 BIMBAM 0.99 HapMap2 306,655 
ERF 
Illumina 6K/318K/370K Bead Studio < 98% < 98% < 1% <10
-6
 
MACH 
v 1.0.15 
HapMap2 487,573 
FHS Affymetrix 500K + 50 
MIP 
BRLMM <97% <97% <1% <10
-6
 
MACH 
v 1.0.15 
HapMap2 378,163 
Health ABC Illumina 1M Beadstudio <97% <97% <1% <10
-6
 MACH v1.16 HapMap2 914,263 
Health 2000 Illumina Human610-
Quad BeadChip 
GenCall <95% <95% <1% <10
-6
 MACH HapMap2 558,388 
HCHS/SOL Illumina Omni 2.5M + 
Custom 
GenomeStudio <98% <98% NA <10
-5 
IMPUTE2 
1000 Genomes 
Phase 3 
2,294,0
32 
JHS 
Affymetrix 6.0 Birdseed <95% <95% NA NA 
IMPUTE 
v2.1.0 
HapMap 
P2.r22.b36, 
CEU+YRI 
868,969 
MESA 
Affymetrix 6.0 Birdseed <95% <90% <1% <10
-4
 
IMPUTE 
v2.1.0 
HapMap2 730,000 
NEO Illumina 
HumanCoreExome-
24v1_A Beadchip 
GenCall <98% <98% NA <10E-5 IMPUTE2 
1000 Genomes 
2011 v3 
361,046 
PROSPER 
Illumina 660K Bead studio <90% 
<97.5
% 
NA <10
-6
 MACH v1.15 HapMap2 557,192 
RS1 Illumina  550k, 
 
BeadStudio 
 
<98% <98% <1% <10
-6
 
MACH1 v 
1.0.15, 
HapMap2 512,349 
RS2 Illumina 550K Duo, 
610KQuad 
GenomeStudio <98% <95% <1% <10
-6
 
MACH 1 v 
1.0.16 
HapMap2 537,405 
RS3 Illimina 610 Quad Beadstudio <98% <95% <1% <10E-6 MACH v1.0.16 HapMap2 466,389 
WHI 
GARNET 
Illumina Human Omni1-
Quad v1-0 B 
BeadStudio v3.1.
3.0 
NA ≤98% NA <10E-4 
BEAGLE 
v3.3.1 
1000G v3 3/2012 NA 
WHI Affymetrix Axiom Birdseed NA ≤90% <0.5 <10E-6 MaCH Hapmap 2 Build NA 
  
1
1
6
 
MOPMAP Genome-Wide Human 
CEU I 
% minimac 36 
WHI 
WHIMS 
Human OmniExpress 
Exome-8v1_B Genome-
Wide Human 
Birdseed NA ≤98% <1% <10E-4 
MaCH 
minimac 
Hapmap 2 Build 
36 
NA 
WHI CT 
SHARe 
Affymetrix 
GeneChip 
SNP Array 6.0 
Birdseed NA ≤95% <1% <10-6 MaCH v1.0.16 
Hapmap 2 Build 
36 (1:1 CEU:YRI) 
NA 
AGES, Age, Gene/Environment Susceptibility – Reykjavik Study; ARIC, Atherosclerosis Risk in Communities; CHS, Cardiovascular Health Study; ERF, 
Erasmus Rucphen Family Study; FHS, Framingham Heart Study; GARNET, Genome-wide Association Research Network into Effects of Treatment; 
Health ABC, Health, Aging, and Body Composition Study;  HCHS/SOL, Hispanic Community Health Study/Study of Latinos; JHS, Jackson Heart Study; 
MESA, Multi-Ethnic Study of Atherosclerosis; MOPMAP, Modification of Particulate Matter-Mediated Arrhythmogenesis in Populations; NEO, the 
Netherlands Epidemiology of Obesity; PROSPER, Prospective Study of Pravastatin in the Elderly at Risk; RS, Rotterdam Study; SHARe, The SNP 
Health Association Resource; WHI CT, Women’s Health Initiative Clinical Trial; WHIMS, the WHI Memory Study 
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Table 21.  Statistical Analysis Methods for 14 Participating Studies Included in the 
Pharmacogenomic Analysis of QT, QRS, and JT in N=78,199 Participants 
Study 
Statistical Analysis (Linear 
Regression, Mixed Model, GEE) 
GWAS Statistical Analysis 
Software  
AGES GEE R bosswithdf 
ARIC GEE R bosswithdf 
CHS GEE R bosswithdf 
ERF Mixed Model GenABEL/ProbABEL 
FHS GEE geepack 
Health ABC GEE R bosswithdf 
Health 2000 Linear Regression ProbABEL v.0.1-6 
HCHS/SOL Mixed Model R 
JHS GEE R bosswithdf 
MESA GEE R bosswithdf 
NEO Linear Regression Probabel v0.4.3 
PROSPER Linear Regression Probabel v0.4.3 
RS1 GEE R bosswithdf 
RS2 GEE R bosswithdf 
RS3 Linear Regression Probabel v0.4.3 
WHI GARNET GEE R bosswithdf 
WHI MOPMAP GEE R bosswithdf 
WHI WHIMS GEE R bosswithdf 
WHI CT Share GEE R bosswithdf 
AGES, Age, Gene/Environment Susceptibility – Reykjavik Study; ARIC, Atherosclerosis Risk in 
Communities; CHS, Cardiovascular Health Study; ERF, Erasmus Rucphen Family Study; FHS, 
Framingham Heart Study; GARNET, Genome-wide Association Research Network into Effects 
of Treatment; Health ABC, Health, Aging, and Body Composition Study;  HCHS/SOL, Hispanic 
Community Health Study/Study of Latinos; JHS, Jackson Heart Study; MESA, Multi-Ethnic 
Study of Atherosclerosis; MOPMAP, Modification of Particulate Matter-Mediated 
Arrhythmogenesis in Populations; NEO, the Netherlands Epidemiology of Obesity; PROSPER, 
Prospective Study of Pravastatin in the Elderly at Risk; RS, Rotterdam Study; SHARe, The SNP 
Health Association Resource; WHI CT, Women’s Health Initiative Clinical Trial; WHIMS, the 
WHI Memory Study 
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Table 22. Loci with Suggestive Evidence of Association with the Thiazide-SNP Interaction Effect on QT 
Interval 
Locus SNP Chr Position
a
 CA CAF 
Interaction Effect in 
ms (SE) P Phet 
European Descent         
KIAA2013 rs17367934 1 11890791 A 0.89 2.4 (0.5)  2x10
-6 
0.9 
SLC14A2 rs4890550 18 41409189 C 0.44 -1.4 (0.3)  3x10
-6 
0.01 
RPS29 rs10143493 14 47999650 A 0.01 -10.6 (2.3)  3x10
-6 
0.4 
NELL1 rs12225793 11 21057283 T 0.12 2.3 (0.5)  4x10
-6 
1.0 
STC2 rs10079004 5 172704698 A 0.71 -1.5 (0.3)  4x10
-6 
0.4 
LCLAT1 rs7608507 2 30447424 A 0.75 1.6 (0.3)  4x10
-6 
0.7 
PPP1R3A rs13223427 7 113199332 T 0.56 1.4 (0.3)  4x10
-6 
0.02 
African American         
ZBTB16 rs10789991 11 113424299 T 0.03 12.3 (2.4)  5x10
-7 
0.6 
DNAH8 rs862433 6 38968057 A 0.25 -2.6 (0.5)  7x10
-7 
0.2 
Intergenic rs9376483 6 140352934 T 0.94 7.2 (1.4)  7x10
-7 
0.5 
CASP8AP2 rs7753194 6 90597484 A 0.02 -11.4 (2.4)  3x10
-6 
0.2 
EBF1 rs11135035 5 157833407 A 0.41 2.1 (0.5)  4x10
-6 
0.9 
LAMA4 rs6926485 6 112630302 T 0.64 2.4 (0.5)  5x10
-6 
0.5 
Hispanic/Latino         
SPDYA rs12475612 2 28883510 T 0.48 -3.5 (0.7)  1x10
-6 
0.9 
BTBD9 rs1950398 6 38666897 T 0.97 9.6 (2.0)  2x10
-6 
0.05 
TDRP rs6558894 8 480495 C 0.14 -4.9 (1.0)  2x10
-6 
0.3 
COLCA2 rs10749974 11 110696967 A 0.09 -6.0 (1.3)  3x10
-6 
0.2 
CRYGGP rs17868255 2 51884417 A 0.97 10.3 (2.2)  3x10
-6 
0.5 
RYR3 rs16968694 15 31376213 A 0.18 4.5 (1.0)  3x10
-6 
1.0 
Trans-Ethnic         
RGSL1 rs2765279 1 180693520 T 0.28 1.4 (0.3)  3x10
-7
 0.4 
ZBTB16 rs10789991 11 113424299 T 0.03 12.3 (2.4)  5x10
-7 
0.6 
PPP1R3A rs17619887 7 113142601 A 0.47 1.2 (0.3)  2x10
-6 
0.07 
KIAA2013 rs17367934 1 11890791 A 0.89 2.3 (0.5)  2x10
-6 
1.0 
LCLAT1 rs6756908 2 30446501 A 0.65 1.3 (0.3)  2x10
-6 
0.5 
FAR1 rs7130476 11 13711632 C 0.90 2.0 (0.4)  3x10
-6 
0.5 
CASP8AP2 rs7753194 6 90597484 A 0.02 -11.4 (2.4)  3x10
-6
 0.2 
SMARCA2 rs1886261 9 2163590 A 0.75 1.5 (0.3)  3x10
-6
 0.9 
ZKSCAN8 rs13205911 6 28232093 T 0.09 -2.5 (0.5)  5x10
-6 
0.6 
a
Build 36 Base-Pair Position 
CA, Coded allele; CAF, Coded allele frequency; Chr, Chromosome; P, P-value; Phet, P-value of 
heterogeneity; SE, Standard error; SNP, Single nucleotide polymorphism 
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Table 23.  P-value of Association for Thiazide-SNP Interaction Effect on QT Interval in European 
Descent Populations at 35 Loci Previously Associated with QT Interval in Main Effects Genome-Wide 
Association Studies
209
 
Index SNP* Locus CA 
Main Effect in ms 
(SE)
209
  
Interaction Effect in 
ms (SE) P 
rs10040989  GFRA3  A -0.85 (0.13) 0.87 (0.44) 0.05 
rs1052536  LIG3  T -0.98 (0.10) -0.56 (0.31) 0.07 
rs10919070  ATP1B1  A 1.68 (0.14) -0.14 (0.44) 0.7 
rs11153730  SLC35F1-PLN  T -1.65 (0.10) -0.15 (0.30) 0.6 
rs11779860  LAPTM4B  T 0.61 (0.10) 0.16 (0.31) 0.6 
rs12143842  NOS1AP  T 3.5 (0.11) 0.29 (0.35) 0.4 
rs1296720  CREBBP  A -0.83 (0.13) 0.57 (0.40) 0.2 
rs12997023  SLC8A1  T 1.69 (0.22) 0.09 (0.72) 0.9 
rs1396515  KCNJ2  C -0.98 (0.09) 0.02 (0.30) 0.9 
rs16936870  NCOA2  A 0.99 (0.16) 1.06 (0.51) 0.04 
rs174583  FEN1-FADS2  T -0.57 (0.09) 0.30 (0.32) 0.3 
rs17784882  C3ORF75  A -0.54 (0.10) -0.18 (0.30) 0.6 
rs1805128  KCNE1  T 7.42 (0.85) -1.16 (1.21) 0.3 
rs1961102  AZIN1  T 0.57 (0.10) -0.41 (0.33) 0.2 
rs2072413  KCNH2  T -1.68 (0.11) 0.26 (0.34) 0.4 
rs2273905  ANKRD9  T 0.61 (0.09) -0.20 (0.34) 0.5 
rs2298632  TCEA3  T 0.7 (0.09) -0.11 (0.31) 0.7 
rs2363719  SLC4A4  A 0.97 (0.16) 0.33 (0.50) 0.5 
rs246185  MKL2  T -0.72 (0.10) -0.96 (0.35) 0.005 
rs246196  CNOT1  T 1.73 (0.11) -0.05 (0.34) 0.9 
rs2485376  GBF1  A -0.56 (0.10) 0.13 (0.32) 0.7 
rs295140  SPATS2L  T 0.57 (0.09) -0.40 (0.30) 0.2 
rs3026445  ATP2A2  T -0.62 (0.09) -0.29 (0.31) 0.4 
rs3105593  USP50-TRPM7  T 0.66 (0.10) 0.25 (0.30) 0.4 
rs3857067  SMARCAD1  A 0.51 (0.08) 0.05 (0.30) 0.9 
rs6793245  SCN5A-SCN10A  A -1.12 (0.10) -0.25 (0.33) 0.4 
rs7122937  KCNQ1  T 1.93 (0.12) -0.38 (0.40) 0.3 
rs728926  KLF12  T 0.57 (0.10) -0.13 (0.33) 0.7 
rs735951  LITAF  A -1.15 (0.10) 0.29 (0.33) 0.4 
rs7561149  TTN-CCDC141  T 0.52 (0.09) 0.10 (0.30) 0.7 
rs7765828  GMPR  C -0.55 (0.09) 0.03 (0.31) 0.9 
rs846111  RNF207  C 1.73 (0.13) 0.27 (0.38) 0.5 
rs938291  SP3  C -0.53 (0.09) 0.26 (0.31) 0.4 
rs9892651  PRKCA  T 0.74 (0.10) -0.04 (0.30) 0.9 
rs9920  CAV1  T -0.79 (0.14) -0.44 (0.51) 0.4 
*Index SNP as identified in a GWAS of QT main effects in European descent populations 
CA, Coded allele; P, P-value; SE, Standard error 
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Table 24. Loci with Suggestive Evidence of Modifying the Thiazide-SNP Interaction Effect on QRS 
Interval 
Locus SNP Chr Position* CA CAF 
Interaction 
Effect in ms 
(SE) P Phet 
European Descent         
L3MBTL2 rs139461 22 39941406 T 0.34 0.8 (0.2)  2x10
-6 
0.8 
CD200R1 rs9864286 3 114147601 A 0.92 1.4 (0.3)  2x10
-6 
0.7 
EDG1 rs10874488 1 101640388 A 0.95 2.1 (0.4)  3x10
-6 
0.6 
HM13 rs6088592 20 29615942 A 0.15 -2.4 (0.5)  4x10
-6 
0.2 
African American         
DDX1 rs2080798 2 15789836 T 0.76 -1.4 (0.3)  1x10
-6 
0.1 
FAM84A rs6711956 2 14204168 T 0.53 1.2 (0.2)  2x10
-6 
0.4 
GAP43 rs7638855 3 116617968 T 0.08 -2.8 (0.6)  2x10
-6 
0.2 
GUSBP1 rs7706102 5 21438324 C 0.92 3.1 (0.7)  3x10
-6 
0.3 
SV2B rs886144 15 89518356 T 0.47 -1.1 (0.2)  3x10
-6 
0.5 
SLC35B3 rs850177 6 8517446 T 0.05 -3.3 (0.7)  3x10
-6 
0.8 
RFP4AP7 rs4363212 8 50466496 A 0.94 2.5 (0.5)  4x10
-6
 1.0 
KCNQ3 rs2469514 8 133218116 T 0.83 1.5 (0.3)  4x10
-6
 0.3 
ZCWPW2 rs6777813 3 28527314 A 0.36 1.1 (0.2)  4x10
-6
 0.7 
FAM65B rs10946735 6 24980918 A 0.16 -1.5 (0.3)  4x10
-6
 0.9 
RASD2 rs2009681 22 34306117 A 0.76 1.3 (0.3)  5x10
-6
 1.0 
Hispanic/Latino         
AK2 rs11591185 1 33274771 A 0.08 3.5 (0.7)  9x10
-7 
0.04 
PKP2 rs12578228 12 33030528 T 0.10 -3.1 (0.7)  2x10
-6 
0.4 
TRPC7 rs12658104 5 135939584 A 0.03 5.2 (1.1)  2x10
-6 
0.4 
GATA3 rs10508356 10 8603852 T 0.42 1.7 (0.4)  3x10
-6 
0.1 
MYRIP rs4557094 3 39690549 T 0.74 2.0 (0.4)  3x10
-6 
0.4 
TOX2 rs8120207 20 41928841 T 0.04 -3.7 (0.8)  4x10
-6 
0.2 
PIGM rs2185214 1 158243375 A 0.88 -2.7 (0.6)  5x10
-6
 0.5 
PITX2 rs4834601 4 112190427 A 0.39 1.8 (0.4)  5x10
-6
 0.6 
Trans-Ethnic         
GAP43 rs7638855 3 116617968 T 0.07 -2.7 (0.5)  2x10
-7
 0.6 
CSMD1 rs17066601 8 3463355 T 0.08 3.0 (0.6)  7x10
-7 
0.09 
CD200R1 rs16860242 3 114125777 A 0.88 1.0 (0.2)  2x10
-6 
0.4 
TSGA10 rs720228 2 99070979 A 0.42 0.6 (0.1)  2x10
-6 
0.5 
ASCL1 rs2176822 12 102115378 T 0.94 -1.3 (0.3)  3x10
-6 
0.6 
DISC1 rs16856677 1 230389995 T 0.20 -1.2 (0.3)  4x10
-6 
0.06 
EDN1 rs7767845 6 12536024 T 0.97 2.3 (0.5)  4x10
-6
 0.5 
*Build 36 Base-Pair Position 
CA, Coded allele, CAF, Coded allele frequency; Chr, Chromosome; P, P-value; Phet, P-value of 
heterogeneity; SE, Standard error; SNP, Single nucleotide polymorphism 
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Table 25. Loci with Suggestive Evidence of Modifying the Thiazide-SNP Interaction Effect on JT Interval 
Locus SNP 
Ch
r Position* CA CAF 
Interaction 
Effect in ms 
(SE) P Phet 
European Descent         
LCLAT1 rs6733641 2 30444156 T 0.27 -2.0 (0.4)  1x10
-6 
0.2 
TEDDM1 rs171980 1 180693220 A 0.20 1.9 (0.4)  3x10
-6 
0.4 
ZNF659 rs6806788 3 21450644 T 0.07 3.0 (0.6)  3x10
-6 
0.7 
FZD8 rs1219593 10 36587628 T 0.83 -2.0 (0.4)  4x10
-6 
0.9 
NELL1 rs7106157 11 21035410 A 0.55 1.5 (0.3)  4x10
-6
 0.2 
African American         
AP4E1 rs7176764 15 49045259 A 0.04 7.3 (1.5)  2x10
-6 
0.4 
LAMA4 rs6926485 6 112630302 T 0.64 -2.2 (0.5)  3x10
-6 
0.4 
ASH1L rs11264369 1 153626454 T 0.72 2.5 (0.5)  4x10
-6 
0.9 
DCC rs7236483 18 49367477 A 0.11 3.5 (0.8)  4x10
-6 
0.6 
Hispanic/Latino         
GALNT13 rs17553946 2 155055407 A 0.23 2.4 (0.5)  9x10
-7 
0.6 
NFKBIZ rs1672383 3 103114652 T 0.80 -2.4 (0.5)  3x10
-6 
0.7 
SH3BGRL2 rs12208969 6 80370016 T 0.73 2.0 (0.4)  4x10
-6 
0.2 
SMARCA2 rs12339569 9 2117762 T 0.96 -4.7 (1.0)  5x10
-6 
0.2 
TGFBR2 rs7632716 3 30332431 T 0.83 -2.3 (0.5)  5x10
-6 
0.6 
Trans-Ethnic         
KCNIP4 rs12648787 4 21225700 C 0.67 -1.3 (0.2)  3x10
-7
 0.6 
SEL1L rs17116425 14 81712421 A 0.89 -1.9 (0.4)  1x10
-6 
0.8 
ECEL1 rs2741279 2 233053235 T 0.49 -1.3 (0.3)  1x10
-6 
0.3 
LCA5 rs1485371 6 80235061 T 0.47 -1.1 (0.2)  1x10
-6 
0.1 
AP4E1 rs7176764 15 49045259 A 0.04 7.3 (1.5)  2x10
-6 
0.4 
IMPG1 rs6905415 6 76949519 A 0.09 2.0 (0.4)  3x10
-6 
0.8 
DPP10 rs9308717 2 116212012 A 0.48 1.1 (0.2)  3x10
-6
 0.1 
*Build 36 Base-Pair Position 
CA, Coded allele, CAF, Coded allele frequency; Chr, Chromosome; P, P-value; Phet, P-value of 
heterogeneity; SE, Standard error; SNP, Single nucleotide polymorphism 
 
 
Table 26. Loci with Suggestive Evidence Modifying the Effect Thiazide Diuretics on QRS and JT 
Intervals After Cross-Phenotype Meta-Analysis 
Locus SNP Chr Position
a 
CA CAF P 
Univariate P-
value 
QRS JT 
European Americans       
PIK3R6 rs1295230 17 8682305 T 0.02 3x10
-6 
0.008 0.001 
African American       
ADGRB3 rs6931354 6 69527128 A 0.21 1x10
-7 
0.005 0.0002 
ADCY8 rs10108730 8 131767803 T 0.79 2x10
-6 
1x10
-5 
0.0003
 
PREX1 rs8119517 20 46464282 A 0.94 3x10
-6 
0.0005 0.02
 
CDH13 rs11649358 16 81415652 A 0.75 5x10
-6 
9x10
-6 
0.001
 
Hispanic/Latino        
AK2 rs11591185 1 33274771 A 0.07 2x10
-6 
7x10
-7 
3x10
-5 
ASS1P14 rs12578228 12 33030528 T 0.10 2x10
-6 
2x10
-6 
2x10
-5 
GALNT13 rs17553946 2 155055407 A 0.23 4x10
-6 
0.005 9x10
-7 
a
Build 36 Base-Pair Position 
CA, Coded allele; CAF, Coded allele frequency; Chr, Chromosome; JT, JT interval; P, P-value; 
QRS, QRS interval; SE, Standard error; SNP, Single nucleotide polymorphism 
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Table 27. Results of Gene Enrichment Analysis with MAGMA for the Association with the Interactive 
Effect of Thiazide Diuretics on QRS Interval Among African Americans (N=11,482) 
Gene Chr Start BP Stop BP N SNPs P FDR 
CNTRL 9 122885395 122981207 69 1x10
-6
 0.01 
CPN1 10 101790555 101836632 33 2x10
-6
 0.01 
FAM65B 6 24946066 24990562 55 2x10
-6
 0.01 
RAB14 9 122978737 123008913 31 5x10
-6
 0.02 
ISY1 3 130329425 130367719 7 1x10
-5
 0.03 
NELL1 11 20642712 21555077 1227 3x10
-5
 0.04 
BP, Basepair; Chr, Chromosome; FDR, False Discovery Rate; N SNPs, Number of SNPs from Analysis 
within Gene Interval; P, P-value 
 
Table 28. Gene-Sets with Enrichment for Genotype-Thiazide Interaction Effects Following Analysis with 
MAGMA 
Trait Population Gene-Set P FDR 
QT Hispanic/Latino Nucleotide Binding 5x10
-6 
0.004 
  Metal Ion Binding 6x10
-6 
0.004 
  tRNA Adenine-N1 Methyltransferase Activity 6x10
-5 
0.03 
  Transcription Coactivator Activity 8x10
-5 
0.03 
  Transcriptional Activity of SMAD2, SMAD3, SMAD4,   
     Heterotrimer 
0.0001 0.03 
  Zinc Ion Binding 0.0002 0.04 
  Other RNA Binding Protein 0.0002 0.04 
  Insulin-like Growth Factor-2 mRNA Binding Proteins  
     (IGF2BPS/IMPS/VICKZS) 
0.0003 0.05 
 Trans-Ethnic General RNA Polymerase II Transcription 4x10
-6 
0.006 
  Transcription 4x10
-5 
0.03 
JT African American Transcription Factor TFIID Complex 7x10
-5 
0.05 
  Aminoacyl-tRNA Synthetase Multienzyme Complex 0.0001 0.05 
  tRNA Aminoacylation for Protein Translation 0.0001 0.05 
  Transcription Factor TFTC Complex 0.0001 0.05 
 Trans-Ethnic Transcription 3x10
-5 
0.03 
  General RNA Polymerase II Transcription Factor 
Activity 
4x10
-5 
0.03 
FDR, False discovery rate; JT, JT interval; P, P-value; QT, QT interval 
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Figure 18.  Quantile-Quantile Plots of P-values for Thiazide-SNP Interaction Estimates for QT Interval, QRS Interval, and JT Interval Analyses 
After Inverse-Variance Weighted Meta-Analysis in METAL 
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Figure 19.  Manhattan plots of P-values for thiazide-SNP interaction 
estimates for QT interval analyses after fixed effects meta-analysis among 
European descent populations, African American populations, 
Hispanic/Latino populations, and all populations (trans-ethnic) 
On each plot, genome wide significance (P < 5x10
-8
) and suggestive 
significance (P < 5x10
-6
) are denoted with dashed lines. 
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Figure 20.  Manhattan Plots of Bayes Factors for Thiazide-SNP Interaction 
Estimates After Bayesian Trans-Ethnic Meta-Analysis in MANTRA Across 
European Descent, African American, and Hispanic/Latino Populations 
Manhattan plots of Bayes factors for thiazide-SNP interaction estimates after 
Bayesian trans-ethnic meta-analysis in MANTRA across European descent, African 
American, and Hispanic/Latino populations.  On each plot, genome-wide 
significance (BF > 10
6
) and suggestive significance (BF > 10
4
) are denoted with 
lines. 
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Figure 21.  Manhattan Plots of P-values for Thiazide-SNP Interaction Estimates for QRS, and JT 
Intervals 
 
Manhattan plots of P-values for thiazide-SNP interaction estimates for QRS and JT interval analyses after 
fixed effects meta-analysis among European descent populations, African American populations, 
Hispanic/Latino populations, and all populations (trans-ethnic).  On each plot, genome-wide significance 
(P < 5x10
-8
) and suggestive significance (P < 5x10
-6
) are denoted with dashed lines 
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Figure 22.  Manhattan Plots of P-values for Thiazide-SNP 
Interaction Estimates After Cross-Phenotype Meta-
Analysis (QRS Interval, JT Interval) 
 
Manhattan plots of P-values thiazide-SNP interaction estimates 
after cross-phenotype meta-analysis (QRS interval, JT interval) 
using aSPU among European descent populations, African 
American populations, and Hispanic/Latino populations.  On 
each plot, genome wide significance (P < 5x10
-8
) and 
suggestive significance (P < 5x10
-6
) are denoted with dashed 
lines. 
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Figure 23.  Quantile-Quantile Plots of P-values for Thiazide-SNP Interaction 
Estimates After Cross-Phenotype Meta-Analysis with aSPU in European Descent, 
African American, and Hispanic/Latino Populations 
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Figure 24.  Statistical Power of a Simulated Pharmacogenomics Study of QT 
The following assumptions were used for the calculations: 2 serial visits measuring 
electrocardiograms (ECGs) and drug exposure, N=50,000 participants, a single-nucleotide 
polymorphism (SNP) minor allele frequency (MAF) of 5% or 25%, and the Nexposed = 8,100.  
Simulation analyses were run using only the baseline visit (cross-sectional) and a 
longitudinal model.  Under the longitudinal model, simulations were run with all 
participants having constant drug exposure across visits or having varied drug exposure 
across visits. 
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Supplementary Material 
Age, Gene/Environment Susceptibility – Reykjavik Study (AGES): The Reykjavik 
Study cohort originally was composed of a random sample of 30,795 men and women born 
in 1907-1935 and living in Reykjavik in 1967.
320
  A total of 19,381 attended, resulting in 
71% recruitment rate. The study sample was divided into six groups by birth year and birth 
date within month. One group was designated for longitudinal follow-up and was examined 
in all stages. Another group was designated a control group and was not included in 
examinations until 1991. Other groups were invited to participate in specific stages of the 
study. Between 2002 and 2006, the AGES-Reykjavik study re-examined 5,764 survivors of 
the original cohort who had participated before in the Reykjavik Study. 
Atherosclerosis Risk in Communities (ARIC) Study: The ARIC study is an ongoing 
population-based cohort of 15,792 predominantly Caucasian and African-American males 
and females aged 45-64 years at baseline and selected using probability sampling from four 
United States communities (Forsyth County NC, Jackson MS, suburban Minneapolis MN, 
and Washington County MD).
321
  Participants were recruited in 1987-1989 to examine 
cardiovascular and pulmonary disease, patterns of medical care, and disease variation over 
time. Standardized physical examinations and interviewer-administered questionnaires were 
conducted at baseline (1987-1989), and at three triennial follow-up examinations (1990-
1998). Eligible participants for this effort were from the NC, MN, and MD field centers, as 
only Caucasian participants were examined in this analysis and the MS center only recruited 
African American participants. 
Cardiovascular Health Study (CHS):  The CHS is a population-based cohort study of 
risk factors for CHD and stroke in adults ≥65 years conducted across four field centers.322  
The original predominantly Caucasian cohort of 5,201 persons was recruited in 1989-1990 
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from random samples of the Medicare eligibility lists; subsequently, an additional 
predominantly African-American cohort of 687 persons was enrolled for a total sample of 
5,888. DNA was extracted from blood samples drawn on all participants at their baseline 
examination in 1989-90. In 2007-2008, genotyping was performed at the General Clinical 
Research Center's Phenotyping/Genotyping Laboratory at Cedars-Sinai using the Illumina 
370CNV BeadChip system on 3,980 CHS participants who were free of CVD at baseline, 
consented to genetic testing, and had DNA available for genotyping. 
Erasmus Rucphen Family (ERF) study: The Erasmus Rucphen Family study 
(http://www.erasmusmc.nl/klinische_genetica/research/genepi/?lang=en) is a family-based 
cohort embedded in the Genetic Research in Isolated Populations (GRIP) program in the 
southwest Netherlands.  The aim of this program is to identify genetic risk factors for the 
development of complex disorders. In ERF, twenty-two families that had a minimum of six 
children baptized in the community church between 1850 and 1900 were identified with the 
help of detailed genealogical records. All living descendants of these couples, and their 
spouses, were invited to take part in the study. Comprehensive interviews, questionnaires, 
and examinations were completed at a research center in the area; approximately 3,200 
individuals participated.  Data collection started in June, 2002 and was completed in 
February, 2005. In the current analyses, 1503 participants for whom complete phenotypic, 
genotypic and genealogical information was available were studied. 
Framingham Heart Study (FHS): The FHS is a prospective, community based cohort 
study that was initiated in 1948 and now spans 3 generations, including the original cohort, 
their offspring and spouses of the offspring (Offspring Cohort, enrolment- beginning in 
1971), and children from the largest offspring families (Generation 3 Cohort, enrolment 
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beginning in 2000).  Details regarding study recruitment and design have been reported 
previously.
325, 391
  Generation 3 cohort individuals with ECGs were used for this study.  QT 
intervals were measured using digital calipers on scanned electrocardiograms in leads II (two 
cardiac cycles), V2 and V5; the average across all measurements was taken as the QT trait 
for analysis.  All study protocols were approved by the Institutional Review Board for 
Boston University Medical Center.  All study participants provided informed written consent. 
Health, Aging, and Body Composition Study (Health ABC): The Health ABC Study 
is a NIA-sponsored cohort study of the factors that contribute to incident disability and the 
decline in function of healthy older persons, with a particular emphasis on changes in body 
composition in old age. Between 4/15/97 and 6/5/98 the Health ABC study has recruited 
3,075 70-79 year old community-dwelling adults (41% African-American), who were 
initially free of mobility and activities of daily living disability. The key components of 
Health ABC include a baseline exam, annual follow-up clinical exams, and phone contacts 
every 6 months to identify major health events and document functional status between clinic 
visits.  Provision has been made for banking of blood specimens and extracted DNA (Health 
ABC repository). 
Health 2000: The Health 2000 Study is a population-based health examination survey 
carried out in Finland in 2000 – 2001.329  A detailed description of the implementation and 
methodology of the survey is available online: 
http://www.terveys2000.fi/doc/methodologyrep.pdf . The study involved a two-stage 
stratified cluster sample representative of the whole adult Finnish population aged > 30 years. 
The Health 2000 sample comprised 8,028 individuals, of whom 79% (6,354 individuals; 
2,876 men and 3,478 women) participated in a comprehensive health examination including 
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questionnaires, clinical measurements (e.g. resting ECG) and doctor’s physical examination. 
DNA samples were collected from 6,597 persons and digital EGCs were available from 
6,295 persons. QT-interval measurements in the Health 2000 Study have been described 
elsewhere.
329
 
Hispanic Community Health Study / Study of Latinos (SOL): The Hispanic 
Community Health Study (HCHS)/Study of Latinos (SOL) is a community based cohort 
study of 16,415 self-identified Hispanic/Latino persons aged 18-74 years from randomly 
selected households in four U.S. field centers (Chicago, IL; Miami, FL; Bronx, NY; San 
Diego, CA) with baseline examination (2008 to 2011) and yearly telephone follow-up 
assessment for at least three years.
53
 The two-stage sampling design selected households 
within census block groups. Households with Hispanic/Latino surnames and individuals over 
45 years of age were oversampled to achieve increased representation of Hispanic/Latino 
individuals with a uniform age distribution. Due to this study design, sampling weights that 
reflect the probability of sampling individuals to the study were calculated for all individuals.  
These sampling weights were used in downstream analyses to protect against potential 
selection bias arising from the sampling scheme. The HCHS/SOL cohort includes 
participants who self-identified as having Hispanic/Latino background, the largest groups 
being Central American, Cuban, Dominican, Mexican, Puerto-Rican, and South American. 
The HCHS/SOL study was approved by institutional review boards at participating 
institutions, and written informed consent was obtained from all participants. 12,803 
individuals were successfully genotyped on an Illumina Omni 2.5M array, and the genotype 
and phenotype data are posted on dbGaP (accession numbers phs000880.v1.p1 and 
phs000810.v1.p1) 
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Jackson Heart Study (JHS): The JHS is a single-site, prospective, population-based 
study designed to explore the environmental, behavioral, and genetic factors that influence 
the development of cardiovascular disease (CVD) among African Americans. A total of 
5,301 women and men between the ages of 21 and 94 were recruited between September 
2000 and May 2004 from a tri-county area of Mississippi: Hinds, Madison, and Rankin 
Counties. Participants were recruited from four sources, including (1) randomly sampled 
households from a commercial listing; (2) ARIC study participants; (3) a structured volunteer 
sample that was designed to mirror the eligible population; and (4) a nested family cohort. Of 
the enrolled participants, 3,630 were recruited uniquely to JHS and did not participate in 
ARIC. Overviews of the JHS including the sampling and recruitment, sociocultural, and 
laboratory methods have been described previously.
331
  All of the participants provided 
written informed consent. Participants were between 35 and 84 years old at first visit, and 
members of the family cohort were ≥ 21 years old when consent for genetic testing was 
obtained and blood was drawn for DNA extraction. The details of first clinic visit procedures, 
including supine 12-lead digital electrocardiography (ECG), venipuncture, and other testing, 
have been previously described.  The definitions of co-morbidities as well as the details of 
ECG measurements and medication collection and coding have also been reported.
24, 392
 
Multi-Ethnic Study of Atherosclerosis (MESA): MESA is a study of the 
characteristics of subclinical cardiovascular disease (disease detected non-invasively before it 
has produced clinical signs and symptoms) and the risk factors that predict progression to 
clinically overt cardiovascular disease or progression of the subclinical disease. MESA 
researchers study a diverse, population-based sample of 6,814 asymptomatic men and 
women aged 45-84. 38 percent of the recruited participants are white, 28 percent African-
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American, 22 percent Hispanic, and 12 percent Asian, predominantly of Chinese descent.
332
   
Participants were recruited from six field centers across the United States. Two physical 
examinations (at baseline-1st and at 5th time points) were conducted since the 
electrocardiography was taken only at baseline and at 5th time points.
 
  The tenets of the 
Declaration of Helsinki were followed and institutional review board approval was granted at 
all MESA sites.  Written informed consent was obtained from each participant. 
The Netherlands Epidemiology of Obesity (NEO) study: The NEO study was 
designed for extensive phenotyping to investigate pathways that lead to obesity-related 
diseases. The NEO study is a population-based, prospective cohort study that includes 6,671 
individuals aged 45–65 years, with an oversampling of individuals with overweight or 
obesity. At baseline, information on demography, lifestyle, and medical history have been 
collected by questionnaires. In addition, samples of 24-h urine, fasting and postprandial 
blood plasma and serum, and DNA were collected. Genotyping was performed using the 
Illumina HumanCoreExome chip, which was subsequently imputed to the 1000 genome 
reference panel. Participants underwent an extensive physical examination, including 
anthropometry, electrocardiography, spirometry, and measurement of the carotid artery 
intima-media thickness by ultrasonography. In random subsamples of participants, magnetic 
resonance imaging of abdominal fat, pulse wave velocity of the aorta, heart, and brain, 
magnetic resonance spectroscopy of the liver, indirect calorimetry, dual energy X-ray 
absorptiometry, or accelerometry measurements were performed. The collection of data 
started in September 2008 and completed at the end of September 2012. Participants are 
currently being followed for the incidence of obesity-related diseases and mortality.   
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Prospective Study of Pravastatin in the Elderly at Risk (PROSPER):  All data come 
from the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). A detailed 
description of the study has been published elsewhere.
334, 335
  PROSPER was a prospective 
multicenter randomized placebo-controlled trial to assess whether treatment with pravastatin 
diminishes the risk of major vascular events in elderly. Between December 1997 and May 
1999, we screened and enrolled subjects in Scotland (Glasgow), Ireland (Cork), and the 
Netherlands (Leiden). Men and women aged 70-82 years were recruited if they had pre-
existing vascular disease or increased risk of such disease because of smoking, hypertension, 
or diabetes. A total number of 5,804 subjects were randomly assigned to pravastatin or 
placebo. A large number of prospective tests were performed including Biobank tests and 
cognitive function measurements.  
Rotterdam Study (RS):  The RS is a prospective population based cohort study 
comprising 7,983 participants aged 55 years or older (RS1), which started in 1990. In 2000-
2001, an additional 3,011 individuals aged 55 years or older were recruited (RS2). 
Furthermore, in 2006-2008, an additional 3,932 individuals aged 45 years or older were 
recruited (RS3).
393
  At baseline, participants were interviewed at home and were examined at 
the research center, which included a 10 second, 12-lead electrocardiogram (ECG). Since 
then, participants are followed continuously and re-examined during several follow-up 
examination rounds. Medical information is available of all participants by collaboration with 
the general
 
practitioners and with the pharmacies in the area of Ommoord.
 
The Rotterdam 
Study has been approved by the medical ethics committee according to the “Wet 
Bevolkingsonderzoek: ERGO” (Population Study Act Rotterdam Study), executed by the 
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Ministry of Health, Welfare and Sports of the Netherlands and written informed consent was 
obtained from all study participants. 
Women’s Health Initiative Clinical Trials (WHI CT):  The WHI is a long-term 
national health study focused on strategies for preventing heart disease, breast and colorectal 
cancer, and osteoporotic fractures in postmenopausal women.  Between 1993 and 1998, it 
randomized 68,132 women aged 50-79 years into one or more clinical trials of hormone 
therapy, dietary modification, or calcium/vitamin D supplementation.
52
  In this context, white 
WHI CT women were controls drawn from the Genome-wide Association Research Network 
into Effects of Treatment (GARNET),
394
 controls drawn from the Modification of PM-
Mediated Arrhythmogenesis in Populations (MOPMAP),
395
 or participants in the Women's 
Health Initiative Memory Study (WHIMS) .
396
  Black and Hispanic WHI CT women were 
participants in the single nucleotide polymorphism (SNP) Health Association Resource 
project (SHARe).
397
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CHAPTER 6: RESEARCH PAPER 2-EFFECT OF PREVALENT USER BIAS AND 
EXPOSURE MISCLASSIFICATION ON PHARMACOGENOMICS STUDIES 
CONDUCTED IN OBSERVATIONAL COHORT SETTINGS: A SIMULATION 
STUDY
2
 
Introduction 
Drug response and efficacy demonstrate high intra- and inter-individual variability, 
posing a significant problem for effective treatment,
2-4
 with adverse drug reactions (ADRs) 
accounting for approximately 100,000 deaths and 2.2 million serious health effects annually.
5
  
Genetics may influence variability in drug response by affecting pharmacokinetic and 
pharmacodynamics pathways.
61
  For example, single nucleotide polymorphisms (SNPs) in 
CYP2C9 and VKORC1 explain up to 50% of the variability in warfarin response,
259
 and 
HLA-B modifies the risk of toxic side effects of carbamazepine
7, 260
 and abacavir.
261
  Given 
that more than half of all American adults take at least one prescription medication, it is 
critical to understand the genetics of drug response across broad, diverse populations.
1
  
 Despite the public health and clinical significance of research evaluating the genetic 
bias of drug response, very few studies have evaluated the merits of alternative 
pharmacogenomics study designs.  Efforts examining pharmacogenomics study designs are 
warranted because, while pharmacoepidemiologic studies are subject to a multitude of biases, 
including selection bias and confounding by indication,
283
 it remains unclear if 
pharmacogenomics studies of gene-drug interactions are similarly susceptible.  Indeed, 
pharmacogenomics studies represent a specific subset of pharmacoepidemiologic studies that 
                                                 
2
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incorporate a third parameter, the SNP.  Unlike other environmental modifiers, an 
individual’s genotype is assigned at conception and therefore not affected by subsequent 
exposures, which may make SNP interaction effects less susceptible to the same biases 
affecting other modifiers.
287, 288
  For example, previous work examining bias from 
confounding by contraindication in observational pharmacogenomics settings demonstrated 
that the degree of bias varied by study design.
47
   
Yet, no studies have yet examined how other common threats to the validity of 
pharmacoepidemiologic studies affect pharmacogenomics studies conducted in observational 
settings, despite the emerging use of observational pharmacogenomics studies that offer large 
sample sizes, a diverse range of phenotypes, numerous medication exposures, and improved 
external validity when compared to clinical trials.
284
  For example, no study to the best of our 
knowledge has evaluated the degree to which pharmacogenomics studies are subject to 
prevalent user bias, whereby the cohort is enriched for prevalent long-term drug users who 
are less likely to have experienced an ADR when compared to new users.
284, 285
  The 
influence of drug misclassification remains similarly understudied in pharmacogenomics 
studies.
398-400
  We therefore conducted a series of simulations examining the influence of 
prevalent user bias and drug misclassification on pharmacogenomics studies by evaluating 
three observational designs (longitudinal, cross-sectional, and new user), two control groups 
(whole cohort and active comparator), and two scenarios (extreme and modest drug effects).  
Results of this study will help guide the design of future pharmacogenomics studies 
conducted in observational settings. 
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Materials and Methods 
A. Simulation Overview 
 We simulated a population with four study visits using QT interval (QT), a heritable 
measure of ventricular depolarization and repolarization,
24-28
 and QT-prolonging drug use as 
our pharmacogenomic model.  QT prolongation, a risk factor for highly fatal ventricular 
arrhythmias,
68, 163
 is most commonly caused by prescription drugs.
133
   
 We simulated four time points (visits 0–3 [V0–V3], Figure 25), as informed by a 
literature review.  V0 represented a wash-out period where the prevalence of drug use was 
0%.  Published clinical and genome-wide association studies (GWAS),
209
 along with 
empirical data from the Atherosclerosis Risk in Communities (ARIC) Study,
321
 informed 
assigned parameter estimates.  For the QT-prolonging medication we simulated a thiazide 
diuretic, a commonly used anti-hypertensive agent with previously reported QT-prolonging 
effects,
146
 which is henceforth referenced to as the index drug.  Participants with treated 
hypertension who were not treated by the index drug were assigned treatment on a 
comparator hypertension medication with no QT-prolonging effects.  In addition to these 
time-varying parameters measured at each visit, age, sex, diabetes status, and SNP genotype 
were simulated at V0, the latter we simulated as the causal SNP (i.e. not in linkage 
disequilibrium with the unobserved causal SNP).  Diabetes status at V0 was used as a 
determinant of index or comparator drug use among those with treated hypertension, where 
those with diabetes were more likely to use the comparator drug (Figure 26).   
To introduce prevalent user bias, whereby the cohort was enriched for long-term drug 
users, we simulated an ADR, which could occur between V1 – V3 (i.e. a maximum of two 
times).  For participants on the index drug, the probability of having an ADR was affected by 
QT at the previous visit.  The probability of remaining on the index drug at the subsequent 
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visit was then affected by the probability of an ADR (Figure 27).  Having an ADR also 
increased the probability that a participant was lost to follow-up.  Correlation between serial 
QT measurements was simulated as a function of unmeasured covariates (i.e. ‘U’, which 
represents heart rate, congenital heart disease, other medication use, other SNPs, 
hypokalemia, myocardial infarction, etc.).
68
   
B. Simulation Parameters and Values 
 We simulated a population size of 120,000, the sample size in a cross-sectional 
pharmacogenomics study necessary to achieve 80% power to detect a 1.6 ms drug-SNP 
interaction on QT (minor allele frequency [MAF] = 25%; 17% drug prevalence; 20 ms 
standard deviation [SD]), an effect estimate similar in magnitude to published SNP main 
effects on QT.
209
  In sensitivity analyses we increased the simulated population size to a 
maximum of 300,000 participants.  
  Age was simulated using a normal distribution with a mean (54.4 years) and SD (5.7 
years) equal to that observed at the ARIC baseline visit among white participants.  Sex was 
simulated as a uniform random variable with a defined probability of being male (47.3%).  A 
uniform distribution also was used to simulated SNP genotype according to a prespecified 
MAF (MAF=0.05, 0.25, and 0.45).  Participant genotype was calculated under the 
assumption of Hardy-Weinberg equilibrium.  Diabetes was predicted conditional on age 
using the logit function: 
𝐿𝑜𝑔𝑖𝑡(𝑝𝑟(𝐷𝑖𝑎𝑏𝑒𝑡𝑒𝑠 = 1)) = 𝛼0 + 𝛼1𝐴𝑔𝑒 + 𝜀 
Unknown/unmeasured confounding (U) was simulated using a normal distribution with a 
mean (0) and SD (20) to approximate the correlation between serial visits observed in ARIC 
(r =0.75). 
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 Hypertension status at each visit was predicted conditional on age and sex and, for 
V1-V3, hypertension status as the previous visit, using the logit function: 
𝐿𝑜𝑔𝑖𝑡(𝑝𝑟(𝐻𝑇𝑁𝑖 = 1)) = 𝛼0 + 𝛼1𝐴𝑔𝑒 + 𝛼2𝑆𝑒𝑥 + 𝛼3𝐻𝑇𝑁𝑖−1|𝑖≥1 + 𝜀 
The probability of having treated hypertension at V1 – V3 was randomly simulated among 
participants with hypertension with a defined probability of treatment (91%).  The prevalence 
of the index drug at V1 was assigned at 17%.  Among participants with treated hypertension 
at V1 – V3, drug treatment (index or comparator) was predicted conditional on diabetes 
status and, for V2 – V3, drug use at the previous visit and occurrence of an ADR between 
visits as: 
𝐿𝑜𝑔𝑖𝑡(𝑝𝑟(𝐷𝑟𝑢𝑔𝑖 = 1)) = 𝛼0 + 𝛼1𝐷𝑖𝑎𝑏𝑒𝑡𝑒𝑠 + 𝛼2𝐷𝑟𝑢𝑔𝑖−1|𝑖≥2 + 𝛼3𝐴𝐷𝑅𝑖|𝑖≥2 + 𝜀 
The probability of using the comparator medication was modeled as 1 – pr(Drug=1).   
Previous work has suggested the potential for measurement error in medication 
assessment conducted in observational settings.
57
  We therefore simulated an alternate 
scenario assuming a reduced sensitivity (97%) and specificity (79%) in the ascertainment of 
the index drug.
57
  
 QT was simulated as a linear function of the SNP, age, sex, U, hypertension, diabetes, 
drug treatment and the interaction between SNP and drug treatment:  
𝑄𝑇 = 𝛽0 + 𝛽1𝐷𝑟𝑢𝑔 + 𝛽2𝑆𝑁𝑃 + 𝛽3𝐷𝑟𝑢𝑔 × 𝑆𝑁𝑃 + 𝛽4𝐴𝑔𝑒 + 𝛽5𝑆𝑒𝑥 + 𝛽6𝑈 + 𝛽7𝐻𝑇𝑁
+ 𝛽8𝐷𝑖𝑎𝑏𝑒𝑡𝑒𝑠 + 𝜀 
where mean QT was simulated as 389 ms when all other variables equaled 0.  A one-year 
increase in age, male sex, one unit increase in U, hypertension status and diabetes status were 
associated with 0.39, -3.84, 2.00, 4.50, and -4.90 ms changes in QT, respectively (Table 29).  
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The occurrence of an ADR between visits among those on drug treatment was predicted 
using a logit model conditional on QT > 450 ms (QTLong) at the previous visit: 
𝐿𝑜𝑔𝑖𝑡(𝑝𝑟(𝐴𝐷𝑅𝑖 = 1)) = 𝛼0 + 𝛼1𝑄𝑇𝐿𝑜𝑛𝑔,𝑖−1 + 𝜀 
Loss-to-follow-up was predicted using a logit model conditional on age and the occurrence 
of an ADR between visits: 
𝐿𝑜𝑔𝑖𝑡(𝑝𝑟(𝐿𝑜𝑠𝑠𝑖 = 1)) = 𝛼0 + 𝛼1𝐴𝑔𝑒 + 𝛼2𝐴𝐷𝑅𝑖 + 𝜀 
 Simulations assumed both extreme index drug effects on QT (i.e. the index drug 
prolonged QT by 30 ms, termed the extreme scenario, Table 29) and modest index drug 
effects on QT (i.e. the index drug prolonged QT by 5 ms, termed the modest scenario).
148
  
Simulations also were performed varying the SNP main effect on QT (range: 0–10 ms), the 
drug-SNP interactive effect on QT (range: -6–6 ms), the log-odds of drug continuation given 
an ADR (range: -50–0), the effect of drug treatment on QT (range: 0–30 ms), and the log-
odds of an ADR given prolonged QT (range: 0–50).  A total of 10,000 iterations were 
simulated for each setting across which results were averaged.  All analyses were performed 
using the statistical programming package SAS (Cary, North Carolina, USA).  
C. Analysis of Drug-SNP Interactions 
 We used our simulations to contrast 12 settings that evaluated in combination three 
study designs (new user, longitudinal, and cross-sectional), two control groups (whole cohort 
and active comparator), and two scenarios (extreme and modest drug effects).  The new user 
design was restricted to V1, where all participants on drug treatment were new initiators 
(Figure 25).  The longitudinal design included V2 and V3 and the cross-sectional design was 
restricted to V3 (Figure 25).  In each design, simulations were run for both the whole cohort 
and the active comparator control groups, the control group for the latter being restricted to 
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participants on the comparator treatment.  Finally, we examined two scenarios, the extreme 
scenario (index drugs with QT-prolonging effects of 30 ms) and modest (index drugs with 
QT-prolonging effects of 5 ms), representing 12 total settings. 
 In the new user and cross-sectional designs, the SNP-drug interaction effect was 
estimated using linear regression with QTi as the dependent variable and the SNP, drug, SNP-
drug interaction, age, sex, diabetes, and HTNi as independent variables, as follows: 
𝑄𝑇 = 𝛽0 + 𝛽1𝐷𝑟𝑢𝑔𝑖 + 𝛽2𝑆𝑁𝑃𝑖 + 𝛽3𝐷𝑟𝑢𝑔𝑖 × 𝑆𝑁𝑃𝑖 + 𝛽4𝐴𝑔𝑒𝑖 + 𝛽5𝑆𝑒𝑥𝑖 + 𝛽6𝐻𝑇𝑁𝑖
+ 𝛽7𝐷𝑖𝑎𝑏𝑒𝑡𝑒𝑠𝑖 
where β3 represents the SNP-drug interaction effect.  For the longitudinal designs, the SNP-
drug interaction effect was estimated using generalized estimating equations with an 
independence working correlation
346
 as follows: 
𝐸[𝑄𝑇𝑖𝑗] =  𝛽0 + 𝛽1𝐷𝑟𝑢𝑔𝑖𝑗 + 𝛽2𝑆𝑁𝑃𝑖 + 𝛽3𝐷𝑟𝑢𝑔𝑖𝑗 × 𝑆𝑁𝑃𝑖 + 𝛽4𝐴𝑔𝑒𝑖 + 𝛽5𝑆𝑒𝑥𝑖 + 𝛽6𝐻𝑇𝑁𝑖𝑗
+ 𝛽7𝐷𝑖𝑎𝑏𝑒𝑡𝑒𝑠𝑖 
where QTij is our outcome for the i
th
 participant at the j
th
 timepoint conditional on the SNP, 
drug, SNP-drug interaction, age, sex, diabetes, and HTNi and β3 represents the SNP-drug 
interaction effect.  Our simulations used a genome-wide α level (5x10-8). 
Results 
 The mean (SD) of QT was 409 ms (26 ms) at V0 for both the modest and extreme 
scenarios and increased to 410 (26) ms and 414 (29) ms at V1 for the modest and extreme 
scenarios, respectively (Table 30).  Exposure to the index drug increased across visits under 
the modest scenario, as participants initiated drug use and few discontinued due to ADRs 
(1.5% of those exposed at V2 and 1.4% of those exposed at V3 discontinued) or switched to 
the comparator drug (6-7% across V1-V3).  As expected, index drug exposure was lower at 
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V2 and V3 in the extreme versus modest scenario (17% at V2 and V3 in the extreme 
scenario), as a larger proportion of drug users were susceptible to an ADR and subsequently 
discontinued drug use (e.g. 33% index drug users before V3; 25% index drug users before 
V4) or were switched to the comparator drug (7-9% across V1-V3). 
 We first tested the performance of our models by examining bias in the index drug 
effect on QT, expecting minimal bias in the new user design.
401
  Our simulations 
demonstrated negligible bias in the drug effect using the new user design both when a 5 ms 
(modest scenario) and a 30 ms (extreme scenario) drug effect were simulated, suggesting that 
our models performed as expected (Figure 28). 
A. Simulations with Drug-SNP Interaction = 0 and Varied SNP Main Effect 
  We then evaluated the influence of prevalent user bias by contrasting the 
performance of the three study designs, two control groups, and two scenarios in the absence 
of a simulated drug-SNP interaction (i.e. drug-SNP interaction=0) but in the presence of a 
SNP main effect (range: 0 to 10 ms), which represented the effect of the SNP on QT 
independent of its interactive effect with the index drug (Figure 28-31).  Under the modest 
scenario, all estimates were minimally biased across simulated SNP main effects (mean bias 
range: -0.02 ms to -0.06 ms, Figure 29A).  Under the extreme scenario, the new user designs 
remained unbiased for both control groups (Figure 29B).  However, bias was observed 
among the remaining cohorts in the extreme scenario, particularly for the active comparator 
control group (maximum bias at simulated SNP main effect=10 ms: longitudinal active 
comparator = 1.34 ms; cross-sectional active comparator = 1.14 ms).  Simulated results with 
MAF of 5% and 45% showed similar patterns of bias (Figure 30, Figure 31). 
 Under both the modest and extreme scenarios, estimates of the false-positive 
proportion (FPP) for the drug-SNP interaction effect remained under 5% for all study settings 
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except the longitudinal active comparator setting under the extreme scenario (Figure 29C-D), 
for which the FPP ranged from 5% at a SNP main effect of 2 ms to 46% at a SNP main effect 
of 10 ms. 
B. Simulations with SNP Main Effect = 0 and Varied Drug-SNP Interaction Effect 
   We next evaluated the performance of the12 settings in the presence of a simulated 
drug-SNP effect (range: -6 ms–6 ms), but the absence of a SNP main effect (i.e. SNP main 
effect = 0).  As with the previous results, the modest scenario showed negligible bias in the 
drug-SNP interaction effect across all designs and control groups (maximum bias = -0.09 ms, 
Figure 32A).  However, under the extreme scenario, while the new user design remained 
unbiased, the whole cohort and active comparator control groups in the context of the 
longitudinal or cross-sectional designs demonstrated opposite patterns of bias, with the 
magnitude of bias being approximately 120% greater in the active comparator compared to 
whole cohort control groups (e.g. 0.77 vs 0.25 ms at a simulated drug-SNP interaction effect 
of 6ms; Figure 32B).  Patterns of bias remained the same when MAF was varied (Figure 33). 
 Despite greater bias in the extreme scenario, power to detect the drug-SNP interaction 
effect was similar under both scenarios (Figure 32C-D).  For example, power to detect the 
drug-SNP interaction effect reached 80% at drug-SNP interaction effects of 2 or 3 ms for all 
study settings except the new user or cross-sectional active comparator settings.  For the new 
user active comparator setting, power exceeded 80% at a drug-SNP interaction effect of 6 
ms.  Power for the cross-sectional active comparator setting never exceeded 50% for the 
modest scenario but reached 80% at 6 ms for the extreme scenario.  For MAFs of 5%, power 
was best for the longitudinal whole cohort setting but only exceeded 80% when a drug-SNP 
interaction effect of 4 ms was simulated.  Power to detect drug-SNP interaction effects 
ranging from -6 to 6 ms remained below 80% in the new user or cross-sectional active 
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comparator setting when MAF was 5% under both scenarios (Figure 34).  As expected, 
power was improved when evaluating SNPs with MAF of 45%, particularly for the active 
comparator control groups. 
C. Simulations with Varied Drug and ADR Effects 
 To test how medications with different degrees of QT-prolongation and the 
probability of ADRs effected bias and power, we then varied the effect of the drug on QT (0–
30 ms), the proportion of participants with a prolonged QT (QT>450 ms) who experienced 
an ADR (log-odds of an ADR given prolonged QT: 0–50), and the probability of medication 
discontinuation given an ADR (log-odds of medication continuation given an ADR: -50–0).  
For these simulations we evaluated a SNP main effect of 0 ms and a drug-SNP interaction 
effect of 5 ms.  There was no bias in the drug-SNP interaction effect for new user designs 
under any of the three scenarios examined (Figure 35).  However, as the simulated effect of 
the drug on QT increased, bias in the drug-SNP interaction effect was observed for the 
longitudinal and cross-sectional designs, which varied based on the control group and 
simulated drug effect (longitudinal whole cohort bias range = -0.53– -0.24 ms; longitudinal 
active comparator = -0.16– 0.62 ms, Figure 35A). 
 Varying the log-odds of an ADR following QT prolongation or the log-odds of 
medication discontinuation given an ADR demonstrated a distinct pattern of bias.  When the 
log-odds of an ADR given QT prolongation was small bias in the drug-SNP interaction was 
negligible (Figure 35B).  However, once the log-odds of having an ADR given QT 
prolongation exceeded 10, corresponding to an ADR probability of 60%, the bias above 
(range:  0.54–0.62 ms in active comparator control groups) and below (range: -0.24– -0.14 
ms in whole cohort control groups) in the drug-SNP interaction effect was observed for all 
designs except the new user design.  The bias also remained the same across increasing log-
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odds of an ADR (>10).  When the log-odds of medication continuation was varied, we 
observed an opposite pattern of bias (i.e. bias[range above: 0.54–0.62 ms in active 
comparator control groups; range below: -0.24– -0.14 ms  in whole cohort control groups] 
increased across decreasing log-odds of drug continuation, but remained uniform after a 
simulation log-odds of -10; Figure 35C).  
D. Simulations with Reduced Specificity and Sensitivity 
 Because medication use may be misclassified,
57
 we evaluated the influence of 
reduced sensitivity (97%) and specificity (79%) of medication use assessment.  Reduced 
sensitivity and specificity were associated with a considerable increase in bias (Figure 36) 
compared to perfect medication assessment (Figure 32).  For example, in both the extreme 
and modest scenarios, reduced sensitivity and specificity biased estimated drug-SNP 
interaction effects toward the null by as much as 59% (e.g. true effect size=6 ms; estimated 
effect size in the presence of drug measurement error=2.49 ms in longitudinal whole cohort 
setting under extreme scenario).   
 Power to detect the drug-SNP interaction effect also was expectedly reduced.  Under 
the extreme scenario, perfect sensitivity and specificity resulted in 80% power to detect the 
drug-SNP interaction effect between 2 and 6 ms, depending on study setting (Figure 32D).  
However, reduced sensitivity and specificity lowered the power so that 80% power was not 
achieved until 3 ms in the longitudinal designs and 4 ms in the new user and cross-sectional 
whole cohort settings (Figure 36D).  The new user cross-sectional active comparator settings 
did not achieve 80% power under any tested drug-SNP interaction effect tested here (range: -
6 to 6 ms).  The modest scenario demonstrated similar power to detect interaction effects as 
the extreme scenario (Figure 36C).  
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E. Power Across Varying Sample Sizes 
Lastly, given the reduced power when simulations were extended to accommodate 
reduced sensitivity and specificity, we evaluated the population size needed to achieve 80% 
power to detect a 2 ms drug-SNP interaction (Figure 37), power estimates consistent with 
study designs that assumed perfect sensitivity and specificity.  With reduced sensitivity and 
specificity, the smallest sample size that achieved 80% power to detect a 2 ms drug-SNP 
interaction was 150,000 for the longitudinal whole cohort setting.  For the cross-sectional 
design, the smallest sample size that achieved 80% power to detect a 2 ms drug-SNP 
interaction was 260,000 (whole cohort control group).  For the new user designs, power to 
detect a 2 ms drug-SNP interaction never exceeded 70% despite a sample size of 300,000 
participants. 
Discussion 
 In these simulations, we examined the influence of prevalent user bias and exposure 
misclassification in pharmacogenomic studies conducted in observational cohort settings by 
contrasting three designs (new user, cross-sectional, and longitudinal), two control groups 
(whole cohort and active comparator) and two scenarios (modes and extreme drug effects on 
QT).  Our simulations identified settings where prevalent user bias caused moderate bias on 
the drug-SNP interaction effect.  Yet, the greatest bias, as well as the largest reductions in 
power were detected when simulations were extended to examine exposure misclassification.  
Given that the amount of bias and potential for reduced power varied by the design, control 
group, and the strength of the drug-induced QT prolongation, these results have broad 
implications for pharmacogenomics studies conducted in observational settings. 
 To date, numerous pharmacogenomics GWAS with likely insufficient power have 
been published, indicating the difficulty in obtaining sample sizes sufficient to detect 
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interactions at stringent GWAS significance thresholds.
282, 402-404
  Indeed, such 
“disappointing” results have prompted the speculation that with noted exceptions,7, 259-261 
there might be fewer instances of large and clinically significant pharmacogenomics effects 
than previously expected.
282, 403, 405
  Yet, our results show that even at sample sizes four times 
larger than QT pharmacogenomics studies published to date,
282
 the influence of exposure 
misclassification makes it difficult to rule-out clinically significant results, generally defined 
as interactions with effects of 5 ms or greater.
44
  Further, the influence of other sources of 
measurement error (e.g. outcome measurement error) and the inability to accommodate other 
important covariates like medication dose in most observational cohort studies likely reduced 
power further.  Indeed, a strength of pharmacogenomics studies of QT is the degree to which 
QT is reliably measured.
74, 406
  However, other phenotypes of interest (e.g. blood pressure 
and glycemic traits) show greater variability in measurement, which warrants evaluation in 
future efforts.
407-409
  
 Given the massive statistical testing penalty of genome-wide association studies and 
the potential for bias in study designs that optimize power (i.e. longitudinal), it is tempting to 
consider hypothesis-based genomic analyses such as a candidate gene studies as an 
alternative to genome-wide analyses.  There has been some success in identifying genetic 
variants in genes associated with congenital long QT syndrome that modify drug-induced 
QT-prolongation.
410
   However, efforts evaluating loci from main effects QT GWAS as 
candidate genes in pharmacogenomic studies of QT-prolonging drugs have not yielded 
positive results.
282
  The lack of positive results is not unique to drug-induced QT-
prolongation.  Efforts by Bis et al. to identify genetic variants that modified the association 
between antihypertensives and cardiovascular disease in genes previously associated with 
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coronary heart disease were similarly unsuccessful.
403
  Lessons from main effects analyses 
have also demonstrated a higher success of GWAS over candidate gene studies, where few 
biologically motivated association studies were consistently replicated
411-413
 while GWAS 
have successfully replicated thousands of associations across populations.
414, 415
 
 Although drug misclassification had the greatest influence on power and bias, 
prevalent user bias also exerted non-negligible effects, which varied by the magnitude of the 
drug-outcome association.  Our simulations suggest that, even with exposure 
misclassification, longitudinal designs optimize the power to detect effects in discovery 
analyses over the other designs considered here but also demonstrated the largest potential 
for bias when the drug-outcome association was large.  Iribarren et al. identified drugs with 
QT-prolonging effects greater than 25 ms,
148
 five times the standard for regulation by the 
U.S. Food and Drug Administration (FDA).
44
  These results demonstrate the necessity of 
considering bias from extreme drug effects not only in studies of QT, but also in studies of 
other drugs with large effects on the outcome, including pharmacogenomics studies of statins 
and low-density lipoprotein levels
416
 or thiazides and antihypertensive response.
272-274
  In the 
context of large drug effects on the outcome, our results suggest the use of a longitudinal 
design with a whole cohort control group to increase power to detect drug-SNP interaction 
effects but acknowledging the potential for a drug-SNP interaction estimate moderately 
biased toward the null.  Our simulations suggested that when the drug had a modest effect on 
the outcome (i.e. indapamide, a thiazide-like diuretic that prolongs QT by under 10 ms),
148
 
bias in the drug-SNP effect was minimal but drugs with stronger effects  or studies with 
exposure misclassification can result in substantial bias in the drug-SNP interaction effect 
with up to half the true effect lost to bias.   
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 It is important to note that the conclusions of this study are limited by the scope of the 
simulations presented herein.  For example, our choice of active comparator encompassed 
any antihypertensive medication other than a thiazide diuretic, which was modeled as our 
drug of interest.  Thus, if a participant had treated hypertension but had an ADR, the 
participant was automatically changed to the active comparator control group.  Our 
simulations therefore do not indicate how prevalent user bias would affect an active 
comparator control group that was chosen from a different group of medications that had a 
different indication of treatment from the drug of interest.  Furthermore, we only investigated 
a single scenario of medication misclassification.  Given the strong effects reduced 
specificity and sensitivity had on prevalent user bias, future work examining how different 
levels of specificity and sensitivity affect prevalent user bias as well as other biases 
potentially affecting pharmacogenomic studies, such as confounding by contraindication, is 
warranted. 
 In conclusion, our simulations suggested that when medication is well assessed and 
the underlying drug effect on the outcome is modest, prevalent user bias may be negligible.  
However, prevalent user bias scales with increasing drug effects, although the bias had only 
moderate effects on study power.  The most striking effects were estimated for exposure 
misclassification, which caused sizable bias in the drug-SNP interaction and large reductions 
in power.  Researchers must carefully weigh different sources of bias and misclassification 
against power considerations when designing their pharmacogenomic analyses in order to 
optimize efforts to identify and characterize SNPs that modify drug-outcome associations. 
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Tables and Figures  
 
Table 29. Parameter Values for the Extreme, Modest, and Alternative Scenarios 
Variable Parameter  Meaning 
Parameter Values 
Extreme 
Scenario 
Modest 
Scenario 
Alternative 
Scenarios 
Diabetes 𝛼0 Value chosen for 13% prevalence of diabetes -6.00 -6.00 -- 
 𝛼𝐴𝑔𝑒  Log odds of diabetes for 1-year increase in age 0.075 0.075 -- 
Hypertension 𝛼0 Value chosen for 33% prevalence of HTN -5.25 -5.25 -- 
 𝛼𝐴𝑔𝑒  Log odds of hypertension for 1-year increase in age 0.08 0.08 -- 
 𝛼𝑆𝑒𝑥 Log odds of hypertension for men versus women 0.16 0.16 -- 
 𝛼𝐻𝑇𝑁 Log odds of hypertension for those with previous hypertension 
versus those without 
-4.74 -4.74 -- 
Drug Treatment 𝛼0 Value chosen for 17% prevalence of drug treatment 1.55 1.55 -- 
 𝛼𝐷𝑖𝑎𝑏  Log odds of drug treatment for those with diabetes versus those 
without 
-90 -90 -- 
 𝛼𝐷𝑟𝑢𝑔 Log odds of drug treatment for those previously on treatment versus 
those not previously on treatment 
4.80 4.80 -- 
 𝛼𝐴𝐷𝑅 Log odds of drug treatment for those who suffered an ADR versus 
those who did not 
-50 -3.75 -50 – 0  
QT 𝛽0 Mean QT for women with 0 copies of the minor allele and the mean 
amount of unmeasured confounding 
389 389 -- 
 𝛽𝐷𝑟𝑢𝑔 Drug effect on QT 30 5 0 – 30  
 𝛽𝑆𝑁𝑃 SNP effect on QT 0 0 0 – 10  
 𝛽𝐷𝑟𝑢𝑔×𝑆𝑁𝑃 Drug-SNP interaction effect on QT 0 0 -6 – 6  
 𝛽𝐴𝑔𝑒  Age effect on QT 0.39 0.39 -- 
 𝛽𝑆𝑒𝑥 Sex effect on QT -3.84 -3.84 -- 
 𝛽𝑈 Effect of unknown/unmeasured correlates of QT 2.00 2.00 -- 
 𝛽𝐻𝑇𝑁 Hypertension effect on QT 4.50 4.50 -- 
 𝛽𝐷𝑖𝑎𝑏  Diabetes effect on QT -4.90 -4.90 -- 
ADR 𝛼0 Value chosen for a 2.5% prevalence of ADR among those on drug 
treatment 
-4.55 -4.55 -- 
 𝛼𝑄𝑇𝑙𝑜𝑛𝑔 Log odds of ADR for those with QT > 450 ms versus those without 50 2.05 0 – 50  
Loss-to-Follow-up 𝛼0 Value chosen for a 4% prevalence of loss-to-follow-up -2.62 -2.62 -- 
𝛼𝐴𝑔𝑒  Log odds of loss-to-follow-up for 1-year increase in age -0.01 -0.01 -- 
 𝛼𝐴𝐷𝑅 Log odds of loss-to-follow-up for those with ADR versus those 
without 
2.89 2.89 -- 
ADR, Adverse drug reaction; HTN, Hypertension; QT, QT interval; SNP, Single nucleotide polymorphism 
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Table 30. Descriptive Statistics Across Visits in Simulation Studies Using the Modest Scenario and 
Extreme Scenario 
 Modest Scenario  Extreme Scenario 
 Visit 0 Visit 1 Visit 2 Visit 3  Visit 0 Visit 1 Visit 2 Visit 3 
N 120,000 120,000 115,016 110,093  120,000 120,000 111,685 104,546 
Mean Age (SD) 54 (6) 54 (6) 54 (6) 54 (6)  54 (6) 54 (6) 54 (6) 54 (6) 
Mean QT (SD) 
409 
(26) 
410 
(26) 
410 
(26) 
411 
(26) 
 
409 
(26) 
414 
(29) 
414 
(28) 
414 
(28) 
% Male 47% 47% 47% 47%  47% 47% 47% 47% 
% Diabetic 14% 14% 14% 14%  14% 14% 14% 14% 
% Hypertensive 31% 36% 40% 43%  31% 36% 39% 41% 
% Exposed to 
Drug 
0% 17% 21% 23%  0% 17% 17% 19% 
% Exposed to 
Comparator 
Drug 
0% 7% 6% 6%  0% 7% 9% 9% 
% ADR -- -- 0.4% 0.5%  -- -- 8% 6% 
 
Figure 25.  Simulation Study Timeline and Study Designs 
Visit 0 represents a wash-out period where no participants are on medications of interest.  At 
visit 1, all users are new initiators, allowing a new-user study design to be applied to this 
visit.  By visit 3, users have been on medication across time and there has been multiple 
opportunities for individuals to initiate, have adverse reactions, and stop drug use, enriching 
visit 3 for participants who are long-term drug users.  For longitudinal analyses, visit 2 is 
included, along with visit 3, as both are enriched for prevalent users. 
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Figure 26.  Decision Tree to Classify Drug Exposure in a Simulation Study 
When participants do not have treated hypertension (HTN), they are unexposed to the drug 
of interest.  If they have treated HTN, their exposure status is conditional on their diabetes 
status. 
Figure 27.  Conceptual Model of Relationship Between QT-Prolonging 
Drug Use, QT Interval, and Adverse Drug Reactions 
 
Single nucleotide polymorphism (SNP) is an effect measure modifier on the 
Drug-QT association.  Drug effects QT at visit 1, modified by SNP, which in 
turn affects ADR, which then effects drug status at visit 2. 
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  Figure 28.  Bias, False Positive Proportion, and Power in a Pharmacogenomic Study 
of QT Under an Extreme and Modest Scenario in the Absence of a Drug Main Effect 
or the Absence of a Drug-SNP Interaction Effect 
The bias in drug or SNP effect estimated for a pharmacogenomics study of QT in the absence 
of a simulated drug-SNP interaction effect over a varied main effect and the bias estimated in 
the absence of a SNP main effect over a varied drug-SNP interaction effect.  The false 
positive proportion or power in the drug effect and SNP effect estimated for a 
pharmacogenomics study of QT in the absence of a simulated drug-SNP interaction effect 
over a varied main effect or in the absence of a SNP main effect over a varied drug-SNP 
interaction effect.  Left column panels represent the drug effect under the modest scenario (5 
ms increase in QT among drug users).  Left center column panels represent the drug effect 
under the extreme scenario (30 ms increase in QT among drug users).  Right center column 
panels represent the SNP effect under the modest scenario.  Right column panels represent 
the SNP effect under the extreme scenario.  Black lines represent the longitudinal study 
design, blue lines represent the cross-sectional study design, and red lines represent the new-
user study design contrasting whole-cohort ( ─ ) and active comparator (- - -) control groups.  
Simulations were performed assuming a population of 120,000 participants with ~17% of 
participants receiving a QT-prolonging medication, with 10,000 simulations performed per 
scenario. 
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Figure 29.  Bias and False Positive Proportion in a Pharmacogenomic Study of QT 
Under an Extreme and Modest Scenario in the Absence of a Drug-SNP Interaction 
Effect 
The bias (A, B) and false positive proportion (C, D) estimated for a pharmacogenomics study 
of QT in the absence of a simulated drug-SNP interaction effect over a varied main effect.  
Left column panels represent the Modest scenario (5 ms increase in QT among drug users).  
Right column panels represent the Extreme scenario (30 ms increase in QT among drug 
users).  Black lines represent the longitudinal study design, blue lines represent the cross-
sectional study design, and red lines represent the new-user study design contrasting whole-
cohort ( ─ ) and active comparator (- - -) control groups.  Simulations were performed 
assuming a population of 120,000 participants with ~17% of participants receiving a QT-
prolonging medication, with 10,000 simulations performed per scenario. 
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Figure 30.  Bias in a Pharmacogenomic Study of QT Under an Extreme and Modest 
Scenario in the Absence of a Drug-SNP Interaction Effect Assuming a Minor Allele 
Frequency of 5% or 45% 
The bias estimated for a pharmacogenomics study of QT in the absence of a simulated drug-
SNP interaction effect under an extreme drug effect on QT and a modest drug effect on QT.  
Left column panels represent the bias in the drug-SNP interaction effect.  Middle column 
panels represent the bias in the drug main effect.  Right column panels represent the bias in 
the SNP main effect.  Top two rows represent simulations with a minor allele frequency 
(MAF) of 5%.  Bottom two rows represent simulations with a MAF of 45%.  Black lines 
represent the longitudinal study design, blue lines represent the cross-sectional study design, 
and red lines represent the new-user study design contrasting whole-cohort ( ─ ) and active 
comparator (- - -) control groups.  Simulations were performed assuming a population of 
120,000 participants with ~17% of participants receiving a QT-prolonging medication, with 
10,000 simulations performed per scenario. 
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Figure 31.  False Positive Proportion or Power in a Pharmacogenomic Study of QT 
Under an Extreme and Modest Scenario in the Absence of a Drug Main Effect or the 
Absence of a Drug-SNP Interaction Effect 
The false positive proportion (FPP) or power estimated for a pharmacogenomics study of QT 
in the absence of a simulated drug-SNP interaction effect over a varied main effect and the 
FPP or power estimated in the absence of a SNP main effect over a varied drug-SNP 
interaction effect under an extreme drug effect on QT and a modest drug effect on QT .  Left 
column panels represent the FPP or power in the drug-SNP interaction effect.  Middle 
column panels represent the power in the drug main effect.  Right column panels represent 
the FPP or power in the SNP main effect.  Black lines represent the longitudinal study design, 
blue lines represent the cross-sectional study design, and red lines represent the new-user 
study design contrasting whole-cohort ( ─ ) and active comparator (- - -) control groups.  
Simulations were performed assuming a population of 120,000 participants with ~17% of 
participants receiving a QT-prolonging medication, with 10,000 simulations performed per 
scenario. 
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Figure 32.  Bias and Power in a Pharmacogenomic Study of QT Under an Extreme 
and Modest Scenario in the Absence of a Drug Main Effect 
The bias (A, B) and power (C, D) estimated for a pharmacogenomics study of QT in the 
absence of a SNP main effect over a varied drug-SNP interaction effect.  Left column panels 
represent the Modest scenario (5 ms increase in QT among drug users).  Right column panels 
represent the Extreme scenario (30 ms increase in QT among drug users).  Black lines 
represent the longitudinal study design, blue lines represent the cross-sectional study design, 
and red lines represent the new-user study design contrasting whole-cohort ( ─ ) and active 
comparator (- - -) control groups.  Simulations were performed assuming a population of 
120,000 participants with ~17% of participants receiving a QT-prolonging medication, with 
10,000 simulations performed per scenario. 
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Figure 33.  Bias in a Pharmacogenomic Study of QT Under an Extreme and Modest 
Scenario in the Absence of a SNP Main Effect Assuming a Minor Allele Frequency of 
5% or 45%. 
The bias estimated for a pharmacogenomics study of QT in the absence of a simulated SNP 
main effect under an extreme drug effect on QT and a modest drug effect on QT.  Left 
column panels represent the bias in the drug-SNP interaction effect.  Middle column panels 
represent the bias in the drug main effect.  Right column panels represent the bias in the SNP 
main effect.  Top two rows represent simulations with a minor allele frequency (MAF) of 
5%.  Bottom two rows represent simulations with a MAF of 45%.  Black lines represent the 
longitudinal study design, blue lines represent the cross-sectional study design, and red lines 
represent the new-user study design contrasting whole-cohort ( ─ ) and active comparator (- - 
-) control groups.  Simulations were performed assuming a population of 120,000 participants 
with ~17% of participants receiving a QT-prolonging medication, with 10,000 simulations 
performed per scenario. 
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Figure 34.  False Positive Proportion or Power in a Pharmacogenomic Study of QT 
Under an Extreme and Modest Scenario in the Absence of a Drug-SNP Interaction 
Effect Assuming a Minor Allele Frequency of 5% or 45% 
The false positive proportion (FPP) or power estimated for a pharmacogenomics study of QT in the 
absence of a simulated drug-SNP interaction effect under an extreme drug effect on QT and a modest 
drug effect on QT.  Left column panels represent the FPP in the drug-SNP interaction effect.  Middle 
column panels represent the power in the drug main effect.  Right column panels represent the power in 
the SNP main effect.  Top two rows represent simulations with a minor allele frequency (MAF) of 5%.  
Bottom two rows represent simulations with a MAF of 45%.  Black lines represent the longitudinal 
study design, blue lines represent the cross-sectional study design, and red lines represent the new-user 
study design contrasting whole-cohort ( ─ ) and active comparator (- - -) control groups.  Simulations 
were performed assuming a population of 120,000 participants with ~17% of participants receiving a 
QT-prolonging medication, with 10,000 simulations performed per scenario. 
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Figure 35.  Bias in a Pharmacogenomics Study With Varying Levels of Drug Effect on 
QT Duration, Prolonged QT Effect on Adverse Drug Reactions and Adverse Drug 
Reactions on Drug Continuation 
The bias estimated for a pharmacogenomics study of QT with bias estimated in the absence 
of a SNP main effect and with a drug-SNP interaction effect of 5 ms under varying effect 
sizes of drug use on QT interval (A), varying effects of QT > 450 ms (QT long) on the 
occurrence of an adverse drug reaction (ADR, B), or varying effects of having an ADR on 
drug continuation (C).  Black lines represent the longitudinal study design, blue lines 
represent the cross-sectional study design, and red lines represent the new-user study design 
contrasting whole-cohort ( ─ ) and active comparator (- - -) control groups.  Simulations were 
performed assuming a population of 120,000 participants with ~17% of participants receiving 
a QT-prolonging medication, with 10,000 simulations performed per scenario. 
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Figure 36.  Bias and Power in a Pharmacogenomics Study Under an Extreme or 
Modest Scenario with Reduced Specificity and Sensitivity of Medication Assessment 
The bias and power to detect a drug-SNP interaction effect estimated for a 
pharmacogenomics study of QT in the absence of a simulated SNP main effect over a varied 
drug-SNP interaction effect under an extreme drug effect on QT (B, D) and a modest drug 
effect on QT (A, C).  Left column panels represent the modest scenario (5 ms increase in QT 
among drug users).  Right column panels represent the extreme scenario (30 ms increase in 
QT among drug users).  Black lines represent the longitudinal study design, blue lines 
represent the cross-sectional study design, and red lines represent the new-user study design 
contrasting whole-cohort ( ─ ) and active comparator (- - -) control groups.  Simulations were 
performed assuming a population of 120,000 participants with ~17% of participants receiving 
a QT-prolonging medication, with 10,000 simulations performed per scenario. 
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Figure 37.  Power to Detect a Drug-SNP Interaction Effect of 2 ms in a 
Pharmacogenomics Study Under an Extreme or Modest Scenario with Perfect or 
Reduced Specificity and Sensitivity of Medication Assessment with Increasing 
Population Size 
The power to detect a drug-SNP interaction effect estimated for a pharmacogenomics study 
of QT in the absence of a simulated SNP main effect with a 2 ms drug-SNP interaction effect 
over increasing population size under an extreme drug effect on QT (B, D) and a modest drug 
effect on QT (A, C).  Left column panels represent the modest scenario (5 ms increase in QT 
among drug users).  Right column panels represent the extreme scenario (30 ms increase in 
QT among drug users).  Top row represents perfect medication assessment.  Bottom row 
represents imperfect medication assessment measured with reduced specificity and 
sensitivity.  Black lines represent the longitudinal study design, blue lines represent the cross-
sectional study design, and red lines represent the new-user study design contrasting whole-
cohort ( ─ ) and active comparator (- - -) control groups.  Simulations were performed 
assuming a population of 120,000 to 300,000 participants with ~17% of participants 
receiving a QT-prolonging medication, with 10,000 simulations performed per scenario. 
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CHAPTER 7: DISCUSSION AND CONCLUSION 
 QT interval (QT) prolongation is a long-known, potentially fatal side effect of many 
common pharmaceuticals, including thiazide diuretics, a common antihypertensive 
treatment.
36, 37, 39
  Pharmacogenomics research represents a promising step forward in 
understanding and preventing adverse drug reactions like QT prolongation, as QT is highly 
heritable (35-40%) and influenced by many common SNPs.
24-28, 209
  Furthermore, 
pharmacogenomics studies of thiazides have identified numerous loci influencing patient 
response and ADRs.
274, 276, 279, 280
  However, underlying mechanisms governing thiazide-QT 
associations are poorly understood.  Theories range from a direct effect of thiazides on 
cardiac conduction mechanisms
43, 258
 to an indirect effect through electrolyte levels.
41, 42, 257
  
Together, these lines of evidence suggest that the thiazide-QT relationship is a promising 
candidate for pharmacogenomics study.  
We therefore conducted the first large, multi-ethnic pharmacogenomics study of 
thiazide diuretics and QT.  Using fourteen large, observational cohort studies (N=78,199), we 
performed a genome-wide analysis of the thiazide-SNP interaction on QT and its component 
parts (QRS interval, JT interval).  Although we used a comprehensive approach that 
considered multi-ethnic populations, leveraged pleiotropy, and accommodated population 
heterogeneity, we did not identify any genome-wide significant SNPs modifying the 
association between thiazides and these ECG intervals.  However, we identified 74 loci with 
suggestive evidence of association through both univariate and cross-phenotype analyses as 
well as enrichment in pathways involved in transcription and translation. 
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Interestingly, our suggestive results included multiple loci involved in ion transport 
and handling, the disruption of which is believed to be an underlying mechanism in drug-
induced QT prolongation,
111
 supporting the hypothesis that common SNPs modify the 
thiazide-QT relationship.  For example, our suggestive results include the PITX2 and RYR3 
QRS loci identified in Hispanic/Latinos, which may directly regulate ion channel genes and 
genes involved in calcium handling.
377
  Moreover, we found suggestive evidence of thiazide-
SNP interactions on QT, QRS, or JT in other genes involved in ion transport and handling, 
including  NELL1,
279
 STC2,
378
 EDN1,
379
 TRPC7,
380
 PKP2,
381
 and DISC1,
382
 as well as a 
voltage-gated potassium channel gene (KCNQ3).   Additionally, our power simulations 
suggested there was limited power to detect interaction effects of 2 ms, sizes consistent with 
QT main effects analyses.
209
   
Our pharmacogenomics study of thiazides and QT, particularly the lack of genome-
wide significant results despite biological plausibility and a sample size surpassing that of 
most published gene-environment studies to date suggested to us that further efforts are 
needed to better characterize pharmacogenomics studies conducted in observational settings 
and potential causes of reduced power.  For example, pharmacogenomics studies are 
increasingly being conducted in observational cohort settings, which provide large, diverse 
sample, deep phenotype characterization, numerous medication exposures, and improved 
external validity compared to clinical trials. 
284
  However, a form of selection bias called 
prevalent user bias affects pharmacoepidemiologic studies conducted in observational 
settings, as does exposure misclassification.  Yet, the effects of prevalent user bias and 
exposure misclassification on the interaction effects under evaluation in pharmacogenomics 
studies are unclear.
284, 287
  Therefore, we conducted a simulation analysis to examine the 
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influence of prevalent user bias, exposure misclassification, study design, and referent group 
on bias, power, and type I error in pharmacogenomics studies conducted in observational 
cohort settings. 
Specifically, we examined the influence of prevalent user bias and exposure 
misclassification in pharmacogenomics studies conducted in observational settings by 
contrasting three designs (new user, cross-sectional, and longitudinal) and two control groups 
(whole cohort and active comparator) under two scenarios (modest and extreme drug effects 
on QT), totaling 12 different settings.  Our simulations identified settings where prevalent 
user bias caused moderate bias on the drug-SNP interaction effect.  Yet, the greatest bias, as 
well as the largest power reductions, were detected when simulations were extended to 
examine exposure misclassification.  For example, our simulations indicated that, even in a 
longitudinal setting which provided the greatest power to detect interaction effects, 
pharmacogenomics studies require at least 150,000 participants to achieve 80% power to 
detect a 2 ms interaction effect, an effect consistent with, or slightly larger than, published 
main effects GWAS,
209
 providing further evidence that our sample size of 78,199 participants 
in our thiazides-QT pharmacogenomics GWAS was insufficient. 
Given that the amount of bias and potential for reduced power, which varied by the 
design, control group, and strength of the drug effect on the outcome, these results have 
broad implications for pharmacogenomics studies conducted in observational cohort settings, 
beyond the work presented here.  For example, recommendations for the optimal 
pharmacogenomics design and control group must balance bias and power and be tailored to 
the research question of interest.  In the context of thiazide-SNP interactions on QT, even if 
increasing the sample size by50% was possible, the influence of exposure misclassification 
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and other yet evaluated sources of measurement error makes it difficult to rule-out clinically 
significant results, generally defined as interactions with effects of 5 ms or greater. 
44
  
However, such increases in sample size are unlikely to occur through incorporating data from 
yet represented observational cohort studies, as the remaining large population-based cohort 
studies (e.g. The National Longitudinal Study of Adolescent to Adult Health [AddHealth]
417
 
or the Reasons for Geographic and Racial Differences in Stroke Study [REGARDS]
418
) do 
not have ECGs or have inadequate ECG characterization (EZ Soliman personal 
communication).  Additionally, while other phenotypes of interest (i.e. blood pressure or 
glycemic traits) are measured in more cohorts than ECG traits, many of these traits show 
greater variability in measurement, 
407-409
  which may require even larger sample sizes than 
required for QT.  Future efforts to evaluate the effect of differing levels of outcome 
measurement error is therefore warranted.  Finally, funding institutes, particularly the 
National Institutes of Health, are moving away from funding new large, population-based 
cohorts, making the de novo collection of requisite data in the future unlikely.
419, 420
  Yet, our 
results underscore the massive sample sizes required in gene-environment interaction studies 
to both identify loci as well as rule out pharmacogenomics efforts of large magnitude,
282, 402-
404
 as false negatives can negatively impact dissemination of results, innovation in drug 
design to prevent future ADRs, and future pharmacogenomics efforts.   
Given that we have identified the majority of cohort studies to date with the requisite 
drug, ECG, and GWAS data, additional avenues are likely needed to grow the analytic 
sample for future efforts.  One potentially attractive option is offered by studies of electronic 
medical records (EMRs).  Strengths of EMRs include the potential to provide a more 
complete medication history, which could enable sensitivity analyses examining variables 
 170 
such as medication dose and duration of use.  Consortia such as the Electronic Medical 
Records and Genomics (eMERGE) Network have demonstrated the feasibility of linking 
EMRs to genetic data for use in genetic research, 
386
 and have successfully identified genetic 
variants modifying drug response. 
387
  However, investigators using EMR data cannot control 
participant recruitment, timing and accuracy of data collection, or population 
representativeness. 
388
  Considering ECG research specifically, cohort studies administer 
ECGs to all participants at study visits using strict quality control procedures, whereas EMRs 
may capture ECGs for patients with medical indications, providing an inherently different 
population.  The selection bias caused through the inclusion of only participants with medical 
indications for specific test would also be of concern to pharmacogenomics studies of 
numerous other phenotypes that are not part of standard medical examinations (e.g. cognitive 
decline, hearing, biomarker assays, etc.).  
Thus, before resources like EMRs can be combined with results from observational 
cohort studies to illuminate pharmacogenomics studies, efforts to understand the potential 
bias and threats to precision are needed.  Unfortunately, prior efforts suggest that most 
pharmacogenomics studies have been performed (and published) before extensive efforts 
validating study designs have been conducted. 
47
  In the context of EMRs, future studies 
should therefore investigate the impact of non-routine testing (e.g. ECGs) on a population 
with medical indications on bias in a pharmacogenomics analysis.  Furthermore, EMRs 
provide the opportunity to include more precise medication data (e.g. dose and duration of 
use), but the impacts of including this information, particularly when it is only available in a 
subset of populations, warrants investigation.  Finally, researchers also must consider the 
limitations of combining different sources of data (e.g. population based cohorts, EMRs, 
 171 
biobanks, etc.) and better characterize how combining such heterogeneous data sources 
impacts bias and power. 
 Given the massive statistical testing penalty of genome-wide association studies 
(α=5x10-8), the potential for bias in study designs that optimize power (i.e. longitudinal), and 
uncertainty surrounding the use of EMRs, a third tempting option may be to consider 
hypothesis-based genomic analyses such as a candidate gene approach.  There has been some 
success in identifying genetic variants in genes associated with congenital long QT syndrome 
that modify drug-induced QT-prolongation.
410
   However, our evaluation of loci from main 
effects QT GWAS as candidate genes in pharmacogenomics studies of QT-prolonging drugs 
did not yielded any positive results.  The observation of loci from main effects GWAS 
having no interactive effect is not unique to pharmacogenomics studies of drug-induced QT-
prolongation.  Efforts by Bis et al. that evaluated whether SNPs with previously reported 
main effects on coronary heart disease also modified the association between anti-
hypertensives and cardiovascular disease were similarly unsuccessful.
403
  It is not surprising 
that SNPs identified in studies of main effects do not demonstrate an interactive effect in 
gene-environment such as pharmacogenomics, as SNPs selected on the basis of an extreme 
P-value for a single main effect may be less likely to harbor heterogeneity across population 
subgroups (i.e. drug users vs. non-users).
282
 
In conclusion, pharmacogenomics research is currently one of the few areas of public 
health genomics for which interventions are not only possible, but are underway, as genetics 
are used to guide drug selection.
7, 13, 259
  In addition to informing drug selection, 
pharmacogenomics research also has the potential to illuminate novel pathways in drug 
response, inform drug development, alter policy and drug labelling, modify dosing regimens, 
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and prevent ADRs, thereby influencing public health at many points of intervention.
10, 11, 13
  
However, the limitations currently posed by pharmacogenomics research have the potential 
to minimize the role of genetics in variable drug response and to naively constrain the 
advancement of pharmacogenomics inquiry.  Therefore, future analyses must seek innovative 
solutions to overcome the inherent challenges in pharmacogenomics work so that this 
contemporary field can reach its full public health potential.  
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APPENDIX 1: SUMMARY RESULTS FROM FIVE LARGEST GENOME-WIDE ASSOCIATION STUDIES OF QT 
(POPULATIONS~10,000 OR GREATER) 
  Author and Year Newton-Cheh 2009 Pfeufer 2009 Holm 2010 Smith 2012 Arking 2014 
  Ancestry European European European African European 
   N 13,685 15,842 9,860 12,097 76,061 
Gene Chr SNP CA MAF 
β  
(SE) P MAF β (SE) P MAF 
β 
(SE) P MAF 
β  
(SE) P MAF 
β  
(SE) P 
RNF207 1 rs846111 C 0.28 1.75 
(0.18) 
1E-16 0.29 1.49 
(0.25) 
4E-9       0.28 1.73 
(0.13) 
7E-40 
TCEA3 1 rs2298632 T             0.50 0.70 
(0.09) 
1E-14 
NOS1AP 1 rs12143842 T 0.26 3.15 
(0.18) 
2E-78 0.24 2.88 
(0.23) 
2E-35    0.20 3.14 
(0.39) 
2E-15 0.24 3.50 
(0.11) 
1E-213 
  rs16847548 C          0.22 2.17 
(0.33) 
2E-10    
  rs16857031 G 0.14 2.63 
(0.18) 
1E-34             
  rs12029454 A 0.15 2.98 
(0.18) 
3E-45       0.31 1.73 
(0.29) 
4E-9    
  rs7534004 A          0.31 1.73 
(0.29) 
3E-9    
  rs10127719 C          0.32 1.64 
(0.29) 
2E-8    
  rs12567315 A          0.33 1.69 
(0.28) 
2E-9    
  rs6692381 T          0.34 -1.71 
(0.28) 
1E-10    
  rs6667431 A          0.33 1.69 
(0.28) 
2E-9    
  rs4306106 A          0.33 1.66 
(0.28) 
5E-9    
  rs10800352 G          0.33 -1.66 
(0.28) 
5E-9    
  rs4480335 C          0.33 -1.67 
(0.28) 
4E-9    
  rs12116744 A          0.33 1.67 
(0.28) 
4E-9    
  rs12027785 A          0.33 1.67 
(0.28) 
3E-9    
  rs3934467 T          0.33 -1.69 
(0.28) 
3E-9    
  rs4391647 G          0.33 -1.74 
(0.28) 
8E-10    
  rs4657175 G          0.33 1.74 
(0.28) 
7E-10    
  rs12123267 T          0.34 -1.70 2E-9    
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(0.28) 
ATP1B1 1 rs12061601 C          0.29 -1.89 
(0.30) 
2E-10    
  rs1320976 A          0.25 -2.06 
(0.32) 
2E-10    
  rs10919071 A    0.87 2.05 
(0.29) 
2E-12 0.88 1.52 
(0.71) 
0.03    0.87 1.68 
(0.14) 
1E-31 
SLC8A1 2 rs12997023 C             0.05 -1.69 
(0.22) 
5E-14 
SP3 2 rs938291 G             0.39 0.53 
(0.09) 
6E-10 
TTN-
CCDC14
1 
2 rs7561149 C             0.42 -0.52 
(0.09) 
7E-9 
SPATS2L 2 rs295140 T             0.42 0.57 
(0.09) 
2E-11 
SCN5A 3 rs11129795 A    0.23 -1.27 
(0.23) 
4E-8          
  rs12053903 C 0.34 -1.23 
(0.18) 
1E-14             
  rs6793245 A             0.32 -1.12 
(0.10) 
4E-27 
C3ORF7
5 
3 rs17784882 A             0.40 -0.54 
(0.10) 
3E-8 
SLC4A4 4 rs2363719 A             0.11 0.97 
(0.16) 
8E-10 
SMARCA
D1 
4 rs3857067 A             0.46 -0.51 
(0.08) 
1E-9 
GFRA3 5 rs10040989 A             0.13 -0.85 
(0.13) 
5E-11 
GMPR 6 rs7765828 G             0.40 0.55 
(0.09) 
3E-10 
PLN 6 rs11153730 T             0.50 -1.65 
(0.10) 
2E-67 
  rs11970286 T    0.44 1.64 
(0.20) 
2E-16          
  rs11756438 A 0.47 1.40 
(0.18) 
5E-22             
CAV1 7 rs9920 C             0.09 0.79 
(0.14) 
3E-8 
KCNH2 7 rs2968864 T 0.25 1.40 
(0.18) 
8E-16    0.22 2.33 
(0.01) 
2E-5       
  rs2968863 T    0.29 -1.35 
(0.23) 
4E-9 0.22 -2.30 
(0.55) 
3E-5       
  rs4725982 T 0.22 1.58 
(0.18) 
5E-16    0.23 1.64 
(0.55) 
0.003       
  rs2072413 T          0.27 -1.68 
(0.11) 
1E-49    
  
1
7
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  rs3807375 T       0.35 4.42 
(0.67) 
5E-11       
NCOA2 8 rs16936870 A             0.10 0.99 
(0.16) 
1E-9 
LAPTM4
B 
8 rs11779860 C             0.47 -0.61 
(0.10) 
2E-10 
AZIN1 8 rs1961102 T             0.33 0.57 
(0.10) 
3E-9 
GBF1 10 rs2485376 A             0.39 -0.56 
(0.09) 
3E-8 
KCNQ1 11 rs2074238 T 0.06 -7.88 
(0.88) 
3E-17    0.04 -2.13 
(0.49) 
1E-5       
  rs7122937 T             0.19 1.93 
(0.12) 
1E-54 
  rs12296050 T    0.20 1.44 
(0.25) 
9E-9 0.15 4.87 
(0.75) 
8E-11       
  rs757092 G       0.34 1.14 
(0.48) 
2E-2       
  rs12576239 T 0.13 1.75 
(0.18) 
1E-15    0.13 2.31 
(0.52) 
8E-6       
FEN1-
GADS2 
11 rs174583 T             0.34 -0.57 
(0.09) 
8E-12 
ATP2A2 12 rs3026445 C             0.36 0.62 
(0.09) 
3E-12 
TBX5 12 rs3825214 G       0.22 2.18 
(0.41) 
1E-7       
KLF12 13 rs728926 T             0.36 0.57 
(0.10) 
2E-8 
ANKRD9 14 rs2273905 T             0.35 0.61 
(0.09) 
4E-11 
USP50-
TRPM7 
15 rs3105593 T             0.45 0.66 
(0.10) 
3E-12 
CREBBP 16 rs1296720 C             0.20 0.83 
(0.13) 
4E-10 
LITAF 16 rs8049607 T 0.49 1.23 
(0.18) 
5E-15 0.49 1.25 
(0.22) 
3E-8 0.52 2.30 
(0.52) 
1E-5       
  rs735951 A          0.46 -1.15 
(0.10) 
2E-28    
MKL2 16 rs246185 C          0.34 0.72 
(0.10) 
3E-13    
NDRG4-
CNOT1 
16 rs37062 G 0.24 1.75 
(0.18) 
3E-25    0.28 2.25 
(0.47) 
1E-6       
  rs246196 C             0.26 -1.73 
(0.11) 
2E-15 
  rs7188697 A    0.74 1.66 
(0.23) 
1E-12 0.71 1.75 
(0.50) 
5E-4       
LIG3 17 rs2074518 T 0.46 1.05 
(0.18) 
6E-12             
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  rs1052536 C             0.53 0.98 
(0.10) 
6E-25 
PRKCA 17 rs9892651 C             0.43 -0.74 
(0.10) 
3E-14 
KCNJ2 17 rs1396515 C             0.52 -0.98 
(0.09) 
2E-25 
  rs17779747 T    0.35 -1.16 
(0.21) 
3E-8          
KCNE1 21 rs1805128 T             0.01 7.42 
(0.85) 
2E-18 
  rs1805127 T       0.39 3.09 
(0.72) 
2E-5       
  rs727957 T       0.19 4.33 
(1.20) 
2E-12       
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APPENDIX 2: STUDY- AND RACE/ETHNIC-SPECIFIC QUANTILE-QUANTILE PLOTS OF P-VALUES FOR 
THIAZIDE-SNP INTERACTION ESTIMATES IN ALL PARTICIPATING STUDIES FOR QT, QRS, AND JT INTERVAL 
ANALYSES 
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AGES, Age, Gene/Environment Susceptibility – Reykjavik Study; ARIC, Atherosclerosis Risk in Communities; CHS, Cardiovascular Health Study; ERF, 
Erasmus Rucphen Family Study; FHS, Framingham Heart Study; GARNET, Genome-wide Association Research Network into Effects of Treatment; H2000, 
Health 2000; Health ABC, Health, Aging, and Body Composition Study;  HCHS/SOL, Hispanic Community Health Study/Study of Latinos; JHS, Jackson Heart 
Study; MESA, Multi-Ethnic Study of Atherosclerosis; MOPMAP, Modification of Particulate Matter-Mediated Arrhythmogenesis in Populations; NEO, the 
Netherlands Epidemiology of Obesity; PROSPER, Prospective Study of Pravastatin in the Elderly at Risk; QT, QT interval; RS, Rotterdam Study; SHARe, The 
SNP Health Association Resource; WHI CT, Women’s Health Initiative Clinical Trial; WHIMS, the WHI Memory Study 
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